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This thesis aims to investigate engagement in Option B+ (life-long 
antiretroviral therapy (ART) for all HIV-positive pregnant and breastfeeding 
women) among pregnant and postpartum women residing in Agincourt health 
and demographic surveillance system (HDSS) in north-east South Africa. 
Paper A describes outcomes for 1325 patients reported as lost to follow-up 
(LTFU) in routine clinic records showing that patients who were pregnant at 
ART initiation have differing outcomes including a lower risk of death. Paper 
B reports on the spatial distribution of 315 patient transfers between clinics 
and identifies risk factors for these transfers, showing that pregnant and 
postpartum women are more likely to transfer their treatment, more likely to 
not report their transfer to their origin clinic, and less likely to transfer to a 
clinic outside the study area, when compared to adults in the general 
population. Paper C evaluates the accuracy of mortality estimates provided 
through routine treatment records in TIER.Net (the national HIV database), 
by comparing them to data generated through the record review and patient 
tracing. The results suggest that TIER.Net underestimates mortality and 
overestimates programme attrition, with important consequences for 
treatment programme policy, planning, and monitoring and evaluation, and 
estimation of the UNAIDS 90-90-90 targets. Paper D draws on in-depth 
interview data with women living with HIV to explore the intersection between 
early infant diagnosis (EID) and maternal engagement in care, finding that 
continued engagement in care promotes utilisation of EID, but also that the 
EID result can undermine maternal engagement in care. Paper E documents 
the challenges faced by patient tracing programmes and the lessons learnt 
during the ascertainment of patient outcomes and gives recommendations for 
future practice.   
The collective findings of this PhD research provide estimates of HIV patient 
outcomes after LTFU from prevention of mother-to-child transmission of HIV 
(PMTCT) programmes and generate new insights into some of the underlying 
causes. This research demonstrates the feasibility of using multiple linked data 




They say the fixations of our childhood become the dogged pursuits of our 
adulthood... 
I was born in 1987, at the dawn of what most people hoped would be the 
beginning of peace and prosperity. Uganda was just emerging from a long 
protracted civil war but unbeknownst to all there was a killer among us, one 
whose propagation we now know was aided by the war.  
What followed was a decade of social devastation and upheaval. In 1991, that 
devastation visited my family when my cousin Natalie not yet a year old passed 
away. My young mind, barely able to contemplate death, was left with many 
questions. Questions that the adults were ill-equipped to answer. It visited 
again in 1992, this time taking my aunt, her mother. Throughout my 
childhood, HIV was my bogeyman. Like most kids I was afraid of vampires and 
werewolves, but I think that deep down inside I always knew those were not 
real. HIV on the other hand had had a tangible effect on my life. Unfortunately, 
in Uganda and Africa, my story is not unique.  
A decade later, we were lulled into a false sense of security as antiretroviral 
medication became more widely available and the devastation of yesteryear 
was pushed into the deep recesses of our minds, and for many, soon forgotten. 
In 2011, the devastation visited again claiming the life of my remaining 
paternal aunt. This event was a devastating reminder of many questions that 
had lain dormant within my mind for many years and led to a change in my 
life trajectory and goals.  
My attempt at facing my bogeyman and hopefully coming out on the other side 
with some clarity and closure has ultimately culminated in this work. It is not 
lost on me that my topic focuses on women and children, the most affected 
population in Africa, as I can personally attest. It is not very often that you can 
say research has been therapeutic or helped to exorcise your demons. In many 
ways my life has come full circle, and this feels like a natural close to an 
important chapter of my life.  
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I dedicate this work to my aunts Dorothy and Helen, and my cousins Natalie 
and Daniel whose lives were directly or indirectly cut short by HIV and the 





“It takes a village to raise a child”, I think this sentiment holds true for the 
completion of a thesis and so I would like to acknowledge the village that 
contributed to this work.  
I would firstly like to thank my supervisors Alison Wringe and Georges Reniers 
for their time and dedication to my research. I would like to thank them for 
their encouragement and guidance over this four-year journey. I am 
particularly grateful to Alison for the multiple Skype and WhatsApp calls 
throughout the lockdown period which helped to keep me focused and 
motivated to complete this work.  
 I would also like to thank my other advisors, Jenny Renju, Francesc Xavier 
Gomez-Olive, Chodziwadziwa Kabudula, and Jim Todd for their inputs and 
feedback on my papers and for their help with editing my thesis chapters. I 
would especially like to thank Jenny whose help with the qualitative 
component of my fieldwork and thesis was invaluable in aiding my 
understanding of qualitative research and its implementation. I would also like 
to thank Brian Rice whose advice and feedback were an immense help in 
formulating some of my thoughts and analyses. 
I am grateful to the staff at the MRC/WITS Rural Public Health and Health 
Transitions Research Unit in Agincourt, whose assistance with implementing 
my fieldwork was invaluable to its timely completion. I would like to thank 
Nkosinathi Masilela who took time out of his busy schedule to help me to get 
around early on in my fieldwork. I am indebted to the fieldworkers who helped 
with data collection for the quantitative component (Gladstone Shabangu, 
Sherly Ndubane, Nobuyiselo Sibuyi, and Boldwin Mkhawanazi) and 
qualitative component (Ella Sihlangu, Violet Ndhlovu, Sherly Ndubane, 
Meriam Maritze, and Princess Makhubela). I would especially like to thank 
Linda and Becca whose companionship and shenanigans made life in the field 
a lot more enjoyable. 
To the many friends I have made at LSHTM and in London at large, your 
companionship has made what can sometimes feel like a very solitary 
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Advances in antiretroviral therapy (ART) have transformed the global HIV 
epidemic (1) and changed HIV infection from a terminal condition to a 
manageable chronic disease (2–4). Added to the individual benefits of ART is 
the reduced horizontal and vertical transmission as a result of reductions in 
individual and community viral load (5–7). Starting in 2001 the World Health 
Organisation (WHO) has recommended some form of antiretroviral drug 
(ARV) prophylaxis for the prevention of mother-to-child transmission of HIV 
(PMTCT) starting with the first recommendation of single-dose and short-
course ARV prophylaxis (8). Since 2015, the WHO treatment guidelines have 
recommended immediate lifelong ART for all pregnant and breastfeeding 
women regardless of disease stage in recognition of the health and 
preventative benefits of ART (9). This new policy also referred to as “Option 
B+” recommends continued testing throughout the pregnancy, postpartum 
and breastfeeding period with an immediate offer of ART for any women who 
test HIV positive, irrespective of CD4 count (a proxy for immunological 
status), or WHO stage (a proxy for disease progression) (10). It is hoped that 
this approach will contribute to the complete elimination of mother-to-child 
transmission of HIV (EMTCT) worldwide (10).  
However, poor engagement in care and low adherence to ART have begun to 
emerge as major hinderances to the achievement of PMTCT programme goals. 
Specifically, patients who become lost to follow-up (LTFU) are a concern and 
may curtail the major accomplishments to date, including increases in 
mothers’ life expectancy and reductions in vertical transmission (11). Loss to 
follow-up has become a term that describes all patients who go a period 
without a clinic visit or are untraceable. Historically, treatment programmes 
were more concerned with patients who remained retained in care and 
patients who became LTFU were censored with the censoring assumed to be 
random or uninformative (12). At the advent of ART, LTFU was low and much 
of LTFU was attributable to mortality (13–15). However, as treatment 
guidelines have changed and more healthy people living with HIV (PLHIV) 
have become eligible for treatment, LTFU has begun to rise, and increasingly, 
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less of LTFU can be attributed to mortality (16). This is particularly pertinent 
for women in “Option B+” programmes as they are often asymptomatic and 
healthy in terms of immunological status and disease progression. As such, 
loss to follow-up amalgamates a number of possible outcomes including death, 
undocumented transfers, and patients who have genuinely disengaged from 
care. However, studies of loss to follow-up have mostly ignored women who 
initiate ART for PMTCT, and few studies have investigated LTFU among 
women in “Option B+” programmes (17–19). This group differs significantly 
from the general treatment population due to changes during the pregnancy 
and postpartum period and in terms of disease progression and symptoms at 
ART initiation, and as such their outcomes after LTFU might differ as well. 
Understanding LTFU among women in “Option B+” programmes has also 
become more important with the advent of “Treat all” which extends universal 
ART coverage to all individuals diagnosed HIV positive (10). “Option B+” 
women represent the first iteration of universal treatment and as such, 
outcomes following LTFU for this group could represent what HIV treatment 
programmes can expect in terms of LTFU with the move to “Treat all”, and the 
increase in the proportion of asymptomatic patients initiating treatment. 
This thesis is a study of loss to follow-up among women who initiated ART 
under “Option B+” in rural north-eastern South Africa where “Option B+” 
became the national treatment guideline in 2015. Fieldwork was conducted 
between August 2017 and December 2018. This research is situated within the 
Agincourt health and demographic surveillance system (HDSS) which has 
been running since 1992 (20).  
As part of this research, I ascertained the outcomes for patients considered to 
be LTFU by conducting a comprehensive record review and tracing study. 
Outcomes for “Option B+” women are compared to non-pregnant women and 
men living with HIV who initiated ART, in order to identify any differences 
between these groups. Additionally, in-depth interviews (IDIs) are utilised to 
explore engagement in care (broadly defined as the process of accessing HIV 
treatment and care services and remaining actively involved with regards to 
guidance given by service delivery personnel) for women under “Option B+” 
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with the aim of understanding this process from the perspective of the 
participants. 
In this chapter, I describe the burden of vertical transmission both globally 
and in South Africa, give a brief background and overview of the problem of 
HIV in pregnancy in sub-Saharan Africa including the problem of poor 
engagement in care. I give a brief overview of the change in treatment 
guidelines for pregnant women living with HIV including the implementation 
of “Option B+”, an overview on definitions of engagement in care, and present 
the argument for utilising clinic visit logs to assess engagement in care. Finally, 
I formulate the rationale for conducting this PhD research, present the main 
aims and objectives of the study, give a brief description of the study setting, 
lay out the structure of the thesis and describe my role in completing this PhD 
research.  
1.1. The global burden of vertical transmission 
HIV remains a major contributor to the global burden of disease. In 2018, an 
estimated 37.9 million people were living with HIV, of whom 1.8 million were 
children (21,22). Furthermore, of an estimated 1.7 million new infections in 
that year, 160,000 were among children (22). 
The Joint United Nations Programme on HIV/AIDS (UNAIDS) estimates that 
about 1.5 million HIV-positive women give birth every year; a number that will 
only be exacerbated by the estimated 900,000 new annual infections among 
women of reproductive age (22). Encouragingly, 80% of HIV-positive 
pregnant women received ART to prevent vertical transmission globally in 
2015 (21,22), representing a 60% increase since 2010. Although there was an 
almost threefold reduction in the mother-to-child transmission rate between 
2010 and 2015, it was still estimated at 10% of all live births to HIV-infected 
women globally by 2015 (21). Worldwide HIV/AIDS accounted for 1.4% of all 
deaths among children aged 0-5 years old in 2015 (23). In sub-Saharan Africa, 
this proportion was estimated at 2.7%. Furthermore, among women aged 15-
49 years old in this region, 11% of deaths in 2015 were attributable to 
HIV/AIDS (23). 
In sub-Saharan Africa (SSA), women are disproportionately affected by the 
HIV epidemic. While 15% of the world’s population lived in SSA in 2018, an 
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estimated 65% of 37.9 million people living with HIV worldwide, were living 
in SSA. This included 77% of all women living with HIV (24). In 2018, 59% of 
new infections in SSA occurred in women and about 90% of all pregnancies 
among women living with HIV occurred in this region (24). Promisingly, over 
80% of pregnant women living with HIV in this region received ART for 
PMTCT in 2018, a figure that rises to 92% if only east and southern African 
countries are considered (24). However, there were still 142,000 new 
infections among children in SSA in 2018 (24).  
In South Africa, the potential for vertical transmission is illustrated in Figure 
1.1 which shows the rise of HIV prevalence in pregnant women since 1990 and 
its plateauing after 2005 (25). In 2013, an estimated 29.7% of women 
attending public sector health facilities were infected (25). In 2014, an 
estimated 240,000 HIV-positive women delivered in South Africa with >95% 
taking some form of ARV prophylaxis during their pregnancy (26). However, 
this was before the introduction of lifelong ART for prevention of vertical 
transmission (Option B+). 
Figure 1.1: Prevalence of HIV infection among pregnant women 
in South Africa, 1990-2013(SA NDoH (25)) 
  
In South Africa, 9200 new-borns were perinatally infected in 2014, a 76% 
reduction in new infections since 2009, and 94% of HIV-exposed infants 
received an early infant diagnosis (EID) test by 2 months as recommended by 
the WHO (26,27); however, testing coverage at the end of the breastfeeding 
period is not as high (28). The transmission rate at 6 weeks postpartum was 
estimated to be 2% and increased to 4% when the breastfeeding period was 
included; a reduction from 15% in 2009 (26). In 2011, 70.4% of maternal 
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deaths and 50% of all deaths of children under five in South Africa were 
attributable to HIV infection (29,30). 
1.2. HIV in pregnant and postpartum women 
Among pregnant and postpartum women living with HIV, continued 
engagement in care has individual and population-level benefits (10). Firstly, 
ART reduces morbidity and mortality which has many benefits for these 
women and their immediate circle of family and friends (6). Secondly, it has 
the benefit of reducing the risk of vertical transmission to almost zero provided 
they remain virologically suppressed throughout the pregnancy and 
breastfeeding phase for both the current and future pregnancies (31). Finally, 
remaining engaged in care and virologically suppressed prevents transmission 
of HIV to HIV-uninfected sexual partners, a major reason underlying the 
change in guidance to test and treat all people who test positive for HIV 
(7,32,33).   
Despite all the important benefits of continued engagement in care, data from 
PMTCT programmes and demonstration projects throughout SSA indicates 
that many women do not remain engaged in care and adherent to treatment 
(11). A systematic review in 2018 found that retention among pregnant and 
breastfeeding women living with HIV in Africa was as low as 42% after 12 
months on ART (11). Long-term studies also had varying retention rates. For 
example, in Malawi, 70% of women were retained after three years on ART 
(34). While in Eswatini, only 53% of women were retained after two years on 
ART (35). 
1.3. HIV treatment guidelines for pregnant and 
postpartum women 
There has been a dramatic shift in the treatment guidelines for pregnant and 
postpartum women in SSA to a more holistic approach emphasising not just 
healthy babies but healthy mothers as well and recognising the value of HIV 
treatment on population health outcomes. This shift occurred concurrently 
with the shift in our understanding of HIV transmission and the role of ART. 
Global guidelines first recommended single-dose and short-course ARV 
prophylaxis for PMTCT in 2001 and have evolved to recommend lifelong ART 
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for those meeting certain criteria, to finally recommending lifelong ART for all 
pregnant and breastfeeding women regardless of CD4 (Figure 1.2).  
Figure 1.2: Evolution of PMTCT recommendations and guidelines1 
 
Universal lifelong ART for pregnant and breastfeeding women, also referred 
to as “Option B+” was first implemented in Malawi in 2011 (36). This was due 
to a lack of the CD4 testing capacity to use CD4 as a criterion for treatment 
initiation and in recognition of the substantial burden and risk of drug 
resistance from stopping and restarting ART during subsequent pregnancies 
both for the women and the health system (37,38). Since its advent, it has 
become the standard of care in all countries in SSA (39). As a result, antenatal 
care (ANC) services have become a major entry point into lifelong ART 
programmes for women (40,41). HIV testing during pregnancy has become 
the norm in most SSA countries with testing coverage among pregnant women 
increasing steadily (41). The elimination of CD4 count as an initiation criterion 
has simplified treatment guidelines, streamlined the process and minimised 
delays in ART initiation during pregnancy and breastfeeding with same-day 
initiation becoming common in SSA (31,41–43). Despite all these 
achievements, the success of PMTCT programmes in SSA is threatened by 
persistent problems with women’s poor long-term engagement in care (41).   
 
1 AZT – Zidovudine, 3TC – Lamivudine, NVP – Nevirapine  
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1.4. The concepts of engagement in HIV care and loss to 
follow-up 
Engagement in care encompasses two main concepts, retention in care and 
adherence to ART which have been identified as significant barriers to 
achieving optimum outcomes in ART programmes (44) and these have been 
defined and conceptualised in myriad of ways. 
Most studies usually present two statistics when reporting on engagement in 
Option B+. The proportion of women retained in care at a specific time point 
following ART initiation, or the proportion of women who drop out of a 
treatment programme at specific points on the treatment cascade (11,35). It 
has been argued that the cross-sectional nature of these metrics means they 
do not accurately present the complicated and cyclical nature of engagement 
in care (45). 
Other authors present different ways of conceptualising engagement in HIV 
care (46–48). Gardner et al describe a spectrum of engagement in care 
(adopted from the Health Resources and Services Administration (HRSA) 
continuum of engagement in ART care) according to which varies between an 
individual not knowing their status to being fully engaged in care, indicated by 
the achievement of viral suppression (46) (Figure 1.3).  
Figure 1.3: The spectrum of engagement in ART care (The Health 
Resources and Services Administration (HRSA) continuum of engagement in 
ART care (49)) 
 
Vrijens et al propose a framework where patients move through several stages, 
initiation, implementation, persistence and discontinuation. Initiation 
pertains to prescription of the first dose of ART, implementation to adherence 
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and non-adherence, and persistence to how long patients remain on treatment 
as prescribed without discontinuing treatment (47). 
Myer et al conceptualise engagement in care using the continuum of two 
metrics: retention in care and adherence (48). According to Myer, an 
individual who remains retained in care and properly adherent is defined as 
engaged in care (Figure 1.4). 
Figure 1.4: A framework for the relationship between ART 
adherence and retention in care (Myer et al (48)) 
 
Furthermore, Myer proposes a time dimension when thinking of engagement. 
As such, all women might be fully engaged in care (retained and adherent) 
when they initiate treatment but as time passes, some women may become 
disengaged from care by either being retained but non-adherent or by no 








Figure 1.5: Engagement in care (retention and adherence over 
time) (Hypothetical depiction from Myer et al (48)) 
 
 
This thesis focuses on retention in care and loss to follow-up after ART 
initiation. These two concepts (as well as adherence) are closely related, 
therefore I outline the differences here. 
Retention in care refers to all patients who remain active within a 
programme and who are routinely visiting a clinic for ART refills. Most ART 
programmes including those for PMTCT report a composite unfavourable 
outcome for patients who are no longer retained in care and who have an 
unknown outcome usually called loss to follow-up (Figure 1.6).  
Loss to follow-up is the antithesis of retention and may be a consequence of 
poor engagement in care. Loss to follow-up is a general term for the unknown 
outcomes of patients who do not return for an ART refill appointment at a 
particular clinic (50–52). This variable amalgamates patients that have 
transferred their treatment to another clinic without proper documentation of 
the transfer (also referred to as unknown transfers (52), undocumented 
transfers (53), ‘silent’ transfers (54), self-transfer (15), or receiving ART at 
another facility) (55), patients that have had a treatment interruption or that 
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have stopped taking ART (also referred to as unstructured treatment 
interruptions (56)), patients that have died (also referred to as unreported 
deaths (52), and unknown death), and patients that have been misclassified 
either because of poor record keeping or human error.  
Figure 1.6: A graphical representation of patients with known 
and unknown outcomes (LTFU) (Adapted from WHO (51)).  
 
Loss to follow-up is commonly defined as a period without a clinic visit, a 
number of days late for an appointment, a missed appointment, or even a 
situation where a patient is untraceable. A systematic review of retention in 
sub-Saharan ART programmes reported eight different LTFU definitions (57). 
Some sources did not include a definition of LTFU. How LTFU is defined can 
significantly impact patient outcomes (58). For example, a short window of no 
visits can increase the number of patient misclassifications (59,60).   
As such, how a programme defines LTFU will have an impact on estimates of 
retention in care. By reducing loss to follow-up, programmes improve their 
retention statistics. The WHO defines LTFU (a general term for non-retention) 
as “patients receiving ART and not seen at the clinic or pharmacy for >90 days 
after the date of their last missed appointment or last missed drug pick-up and 
who are not known to have transferred or died” (51). Importantly, the WHO 
recommends that a distinction should be made between patients with an 
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unknown outcome (LTFU) and patients who cease to engage in the continuum 
of care because of their own wishes, beliefs or because of barriers to continued 
access to care (due to transportation, stigma, resources, etc), referring to the 
latter as disengagement from care (51).   
Adherence is a marker that measures how well a patient is taking ART as 
prescribed in terms of correct times and frequencies. As such, in order to be 
adherent, a patient should have a constant supply of ART and must therefore 
be retained in care (61). However, a patient can be retained in care but non-
adherent for example if they attend their clinic visits regularly and collect their 
treatment but do not take ART as prescribed. The WHO defines ART 
adherence as “the extent to which a person’s behaviour corresponds with the 
agreed recommendations from a healthcare provider” (62).  Adherence can be 
measured in myriad ways including objective measures such as directly 
observed therapy (DOT) (63), drug concentrations (64,65), pill counts (66,67), 
pharmacy refill data (68–70), and electronic pill monitoring systems (71); and 
subjective measures such as self-reported adherence (72–74). Increasingly, 
viral load is being used as a proxy marker for adherence as adherent patients 
should have an undetectable viral load, provided that they do not have drug 
resistant HIV (75,76). By the end of 2018, 60% of low- and middle-income 
countries had fully implemented viral load monitoring, but multiple obstacles 
still exist that curtail the optimum implementation of these programmes, 
particularly in SSA (39,77). Viral load monitoring has its weaknesses, principle 
among these is that it is only taken periodically and as such might not be very 
informative about patterns of adherence (64). Viral load is also to a lesser 
extent driven by other factors such as drug resistance and comorbidities 
(78,79). Therefore, other measures of engagement in care remain important to 
monitor ART programmes and evaluate their outcomes particularly in SSA 
where viral load testing is not yet fully implemented (41,44). While adherence 
is an important measure for evaluating the benefits of ART, this thesis does 
not specifically address adherence and its challenges. 
Epidemiological assessment of engagement in care still has its merits. 
Consequently, for the purpose of this thesis, engagement in care will 
concentrate primarily on retention in care, specifically looking at clinic visit 
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logs. Frequent viral load testing was not possible and viral load monitoring 
data was scant at the time of analysis but is being updated and provides 
potential future research directions. A patient was considered to be LTFU if 
they were >90 days late for a scheduled appointment keeping with the WHO 
definition. Patients that were LTFU could re-engage in care and so the Myer et 
al and Gardner et al definitions are also loosely considered.  
Finally, it is important to consider that some facets of engagement in care may 
be non-quantifiable and as such might require other methods to assess them. 
Engagement in care is not as neat as cascade diagrams would have us believe 
and therefore there are merits of a social science approach to exploring 
engagement (45). The concept of engagement in care as a linear, unidirectional 
cascade or continuum in which patients initiate treatment and remain in care 
until a terminal event is narrowly focused. Measures of engagement in care 
such as retention and adherence (usually measured through a viral load) are 
not a goal to be achieved per se but a state that needs to be maintained over 
time. While important concepts, that are essential for surveillance and a good 
barometer with which different treatment programmes can compare and 
gauge their progress, they do not shed light on the lived experience of those in 
care. As such, social concepts within engagement that are difficult to quantify 
are therefore missed in quantitative explorations of engagement. Therefore, 
aspects such as social and structural features of engagement in care may be 
better investigated and understood using qualitative methods (45). 
1.4.1. Practice theory to explain engagement in care 
Practice theory is increasingly being used to understand engagement in HIV 
care in sub-Saharan African settings (80–82). Practice theorists treat practices 
– “the elements that shape our perceptions, interpretations and actions” 
(83,84) – as their primary units of enquiry and contend that people’s practices 
can be explained by generic ‘elements’ which include materials or tools 
required to enact a practice, symbolic meanings associated with a practice, and 
competence and know-how to enact a practice (Figure 1.7). Each individual 
has a constellation of practices that they engage in, with some of these 
practices interacting either harmoniously or in conflict. Consequently, the 
enactment of one practice is likely to affect other practices (83,85–87). As 
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such, the impact of all these factors is likely to be dependent on individuals’ 
unique constellations of practices and their perceptions about HIV and its 
treatment (83). This theory will feature prominently in my conceptualisation 
and explanations of engagement in care, especially pertaining to the 
qualitative component of my thesis. 
Figure 1.7: Summary of the practice theory framework (Adapted 
from Skovdal et al (83)) 
 
1.5. Study Rationale 
The overall rationale of this thesis follows from the global push to eliminate 
vertical transmission of HIV. This will only be possible if pregnant women 
living with HIV have access to services that enable the health system to identify 
them in a timely manner, refer them to the appropriate HIV care, keep them 
retained in care for life, and follow-up on their exposed infants adequately and 
appropriately. Many studies in sub-Saharan Africa have reported sub-optimal 
rates of retention in care (11,88,89), which threaten the success of the 
intervention. While more recent findings suggest that Option B+ women 
retained in care past the first and second year of ART are lost to follow-up at a 
similar rate to the general HIV treatment cohort (34), work still has to be done 
to understand why their retention rates are lower than the general HIV 
treatment cohort in the first two years. Research to improve the efficacy of 
Option B+ will remain an important area, in order to bring vertical 
transmission rates around the world close to zero.  
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Understanding the true outcomes of women who become LTFU after initiating 
ART through Option B+ will help to accurately monitor and report on 
indicators for national ART programmes and better target tracing efforts. 
LTFU can lead to underestimation of retention and deaths and is likely to 
overestimate attrition rates (90). Accurate mortality estimates are especially 
important as these are used as parameters for projections in software packages 
such as UNAIDS spectrum package (91,92). Understanding engagement in 
care for HIV-positive pregnant women who are often asymptomatic will also 
help to understand engagement in care for patients initiated under “treat all” 
initiatives which provide ART to HIV-positive individuals, irrespective of their 
immunological or clinical status (9,10,93–96). Furthermore, with the 
ambitious UNAIDS targets (97,98), ascertaining HIV patients’ treatment 
outcomes is important especially to accurately measure the proportion of 
people diagnosed with HIV receiving sustained ART. 
Many HIV treatment programmes in sub-Saharan Africa still rely heavily on 
paper-based registers which suffer from several problems including 
incompleteness, cumbersomeness that results from increasing patient 
numbers and length of patient follow-up, and a lack of unique identifiers (99–
101). The lack of unique identifiers in most programmes makes it impossible 
to link all pertinent patient data together especially for pregnant women who 
may attend a separate clinic for ANC and for HIV care and treatment. The lack 
of linkages between clinics also means that “silent transfers” (whereby patients 
change clinics informally, without accompanying documentation), are often 
missed (15,99,102). Furthermore, despite facing serious health challenges, 
many of these programmes lack high-quality data required to monitor and 
mitigate these challenges.   
Long-term community cohorts (20) provide an opportunity to investigate the 
uptake and impact of Option B+ at a population level. These community 
cohorts collect demographic, behavioural and health information regularly 
and have unique identifiers for each individual. Agincourt Health and 
Demographic Surveillance System (HDSS) in South Africa, run since 1992 by 
the MRC/WITS Rural Public Health and Health Transitions Research Unit 
under the University of Witwatersrand is one of these community cohorts(20). 
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In 2014, Agincourt HDSS also started an innovative procedure known as 
Point-of-contact interactive record linkage (PIRL) linking demographic and 
clinical data from nearby clinics (103,104). Given that most previous Option 
B+ retention studies have been conducted as clinical cohorts, this linkage of 
multiple data sources allows for the utilisation of data not captured at the clinic 
level such as socioeconomic status, changes in residence and marital status. 
Agincourt HDSS also conducts verbal autopsies (VA) which seek to ascertain 
probable causes of death for HDSS residents through a structured interview 
conducted with people closely related to or who took care of the deceased and 
can report on symptoms (105,106). With the availability of VA data, causes of 
death for all patients found to have passed away can give an indication of 
predominant causes of death in mothers LTFU. Such an endeavour will allow 
for accurate estimation of Option B+ coverage rates, undocumented transfers 
between clinics, deaths, outcome misclassifications and genuine ART 
discontinuation. It would also allow us to understand at which specific steps 
in the cascade most mothers are LTFU and thereby identify interventions to 
mitigate these leakages. 
South Africa is one of the priority countries identified by UN Global Plan 
towards the elimination of new HIV infections among children. In 2019 South 
Africa had the highest number of HIV-positive pregnant women among the 21 
priority countries (an estimated 310,000) (24) and had the second highest 
number of children acquiring HIV through vertical transmission in 2014, an 
estimated 29,100 (107). Whereas UNAIDS figures indicate that >95% of HIV-
positive pregnant women received ART in South Africa in 2017, studies from 
the country have shown that attrition rates following ART initiation vary in 
this setting (43,102,108,109). Compared to other SSA countries, South Africa 
had higher ARV prophylaxis and ART coverage rates and lower vertical 
transmission rates with regards to Option A, likely due to a well-resourced 
healthcare system (110). However, they were late in implementing Option B+. 
This well-resourced healthcare system offers some advantages for research 
into engagement with Option B+ services, most especially a well-established 
electronic HIV patient monitoring system called TIER.Net.  
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Global HIV/AIDS programmes and organisations including UNAIDS and 
WHO use routine data from national treatment programmes such as those 
produced by TIER.Net to measure progress and plan future targets. As a result, 
any biases in data from routine data systems have the potential to mislead 
national and international programmes and may lead to investment in the 
wrong areas. Coverage may be mis-estimated due to uncertainty in national 
estimates. Uncertainty arises because of (i) uncertainty around true outcomes 
following LTFU, (ii) human error in recording data into the system. This is 
discussed further in paper C. UNAIDS has called for improvements to 
collection and use of routine data in order to inform policy, planning and 
programming with the ultimate goal of improving health outcomes for HIV-
positive patients including pregnant women and their infants (111). An 
evaluation of TIER.Net would therefore help to understand its biases and 
improve estimates generated from data obtained from it.    
The aim of the quantitative analyses presented in this thesis is to describe HIV 
patient outcomes after they become lost to follow-up and to compare the 
outcomes of women who initiated treatment while pregnant (under Option 
B+) to those of the general population, more specifically non-pregnant women 
and men aged 18 years or older. Men in sub-Saharan Africa have been 
identified as a priority population, as several studies have shown them to be 
lagging behind women in many treatment indicators including timely ART 
initiation, and retention in care (112,113). As late presenters, they represent 
the proportion of the population that seek care later in the progression of HIV 
and give an indication of how effective treatment programmes may be for 
people who initiate treatment late.  These analyses include in-depth 
investigations of mortality, re-engagement in care and transfers to other 
facilities. A second aim of the quantitative analyses is to evaluate TIER.Net in 
order to improve estimates generated from this system for planning and 
modelling purposes. Finally, qualitative methods aim to explore the 
intersection between EID and engagement in care further exploring factors 
that may influence women’s decision to remain engaged in care. The mixed 
method approach used in this thesis will allow for a nuanced exploration of 
engagement in care and will help to provide recommendations for improving 
HIV services in this rural community, in South Africa and comparable settings.   
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1.6. Aims and objectives 
The overall aim of this PhD research is to investigate HIV-positive women’s 
treatment outcomes after loss to follow-up following uptake of PMTCT 
services and compare their outcomes to the general treatment cohort of HIV-
positive patients in a rural community in north-eastern South Africa 
(Agincourt HDSS), in order to inform strategies to improve retention in the 
PMTCT programme.  
The objectives are as follows: 
1. To investigate loss to follow-up among patients who initiated ART 
under Option B+ with the following specific objectives 
a. To understand the outcomes of these patients after they become 
LTFU in South Africa (Agincourt HDSS) 
b. To compare their outcomes to the general HIV patient treatment 
cohort 
c. To explore factors associated with different outcomes following 
loss to follow-up 
2. To critique data sources and methods typically used to investigate 
retention in care following uptake of PMTCT services  
a. To critique routine tracing procedures and methods used to 
investigate attrition from HIV treatment in primary health care 
in rural South Africa (Agincourt HDSS) 
b. To investigate discrepancies and biases in the official HIV-
patient treatment statistics on retention rates, LTFU and 
mortality produced by TIER.Net, the South African HIV-patient 
electronic monitoring system. 
3. To explore the link between maternal engagement in care and early 
infant diagnosis of HIV 
4. To identify and recommend strategies to improve retention in 






Table 1.1: Research objectives with methods to address each 
objective 
RESEARCH OBJECTIVE METHODS AND DATA SOURCES 
To understand the outcomes of these 
patients after they become LTFU in 
South Africa (Agincourt) 
A review of published literature 
 
A quantitative analysis of the outcomes of 
patients after they become LTFU using the 
PIRL dataset and record review and tracing 
data (Paper A) 
To compare their outcomes to the 
general HIV patient treatment cohort 
A spatial analysis of mobility and clinic 
switching after patients become LTFU 
using the PIRL dataset and record review 
and tracing data (Paper B) 
 
A quantitative analysis of the outcomes of 
patients after they become LTFU using the 
PIRL dataset and record review and tracing 
data (Paper A) 
To explore factors associated with 
different outcomes following loss to 
follow-up 
A quantitative analysis of factors associated 
with mortality after patients become LTFU 
using the PIRL dataset and record review 
and tracing data (Paper A) 
 
A quantitative analysis of factors associated 
with transfer to another facility after 
patients become LTFU using the PIRL 
dataset and record review and tracing data 
(Paper B) 
To critique routine tracing 
procedures and methods used to 
investigate attrition from HIV 
treatment in South Africa (Agincourt) 
A critical assessment of the challenges with 
tracing patients who are late for clinic 
appointments in rural South Africa (Paper 
E) 
 
Reflections, observations and informal 
discussions with local stake holders 
including healthcare workers and local 
researchers 
To investigate discrepancies and 
biases in the official HIV-patient 
treatment statistics on retention 
A quantitative analysis on misreporting of 
patient outcomes in the South African 
national treatment database, TIER.Net 
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rates, LTFU and mortality produced 
by TIER.Net the South African HIV-
patient electronic monitoring system  
using the PIRL dataset and record review 
and tracing data (Paper C) 
To explore the link between maternal 
engagement in care and early infant 
diagnosis of HIV 
A qualitative exploration of the intersection 
between women’s experience of early infant 
diagnosis and their engagement in care 
using IDIs (Paper D) 
To identify and recommend 
strategies to improve retention in 
PMTCT services  
A review of published literature 
 
A critical assessment of the challenges with 
tracing patients who are late for clinic 
appointments in rural South Africa (Paper 
E) 
 
Discussions with local stakeholders 
 
1.7. Research setting 
This PhD research took place in the Agincourt HDSS, a rural north-eastern 
area of South Africa located in the Bushbuckridge local municipality in 
Mpumalanga province. The study site is run under the MRC/Wits Rural Public 
Health and Health Transitions Research Unit, administrated by the School of 
Public Health at the University of Witwatersrand (WITS) and has been 
tracking demographic and health events in xiTsonga or Shangaan people since 
1992 being the longest running community cohort study in South Africa and 
one of the oldest in Africa as a whole. The Agincourt HDSS study area covers 
475 km2 and the primary healthcare system is organised into three community 
health centres, five clinics, and three hospitals 25-60km away from the study 
site. As of 2014, the population was approximately 115,000 people living in 
17,000 households spread over 30 villages (20). Agincourt is part of multiple 
global research networks including the INDEPTH network, Analysing 
Longitudinal Population-based HIV/AIDS data on Africa (ALPHA) network 
and the South African Population Research Infrastructure Network (SAPRIN).   
In parallel to demographic surveillance, a key element of the data 
infrastructure for this research consists of HIV patient visit logs collected by a 
study fieldworker in the health facilities that provide ART in the area. This 
work started in April 2014 at seven government facilities and was extended in 
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2015 to include one additional health facility. In addition to logging patient 
visits, these records are linked to the Agincourt HDSS using a procedure 
known as Point-of-Contact Interactive Record Linkage (PIRL) (103,104). In 
brief, a fieldworker conducts a short uptake interview with patients in the 
waiting area of the clinic. Patients who consent are asked to declare a few 
personal identifiers that are used to search a local copy of the Agincourt HDSS 
database using a probabilistic algorithm. Matches are confirmed during 
interactions with the patients, and the names of other household members are 
used as a key attribute to adjudicate between possible matches (114). 
Every HIV-positive patient in the eight health facilities included in record 
linkage has a clinical file that is updated at each clinic visit. Following the 
clinical visit, information from the patient file is entered into an electronic 
database called TIER.Net (National HIV patients’ medical records electronic 
database). Two non-profit organisations (Home-Based Carers (HBC) and 
Right-to-care (RtC)) lead tracing activities in the region. RtC has provided 
tracing and technical assistance in the area since 2010.  
Further details of record linkage, health facilities, study population and 
Agincourt research activities are provided in chapter 3. 
1.8. Data sources 
Data for this thesis were drawn from four sources (both primary and 
secondary): (i) an observational cohort study of PLHIV which involved a 
comprehensive record review and tracing to ascertain their treatment and vital 
status following reported disengagement from HIV services at eight facilities 
located in the Agincourt HDSS, (ii) secondary data routinely collected at the 
eight health facilities for all patients receiving HIV care and treatment, (iii) 
secondary data generated through annual demographic surveillance surveys 
in the Agincourt HDSS, and (iv) IDIs conducted with a sample of patients who 
had ever received care from any of the eight facilities in the Agincourt HDSS. 
1.8.1. Record review and tracing study 
All HIV-positive adults (18 years or older) who had declared residence in the 
Agincourt HDSS during record linkage and who had enrolled in HIV care since 
2014 were eligible for the study. Using the PIRL database, patients who met 
the criteria for LTFU (>90 days late for a scheduled appointment) were 
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identified. The current status of these patients was ascertained through a 
comprehensive record review that involved querying all available data sources 
in the clinics including (i) TIER.Net (the national electronic patient 
monitoring system) (ii) patient clinic files (iii) logbooks kept by all actors 
responsible for routine tracing. This was followed by a review of the PIRL 
database for duplicate patients (the same individual linked to multiple clinic 
records which probably indicated silent transfers) and a review of residency 
and vital status from the demographic surveillance data in the Agincourt 
HDSS database. A list of patients who did not have a final outcome following 
this process was handed over to the clinics for supplementary tracing through 
HBC.   
These data sources are described in more detail in chapter 3. 
1.9. Structure of the thesis 
This thesis is presented in research paper style, including five published, in 
press, or submitted (and under review) publications in peer-reviewed journals 
(A-E), and four additional chapters including this introductory chapter.  
Chapter 2 is the literature review and gives an in-depth account of the global 
interventions to curtail vertical transmission of HIV which culminated in the 
introduction of “Option B+”. This chapter also collates information from 
published literature on the issues that have plagued the implementation of 
“Option B+” including poor retention in care and low uptake of early infant 
diagnosis. The chapter concludes by synthesising published knowledge on loss 
to follow-up, providing data on patient outcomes like mortality. This chapter 
serves as the launching pad for the investigation of engagement in care, loss to 
follow-up, and early infant diagnosis that follow in the results chapters.  
Chapter 3 is the methodology chapter and provides details of the study setting, 
including local health facilities, as well as Agincourt HDSS activities. It also 
presents the methods used for quantitative analyses, including fieldwork 
undertaken to prepare databases and detailed statistical analysis methods 
used to analyse the data generated. The chapter concludes with an overview of 
the qualitative research methods and also provides full details of the 
qualitative fieldwork and all the analyses conducted on the data generated 
through this route.  
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Chapters 4, 5 and 6 present the results of quantitative analyses using linked 
demographic surveillance and clinic datasets. Chapter 4 is the first research 
paper (paper A), published in the Journal of Acquired Immune Deficiency 
Syndrome (JAIDS), describing the true outcomes for patients who had been 
reported as LTFU from eight health facilities in the Agincourt HDSS. The 
paper compares outcomes for “Option B+” women to the general HIV patient 
treatment population in order to identify any differences. The paper also 
identifies factors associated with mortality following loss to follow-up. Chapter 
5 is a research paper (Paper B) submitted to the Journal of AIDS Care and 
currently under review. This paper describes health facility transfers and 
mobility for patients reported as LTFU at the facility at which they initiated 
ART. Chapter 6 is a research paper (Paper C) published in Frontiers in Public 
Health, assessing the discrepancies and biases that would arise from relying 
solely on patient outcomes reported in TIER.Net compared to utilising 
outcomes ascertained through multiple data sources from the record review 
and supplementary tracing process.  
Chapter 7 is a research paper (Paper D) presenting the findings from the 
exploration of the data generated through the qualitative fieldwork. This paper 
published in the Journal of Global Public Health, explores the relationship 
between pregnant and postpartum women’s engagement in care and their 
experiences of early infant diagnosis of HIV and how these processes interact 
to either undermine or support each other. 
Chapter 8 is a research paper (Paper E) published in Global Health Action 
(GHA), describing the challenges observed with routine tracing in the health 
facilities that serve the Agincourt HDSS.  
The thesis concludes with a discussion (chapter 9) of overall findings drawing 
from each of the results papers, recommendations and areas of future 
research, as well as the strengths and limitations of the PhD research.  
The appendix includes all the study tools, and other disseminated work, 
including posters and slides presented at international conferences. 
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Table 1.2: List of papers with their objectives and data sources 
 PAPER TITLE SPECIFIC OBJECTIVES OF THE PAPER 

















A Outcomes after being lost to follow-up differ 
for pregnant and postpartum women when 
compared to the general HIV treatment 
population in rural South Africa (115). 
To describe and measure outcomes for pregnant 
and postpartum women following loss to follow-
up and compare these outcomes to the general 
HIV treatment population. 
   
 
B Getting on with their lives: Understanding 
clinic transfers among HIV patients considered 
lost to follow-up in rural South Africa. 
To investigate and describe health facility 
mobility of residents of the HDSS who initiated 
ART and who were recorded as LTFU.    
 
C Misreporting of patient outcomes in the South 
African national HIV treatment database: 
Consequences for programme planning, 
monitoring, and evaluation (116). 
To assess misreporting in TIER.Net and 
potential biases in the national programme 
statistics reported from the TIER.Net database.    
 
D “If the results are negative, they motivate us.” 
Experiences of early infant diagnosis of HIV 
and engagement in Option B+ (117). 
To explore the nature of engagement in care for 
“Option B+” women and its relationship with 
experiences of early infant diagnosis of HIV. 
   
 
E Challenges with tracing patients on 
antiretroviral therapy who are late for clinic 
appointments in rural South Africa and 
recommendations for future practice (118). 
To elicit challenges in the implementation of 
HIV patient tracing as described in the national 







1.10. Role of the candidate 
1.10.1. Overall design and planning 
I led the overall conceptualisation of this research. As this research was not 
part of an existing study, I submitted a funding application for my proposed 
topic to the Economic and Social Research Council (ESRC). This included 
writing the research protocol for the funding application. I was also 
responsible for framing of the objectives and research questions and the design 
of the record review and tracing study, which is the primary source of data 
used in this research. I received academic support and feedback during this 
process from my supervisors Alison Wringe (AW) and Georges Reniers (GR). 
Technical support in the field and advice on the local setting was given by 
Francesc Xavier Gomez-Olive (FXGO) and Chodziwadziwa Kabudula (CK). I 
also designed the qualitative research component of my research with input 
from AW and Jenny Renju (JR). I prepared all ethics applications associated 
with my research project.  
1.10.2. Quantitative data collection and analysis 
My quantitative work in this thesis utilises secondary data generated through 
annual demographic surveillance surveys in Agincourt HDSS. I was not 
responsible for the design or management of these surveys.  
For the comprehensive record review process of my fieldwork, I selected 
fieldworkers in collaboration with the human resources manager in Agincourt. 
I trained the chosen fieldworkers and designed the data entry tool in Microsoft 
Access (Appendix 11.3.1) to capture the data from the clinics. Data collected in 
this process included routine clinic data in patient files, data on TIER.Net and 
data captured in tracing logbooks kept by RtC and HBC. I spent a total of six 
months in Agincourt supervising fieldworkers and collecting some of this data 
myself. 
I worked in collaboration with one fieldworker, FXGO, HBC and clinical staff 
to conduct the supplementary tracing for patients who did not have a final 
outcome following record review. Further details on this and the record review 
are discussed in chapter 3. 
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I merged, cleaned and prepared the final database for analysis. I designed and 
carried out all the analyses with guidance from my supervisors, my advisory 
committee and other collaborators on my papers.  
1.10.3. Qualitative data collection and analysis 
For the qualitative component of this PhD, I designed the data collection tools, 
wrote the study protocols and constructed the sampling frame using secondary 
datasets. I worked closely with AW and FXGO in this process. I selected 
fieldworkers in collaboration with the human resources manager in Agincourt. 
I spent one month in Agincourt on the qualitative component. During this 
time, I trained the fieldworkers with remote assistance from JR and AW. I 
drove the fieldworkers to their interviews, supervised fieldwork activities and 
held debriefing discussions.   
I conceived the idea for the qualitative paper presented in this thesis and 
performed the analyses. JR double-coded a portion of transcripts and AW and 
Shona Horter (SH) gave guidance on qualitative analysis methods.  
 
1.10.4. Post-graduate diploma 
As part of the four-year ESRC studentship, I was expected to complete the 
equivalent of 120 credit hours within my registered department. I took the 
following modules offered at the London School of Hygiene and Tropical 
Medicine (LSHTM): Demographic Methods, Population Studies, Population 
Dynamics and Projections, Analysing Survey and Population Data, Analysis of 
Hierarchical and other Dependent Data, Principals of Social Research, 
Generalised Linear Models, Modelling and Dynamics of infectious diseases, 
and Advanced Statistical Modelling. 
1.10.5. Dissemination 
I wrote all the papers and additional chapters which are presented in this PhD, 
incorporating feedback from co-authors and peer-reviewers for the published 
collaborative papers. I attended international conferences for poster and oral 
presentations of findings from my research and will also disseminate the 
findings locally (conference posters are included in Appendix 11.1 and 
dissemination efforts are discussed further in chapter 9).   
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1.11. Ethical clearance 
Ethical approval for the research in this thesis was granted by the London 
School of Hygiene and Tropical Medicine (Ref: 14296, Appendix 11.2.2), the 
University of Witwatersrand human research ethics committee (Clearance 
certificate number M170850, Appendix 11.2.2) and the Mpumalanga 
Department of health research committee (Ref: MP_MP_201709_12, 
Appendix 11.2.2). Informed written consent to record, analyse and 
disseminate information from interviews was obtained from each participant 
(Appendix 11.3.2 and Appendix 11.3.3).  
1.12. Funding 
I was awarded a four year Economic and Social Research Council (ESRC) 
studentship that covered all my research degree fees. The studentship was 
supplemented by an Advanced Quantitative Methods (AQM) stipend to 
encourage further training in AQM to be used in this research and beyond. The 
studentship also provided an annual stipend and covered all expenses for 
travel, accommodation, and sustenance at conferences through the Research 
Training Support Grant. The ESRC studentship also granted a one-time 
fieldwork travel grant through its Overseas Fieldwork grant which covered my 
first field visit. The majority of my fieldwork costs were covered by a Bill and 
Melinda Gates foundation grant to the Measurement and Surveillance of HIV 
Epidemics (MeSH) consortium (grant number: OPP1120138).  Other costs 
were covered by a Medical Research Council (MRC) grant to the Strengthening 
Health systems for the Application of Policy to Enable Universal Test and Treat 
(SHAPE-UTT) study (grant number: MR/P014313/1) and a UNAIDS/BMF 
grant to the ALPHA network (grant number: OPP1164897). The ongoing 
Agincourt HDSS activities are supported by University of Witwatersrand, 
South African Medical Research Council (SAMRC), and Wellcome Trust 





2. Literature review 
 
2.1. Overview 
This literature review starts with a brief history of vertical transmission of HIV 
and its prevention both worldwide and specifically in sub-Saharan Africa, 
showing the great strides that have been made in the PMTCT and identifying 
paradigm shifts that helped to make this possible.  
The review then summarises the published literature on engagement in HIV 
care for pregnant and post-partum women on ART, giving an overview of the 
evidence on maternal engagement, proposing key frameworks to consider 
when investigating maternal engagement in care, identifying barriers and 
facilitators of engagement, and reporting on outcomes among patients who are 
lost to follow-up.  
This chapter also considers the multiple data sources and methods that have 
been used to measure engagement in care in Option B+ programmes, looking 
specifically at measures of adherence and retention in sub-Saharan African 
settings.  
2.1.1. Search strategy 
This review was undertaken by searching PubMed for literature on PMTCT, 
adherence or retention under Option B+ in sub-Saharan Africa, and outcomes 
after becoming lost to follow-up. It is not intended to be an exhaustive or 
systematic review but rather to present key aspects of published literature that 
are important to understand engagement in care under Option B+.  
Nine key concepts were identified as important to the literature review and key 








Table 2.1: Key concepts and key terms used for the literature 
Key concept Key terms 
HIV/AIDS Human immunodeficiency virus, 
Acquired Immune Deficiency 
Syndrome, Opportunistic infection*, 
WHO stage, Viral*, OIs, Disease*, 
HIV*, AIDS*, Virus* 
Prevention Prevent*, Treat*, Medic*, Control*, 
Eliminat*, Treatment as prevention, 
Tasp 
Transmission Transmiss*, Infect*, vertic* 
ART Antiretroviral*, ARV*, Highly 
active*, ART, HAART, AZT, 
Zidovudine, Nevirapine, Retrovir*, 
NVP 
Infants Child*, Baby, Birth*, New-born, 
Fetal*, Perinatal*, Premature*, 
Infant*, Early infant diagnosis, EID, 
DNA*, PCR, Polymerase chain 
reaction, Replacement fe*, Mixed 
fe*, Paediatric*, Pediatric* 
Mothers Maternal*, Wom*, Parent*, 
Female*, Patient*, Pregnancy*, 
Prenatal*, Antenatal*, ANC*, 
Adult*, Mother*, Breast* 
Mortality Mortalit*, LTFU, Loss*, Dea*, 
Fatal*, Retention*, Retain*, RIC*, 
default*, engage*, disengage* 
PMTCT Option*, PMTCT*, B+ 
Limited resource settings Poor, Sub-Saharan*, Africa*, 





The search was first conducted in November 2016 using different query 
combinations (Table 2.2). The inclusion of the limited resource setting concept 
produced no results and so this was removed from all the queries.   
Table 2.2: Key term combinations used in the literature review 
Number Key concept combinations 
1 HIV AND Prevention AND ART AND infant AND mother AND PMTCT 
2 HIV AND Prevention AND Transmission AND ART AND infant AND 
mother AND PMTCT 
3 HIV AND Prevention AND Transmission AND Mortality AND ART 
AND infant AND mother AND PMTCT 
4 HIV AND [Prevention OR Transmission OR Mortality] AND ART AND 
[infant OR mother] AND PMTCT 
5 [HIV OR ART] AND [Prevention OR Transmission OR Mortality] AND 
[infant OR mother] AND PMTCT 
6 HIV AND [Prevention OR Transmission OR Mortality] AND [infant OR 
mother] AND [PMTCT OR ART] 
  
Using combinations 1, 2, and 4, I identified 353 articles that warranted further 
investigation. Each article’s abstract was individually reviewed with 85 articles 
chosen for full review. The reference lists of these 85 articles were also 
searched for any other pertinent publications.  




[[LTFU]OR ["loss to follow up"]OR["loss to follow-up"]OR["lost from 
treatment"]]AND[[HIV]OR[AIDS]OR[ART]] 
["prevention of mother to child transmission" OR [PMTCT]] 
These alerts were reviewed until November 2019 with pertinent papers 
reviewed and their reference lists checked for any further publications of 
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interest.  This exercise identified a further 435 articles for review with 105 
identified as relevant to this literature review.  
Finally, I conducted a PubMed search in July 2020 using the following key 
terms and restricted to articles published within the last two and a half years.  
(((((((Human immunodeficiency virus OR Acquired immune deficiency 
Syndrome OR Opportunistic infection* OR WHO stage OR Viral* OR OI* OR 
Disease* OR HIV* OR AIDS* OR Virus*)) AND ((Prevent* OR Treat* OR 
Medic* OR Control* OR Eliminat* OR Treatment as prevention OR Tasp))) 
AND ((Antiretroviral* OR ARV* OR Highly active* OR ART OR HAART OR 
AZT OR Zidovudine OR Nevirapine OR Retrovir* OR NVP))) AND ((Child* 
OR Baby OR Birth* OR New born OR Fetal* OR Foetal* OR Perinatal* OR 
Premature* OR Infant* Early infant diagnosis OR EID OR DNA* OR PCR OR 
Polymerase chain reaction OR Replacement f* OR Mixed f*))) AND 
((Maternal* OR Wom* OR Parent* OR Female* OR Patient* OR Pregnancy* 
OR Prenatal* OR Antenatal* OR ANC* OR Adult* OR Mother* OR Breast*))) 
AND ((Option* OR PMTCT* OR B+ OR B plus))) AND ((Mortalit* OR LTFU 
OR Loss* OR Dea* OR Fatal* Retention* OR Retain* OR RIC* OR engage* 
OR dis-engage* OR default*)) 
This search yielded 250 further manuscripts to review with 79 ultimately 
chosen as pertinent to this literature review. The titles of these 79 articles were 
reviewed and 16 were chosen for perusal with their reference lists also checked.  
2.2. Prevention of mother-to-child transmission of HIV  
2.2.1. A brief history of PMTCT efforts worldwide 
Following the identification of the etiologic agent of Acquired Immune 
Deficiency Syndrome (AIDS) in 1983, many researchers proposed the 
possibility of perinatal transmission, as had been seen with other sexually 
transmitted infections (STIs). In 1984, Scott et al described AIDS in infants, 
finding that only one of fourteen infants had received a blood transfusion 
before development of clinical symptoms (119). As early as 1985, the Centres 
for Disease Control and Prevention (CDC) published their recommendations 
for assisting in the prevention of perinatal transmission of human T-
lymphotropic virus type III (HTLV-III)/lymphadenopathy-associated virus 
(LAV) – both early names of what would come to be known as human 
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immunodeficiency virus (HIV) – in their morbidity and mortality weekly 
report (120). They reported that 76% of cases of AIDS in children under 13 
years of age reported as of 1 December, 1985 in the United States (US) had as 
the only risk factor a mother from a high-risk group – defined as intravenous 
drug users, female sex workers, women born in countries with high rates of 
heterosexual transmission, and sexual partners of men in high-risk groups 
which also included men who have sex with men (MSM). Even at this early 
stage, it was known that perinatal transmission was not automatic and was 
estimated at anywhere between 0–65% (120). There was concern over the 
increased risk of progression to full-blown AIDS from this transmission route 
(120).  
The CDC’s recommendations included: targeted counselling and testing for 
antibodies to HIV for pregnant women or those who may become pregnant 
who already had evidence of HIV infection, or who were intravenous drug 
users, women born in countries where there is a high rate of heterosexual 
transmission of HIV, female sex workers, or the sexual partners of men in 
high-risk groups (120). They suggested that such counselling and testing be 
made available through the settings that women at increased risk frequented, 
including drug abuse treatment programmes and clinics for sexually 
transmitted diseases. Other recommendations were (i) that infected women be 
advised to delay pregnancy until more was known about the perinatal 
transmission of HIV, (ii) pregnant infected women be closely monitored for 
the development of opportunistic infections as well as psychosocial difficulties, 
and (iii) that men who were infected with HIV also be counselled about risks 
of perinatal transmission (120). Programmes for the prevention of mother-to-
child transmission of HIV evolved from these recommendations.  
In 1986, Ando et al published findings that suggested that transmission of 
HTLV-I – a related virus with similar transmission dynamics – through 
breastmilk, could be mitigated by a freeze-thawing process (121). With the 
recognition that women and children were the fastest growing demographic of 
AIDS cases and new HIV infections (122,123), there was a growing need for 
acceleration of PMTCT endeavours. Most early interventions were 
concentrated on behaviour change (122), directed towards limiting pregnancy 
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among women living with HIV (WLHIV) and the prevention of infection of 
women of childbearing age (124).  
In 1985, scientists found that Zidovudine (Azidothymidine) (AZT) had potent 
efficacy against HIV in vitro (125), and following human clinical trials, 
received US Food and Drug Administration (FDA) approval for use against 
HIV and AIDS on March 20, 1987 (126). It took 25 months between the first 
demonstration that AZT was active against HIV in the laboratory and its 
approval, the shortest period of drug development, at the time (127). AZT was 
subsequently approved for use in infant and child treatment in 1990 (126,127). 
In 1994, CDC published preliminary findings from a randomized, multicentre, 
double-blinded clinical trial of AZT to prevent HIV transmission from mothers 
to their infants (AIDS Clinical Trials Group [ACTG] protocol 076), the first 
trial of its kind and the first proof of pre-exposure prophylaxis (128,129). With 
the rapidly changing antiretroviral drug (ARV) landscape, other PMTCT trials 
soon followed. The ACTG established nine Nevirapine (NVP) sites (ACTG 250) 
in the US and Puerto Rico in 1995 (130). Following the introduction of highly 
active antiretroviral therapy (HAART) in 1996 after seminal work presented at 
the 11th International Conference on AIDS in Vancouver, British Columbia 
(131–133), there was an exponential growth in number of ARV trials and 
subsequently the number of available ARVs effective against HIV.  
Over the past decade, significant progress has been made in PMTCT in sub-
Saharan Africa. The first attempts to prevent vertical transmission in sub-
Saharan Africa were randomised control trials to determine the effect of 
perinatal vaginal lavage on HIV transmission (134), shown to be an ineffective 
public health measure (134–136). These were followed by trials on vitamin 
supplements for prevention of vertical transmission (137,138) and 
presumptive treatment of STIs during pregnancy (139) which also proved 
futile. There were also multiple randomised control trials of antiretroviral 
drugs in the prevention of mother-to-child transmission of HIV-1 in 
breastfeeding mothers in Africa with a myriad of intervention arms (140–147). 
These showed some promise with long term efficacy ranging from 7% to 66%.  
In 2001, the WHO published its first recommendations on the use of ART for 
PMTCT (8) and it has since been promoted as a method of curtailing the HIV 
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epidemic. The first recommendations concluded that all regimens that had 
been shown to be effective in controlled clinical trials be recommended for use 
in these settings. These regimens include AZT alone, AZT plus lamivudine 
(3TC), and NVP alone. It was agreed that there was no longer any justification 
to limit these measures to research and pilot project settings (8).  
In 2001, the United Nations General Assembly Special Session (UNGASS) on 
HIV/AIDS identified PMTCT as a priority need (148). One of the specific goals 
set for programmes was a 20% reduction in the proportion of infants infected 
with HIV by 2005 and a 50% reduction by 2010 (148). This gave many 
HIV/AIDS prevention programmes the impetus they needed to advocate for 
better PMTCT services. For example, in 2002, the South African high court 
ordered the government to make NVP available for PMTCT following legal 
action by the Treatment Action Campaign (TAC) (149). Whereas all the trials 
showed encouraging results, a major concern with the use of ARVs for PMTCT 
was the development of viral resistance (8,150) and loss of future ART 
regimens (151,152), with most of the ARV drugs used early on, particularly 
NVP, having a very low genetic barrier (153,154). Following mounting 
evidence on viral resistance for single drug prophylaxis (155,156) use of ARV 
drug combinations for PMTCT became commonplace (157,158). Dabis later 
proposed that the role of HAART in PMTCT be scientifically assessed (157) as 
NVP and AZT had little effect in prevention of transmission from mothers with 
advanced HIV infection (145,147).  
Whereas many of the most developed countries (MDCs) had virtually 
eliminated perinatal HIV transmission by 2010, or were well on their way to 
its elimination (159), the least developed countries (LDCs) were lagging 
behind due to a number of factors including inequity in access to ART (160). 
From very early on in the HIV epidemic, sub-Saharan Africa had the fastest 
growing epidemic (161–163). Transmission by blood transfusions, 
contaminated injections and from mother to child was occurring more 
frequently than in Europe (164). Piot suggested that AIDS would probably 
have a profound impact on health care programmes and economic 
development in the continent – something that has since come to pass – and 
that its control should be a public health priority (164). Some aid agencies like 
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Médecins Sans Frontières (MSF) had implemented pilot ART programmes, 
providing free treatment since 2001 (165,166). In 2003, several countries in 
SSA established national ART programmes (166), drawing impetus from the 
WHO/UNAIDS “3 by 5” initiative launched on World AIDS Day in 2003 to 
provide three million people living with HIV/AIDS in low- and middle-income 
countries with life-prolonging ART by the end of 2005 (167). This was 
principally due to the global AIDS advocacy movement and following the 
establishment of ambitious programmes funded by newly established donors 
such as the Global Fund to fight AIDS, Tuberculosis and Malaria (166) and the 
U.S. President's Emergency Plan for AIDS Relief (PEPFAR). It is also 
noteworthy that the FDA played an important role in making ART affordable 
to LDCs by implementing a number of policies to enable distribution of ARVs 
to developing countries at low costs, even if there was still patent or market 
exclusivity protection for the ARVs in the USA (127).  
These endeavours rapidly reduced AIDS-related mortality (2,168–174). The 
early impact of ART in sub-Saharan Africa was primarily because patients with 
more advanced disease, and most likely to die, were given priority in accessing 
treatment. This experience also showed that very sick patients could derive 
benefit from ART, even in the absence of advanced health care systems that 
were available in MDCs (127).  
In 2004, the WHO published its first recommendations for PMTCT in resource 
constrained settings (175). Starting with Option A in 2006 (176), the guidelines 
were updated to recommend Option B in 2010 (177). In 2012, WHO released 
an update which while not an official guideline was considered an 
endorsement of Option B+ (178,179) and since 2015, have officially advocated 
for Option B+ (9) where all pregnant or breastfeeding WLHIV initiate ART for 
life (180) (Figure 2.1).  
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Figure 2.1: Recommended WHO PMTCT guidelines for maternal 
and infant treatment and prophylaxis (2010) 
 
2.2.2. The advent of Option B+ in sub-Saharan Africa 
In 2010, the Malawian government developed Option B+ because the 
prevailing WHO guidelines for PMTCT were not feasible in this setting. The 
WHO guidelines were reliant on availability of a CD4 count to determine ART 
eligibility and this was not practical in Malawi as CD4 machines were not 
available in most rural areas. The programme was rolled out in July 2011 
following extensive training of health staff and quickly became the gold 
standard for PMTCT efforts globally (180–182). Also in 2011, UNAIDS 
launched a “Global plan” to reduce the number of vertical infections of HIV by 
90% (183). The plan identified 22 priority countries – 21 of which are in sub-
Saharan Africa – with the highest estimated numbers of pregnant WLHIV 
(183). These initiatives represented a paradigm shift away from just 
preventing vertical transmission, towards a more holistic goal of an HIV free 
infant and a healthy, living mother. In resource-limited settings, Option B+ 
represented an important change in messaging to patients, transitioning from 
advice to wait until they got sick or their CD4 counts were low to start 
treatment for their own health, to an immediate initiation of ART. This called 
for a massive sensitization and education campaign to help the population 
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understand this shift. This was an enormous undertaking that was not feasible 
in most settings, presenting another potential problem for Option B+ 
programmes (184).  
This new approach also represented a shift away from PMTCT goals being to 
eliminate vertical transmission to a strategy that was concerned with maternal 
health and survival (183,185,186), as well as prevention of transmission to 
uninfected partners (7,31,187,188) and PMTCT in subsequent pregnancies 
(7,36,180). It also simplified PMTCT guidelines, potentially improving access, 
feasibility, and acceptability (measured by uptake and retention) and 
generated excitement as the most promising approach to EMTCT. The 
implementation of Option B+ called for enhanced adherence support, 
increased funding, decentralisation of services as well as adoption of 
innovative service provision strategies like task-shifting of specific processes 
on the PMTCT continuum because of increased numbers of patients needing 
initiation into the programme (180,189), perhaps to a degree greater than 
current health systems could absorb (179).  
Option B+ was initially met with resistance by some national programmes 
owing to perceived increased programme costs as well as a reluctance to task-
shift ART initiation away from doctors, a prerequisite for a successful Option 
B+ programme (40,179,190). Option B+ was also met with reluctance by some 
public health practitioners because of the limited evidence on the effects of 
long-term exposure to ART in utero (31). Development of surveillance systems 
for birth defects and toxicity from ART exposure was proposed as a critical 
element of early Option B+ demonstration projects (31,178). In addition, 
questions were raised on the ethics of prioritization of healthy patients for 
early ART when there were many severely immunosuppressed patients, at 
high risk of death and in urgent need of treatment (179). The move to an ART 
eligibility threshold of a CD4 less than 500 copies/mL (177) meant that most 
pregnant women met the criteria to initiate ART. As such, PMTCT 
programmes would be expending considerable effort to find a minority of 
patients who would qualify for prophylaxis rather than ART (31), making 
Option B+ the obvious choice from an implementation perspective. Finally, 
the ethics of preferentially providing early ART to pregnant women rapidly lost 
58 
 
its relevance once the eligibility criteria were expanded to include all patients, 
following recommendations from WHO for “Treat All” which were released in 
2015 (9).  
Kenya was the next African country to implement Option B+, starting in 2011, 
although they chose a phased or piloting implementation strategy where 
specific sites employed Option B+ to determine the feasibility of this approach 
in their setting (191). It was argued that phased implementation could lead to 
mothers potentially hearing mixed messages regarding ART eligibility as other 
strategies would still exist in parallel if there was not sufficient geographic 
distance between Option B+ implementation sites and those following the 
national standard of care (184). By January 2013, 11 countries had endorsed 
Option B+ for their national PMTCT programmes with six others actively 
costing and developing operational plans to switch over (31,191).  
Option B+ was estimated to cost 2-2.5 times Option A or B over ten years in 
Malawi (192). However, it has also been shown to potentially increase 
maternal life expectancy by 1.12 years compared to Option B (31,193) and in 
general, health outcomes are much better with early treatment for individuals 
(194,195) and with Option B+ for mothers (31,192). As cost effectiveness 
analysis showed Option B+ to be a favourable policy option (192), and 
following WHO recommendation of Option B+ in its guidelines in 2015 (9) all 
sub-Saharan African countries had switched to Option B+ at the end of 2016 
(196). With the widespread adoption of “Treat All” (39), as of 2018, 74% of HIV 
positive women of childbearing age in sub-Saharan Africa were receiving ART 
further improving PMTCT (24). 
The early optimism and enthusiasm regarding Option B+ was tempered owing 
to a myriad of issues that were identified during demonstration projects and 
through routine programme data in sub-Saharan Africa (179). Principal 
among these is that several studies from sub-Saharan Africa showed that 
pregnant and postpartum women have poorer engagement in care than men 
and non-pregnant women (11,34,68,89). This forced PMTCT programmes to 
come to terms with how much financial and human resource investment 
would be needed to make this new endeavour viable and effective. 
Furthermore, much is still unknown about what happens after pregnant and 
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postpartum women’s treatment attrition and regarding the underlying 
mechanisms that drive this attrition (197). Although Option B+ is still 
recognised as the best method to achieve EMTCT, there are many 
programmatic gaps that still need to be addressed including low rates of repeat 
testing during the third trimester or during delivery for mothers who tested 
negative during the first trimester, low EID completion rates, and how to 
achieve optimum engagement in care for each patient (48,198). 
2.3. Engagement in care under Option B+ 
As mentioned previously, engagement in Option B+ has been reported as 
lower than engagement for other adults on ART (11,199). Several hypotheses 
have been postulated for this lower engagement. This section looks at the 
Option B+ cascade of care identifying periods when women may be at higher 
risk of disengagement from care, summarising retention rates and identifying 
factors that influence engagement in Option B+ using a framework proposed 
by Myer et al (48) to summarise these factors.  
2.3.1. Retention in care following ART initiation 
Most studies on retention in care in Option B+ programmes in African settings 
have reported outcomes up to 12 months on ART (11,34,35,200–203). While 
the definition of retention varied widely between these studies, they reported 
retention rates 12 months after ART initiation ranging from 42% in 
Mozambique (204) to 97% in Malawi (70). In Malawi, more encouraging was 
the fact that excluding women who transferred their care to other facilities 
(9.7%), the 12-month retention in care rate was 77% similar to the rate for 
adults in the national ART programme (36). A 2018 meta-analysis reported a 
pooled retention estimate of 76% at 12 months (11). In comparison, this rate 
was slightly lower than the 81% reported for adults 12 months after ART 
initiation in Africa prior to the roll-out of universal ART (199). Some longer-
term studies have more recently been published describing retention in care 
three to five years after ART initiation in the pregnancy and breastfeeding 
periods (34,35,202). With regards to long-term retention rates, these ranged 
from 41% in Malawi (200,201) to 77% in Ethiopia (203) after 24 months on 
ART. One study in Malawi showed that 70% of women remained retained in 
care after 3 years following ART initiation, which was similar to the adult 
treatment cohort, however, adequate adherence was below 30% (34). In 
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Uganda, it was estimated that 68% of women were retained in care 4 years 
after ART initiation (202) (Table2.3). Most study estimates were well below 
the UNAIDS second 90 target of 90% of patients who know their status being 
on ART (97). As such, questions still remain regarding the factors driving long-
term retention in care given that mothers are initiating ART while still 
asymptomatic and often times before they have had time to digest the news of 
their HIV diagnosis. 
2.3.2. The Option B+ treatment cascade and points of high risk 
of disengagement 
The HIV treatment cascade was first depicted in early PMTCT studies to 
describe the various steps in preventing vertical transmission (205–207) and 
has since been expanded to include other facets of HIV treatment most notably 
the challenge of loss to follow-up from treatment programmes (208–213) and 
the uptake of viral load testing (76). The cascade is usually used to depict the 
proportion of patients lost or not reached at each step, giving an easily 
understandable summary of the magnitude of attrition at each step and 
potentially where interventions are needed to improve engagement. For an 
Option B+ programme, understanding the levels of attrition at each stage of 
the cascade is particularly pertinent as mothers not on treatment are more 
likely to transmit HIV to their infants if this attrition happens at any point 
before breastfeeding cessation (214).  
The stages of the cascade vary with different studies. However, the Option B+ 
cascade is often depicted as having five steps: at least one antenatal care visit; 
offer, acceptance, and reception of HIV testing and results; maternal 
antiretroviral therapy (ART) initiation and adherence; infant ART initiation 




Figure 2.2: The Option B+ treatment cascade 
 
Certain steps in the cascade can be expanded or contracted and increasingly, 
more steps are being added to the cascade that deal with infants and their 
outcomes. For the purpose of this review, I will use a slightly altered cascade 
to better illustrate which parts of the cascade this review concentrates on 
(Figure 2.3).  




The pregnancy and postpartum periods are times of change regardless of HIV-
status, especially for first-time mothers. The transition through pregnancy and 
into motherhood comes with multiple personal milestones and unique 
pressures which may be exacerbated by an HIV diagnosis. Women must 
navigate maternal and child health clinics in addition to HIV clinics as well as 
the economic, social, psychological, and physiological changes that women 
undergo during the pre- and postnatal period (215–217).   
The prenatal period 
 
HIV testing 
The circumstances under which most pregnant women discover their HIV 
status differs from the general population. Pregnant women are encouraged to 
attend ANC clinics, the entry point into most PMTCT programmes and the first 
step in the PMTCT cascade. It is important to note that utilisation of ANC 
services is still an issue in multiple settings for many reasons including 
socioeconomic factors, lack of autonomy and agency, and long distance to 
health facilities (218–221). As part of ANC services, women are encouraged to 
test for HIV, something they may not have planned to do. Testing all pregnant 
women for HIV proved initially challenging for PMTCT programmes in sub-
Saharan Africa with 51% pregnant women being tested in 2013, showing 
heterogeneity across the continent ranging from 35% in west and central 
Africa to 74% in east and southern Africa (222).  However, most of these 
programmes are now testing more than 95% of pregnant women who attend 
ANC (26).  
During pregnancy, women may be at higher risk for HIV seroconversion 
especially in areas with high population HIV prevalence (223). As such, for 
those pregnant women that test negative, repeat testing throughout the 
vertical transmission risk period is of paramount importance to identify any 
new seroconversions. To do this, repeat testing for HIV-negative pregnant 
women is recommended in the third trimester and again in the postpartum 
period in high prevalence settings (224). However, this has been implemented 
to varying degrees of success, with some countries doing better than others 
(225). The major barriers to achieving optimal levels of repeat testing include 
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client-level barriers such as late presentation for ANC or low completion of 
recommended ANC visits. Provider-level barriers include heavy workloads, 
time limitations, and forgetting to check retest eligibility at every facility visit. 
Facility-level barriers include inconsistent volume of clients and lack of 
dedicated space for confidential HIV testing. Finally, health system barriers 
include test kit supply chain ruptures and the design of ANC patient registers 
(226). Repeat testing has been an issue for PMTCT programmes since their 
inception, but it has become more pronounced with the move to Option B+. 
ART initiation 
Once pregnant women have tested positive for HIV, current WHO 
recommendations suggest prompt initiation of ART and achievement of 
adherence to ensure virologic suppression by the time of delivery. In Malawi 
by 2012, a year into implementation of Option B+, quarterly ART initiations 
for pregnant and breastfeeding women jumped up by 748% (36). These high 
rates of uptake also reported by the Ministry of Health (227) were likely due to 
excellent sensitisation and mobilisation campaigns (184). Since then, several 
clinical cohorts of pregnant women who have tested positive for HIV have been 
followed with varying levels of ART initiation reported (11,228,229). These 
varying levels of initiation were likely due to health system barriers such as 
poor integration of ART and ANC services (230), and slow patient treatment 
preparation procedures (231,232), coupled with delayed presentation to ANC 
services (233), as well as psychosocial barriers including denial of HIV status 
and fear of disclosure (234). 
Women diagnosed during pregnancy face a triple burden of the transition into 
pregnancy, acceptance of an HIV diagnosis and the requirement to initiate 
lifelong ART as soon as possible (232). Rapid ART initiation is one reason why 
messaging often focuses on protection of the unborn child as the principle 
reason for initiating ART, which potentially introduces ART adherence 
problems postpartum (235). The need to initiate ART quickly has led to most 
PMTCT programmes advocating for same-day ART initiation provided that 
the patient seems ready to start (and do not have tuberculosis or cryptococcal 
meningitis)  which is also a WHO recommendation (236).  
64 
 
The first part of the Option B+ treatment cascade i.e. the proportion of 
expectant mothers who attend ANC, consent to HIV testing and receive their 
results and are subsequently offered and initiate ART varies for different 
Option B+ programmes in sub-Saharan Africa. For example, while >95% of 
pregnant WLHIV receive ART for PMTCT in South Africa this proportion was 
estimated at 25% in Chad (26).  
Early data from PMTCT programmes suggests that the major obstacle to 
achieving optimal PMTCT goals is not about convincing women to start but 
rather keeping them on treatment for life (36). Even with the need to protect 
their unborn child being a major motivating factor (237–240), ART initiation 
rates in PMTCT programmes vary in different settings (36,241). A first leakage 
in the PMTCT cascade is the small proportion of women who refuse treatment 
outright and women who accept treatment but never return for subsequent 
visits (11).  
ART adherence 
Following ART initiation, several studies have shown that the risk of 
disengagement from care is highest just after initiation and then reduces 
steadily the longer women remain in care (11,42). The biggest losses have been 
observed immediately after initiation with no further clinic visits following the 
ART initiation visit , with up to 46% of women never returning for another 
clinic visit following their initial ART initiation visit (11,42).   In spite of several 
barriers including coming to terms with the reality of lifelong ART, many 
studies have reported higher levels of ART adherence and viral suppression 
during pregnancy compared to the postpartum period (68,242–244). This 
might be due to several reasons, for example, the expectation of regular 
attendance of a health facility makes it easier to explain monthly clinic visits 
for ART refills and the need to take daily medication (245). 
Delivery 
Women living with HIV are encouraged to deliver their child at a health facility 
as this allows for interventions to reduce the risk of transmission at birth 
(246). New-borns are also tested for HIV and can be initiated on ART at this 
point if necessary (224). Furthermore, for infants who test negative, mothers 
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are provided with prophylaxis to further reduce the risk of transmission 
(9,177). While beyond the scope of this review, facility delivery is still a major 
hurdle in multiple settings with only 22% of deliveries occurring in a health 
facility in 29 sub-Saharan African countries with heterogeneity by region and 
socioeconomic status (247,248). 
The postnatal period 
 
ART adherence 
Some studies have reported high risk of disengagement from care in the first 
year on ART often following delivery or breastfeeding cessation (203,249–
251). In the postpartum period, changes in motivation to continue treatment 
following delivery and weaning possibly contribute to women’s disengagement 
(245,251,252).  
The success of Option B+ in the antenatal period has meant that mother-to-
child transmission of HIV is increasingly occurring through breastfeeding in 
the postpartum period (253). Provided that mothers remain adherent to ART, 
the risk of transmission through breastfeeding is negligible and is far 
outweighed by the benefits accrued from breastfeeding (253). In resource 
limited settings formula-feeding is less feasible owing to the economic burden 
this entails. Formula feeding also presents an increased risk of diarrhoeal 
diseases due to contamination (especially due to a lack of clean water sources). 
Given that diarrhoea and malnutrition are common causes of child mortality 
in these settings, the World Health Organisation (WHO) now recommends 
breastfeeding up to 24 months in low-income settings (254). 
In the postpartum period, new mothers must navigate several activities or 
practices. In addition to remaining adherent to their own treatment, mothers 
must also administer antiretroviral prophylaxis to their infant and adhere to 
infant feeding recommendations, which can be a burden (197). If the risk of 
transmission through breastfeeding is understood by the mothers, then their 
motivation to stay in care for the health of their infant might still be high 
(252,255). However, relief at a negative HIV test result for the infant may be a 
barrier to their own continued engagement in care (252,255). 
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The first 24 months of child-rearing still involve routine visits to the clinics for 
immunisation as well as early infant diagnosis. Women are assumed to have 
integrated into the adult ART population. Retention rates and reasons for 
treatment discontinuation during the period following breastfeeding cessation 
have not been well described, with most research focusing on the periods of 
pregnancy and breastfeeding. However, following delivery and breastfeeding 
cessation, women disengage from care at higher rates than the rest of the adult 
ART population (11,197). Whereas some PMTCT programmes provide 
integrated care throughout the breastfeeding period, in some settings, women 
are expected to transfer their care to an adult ART clinic (256,257) and this 
transfer may also undermine their continued engagement in care. This 
transition presents a new set of challenges. Women must find reasons other 
than the health of their infant to motivate themselves to continue adhering to 
treatment. This sometimes proves difficult given that most of them were 
asymptomatic when they initiated ART (258,259).  
In regions with high fertility, women may move between pregnancy, 
breastfeeding, and post-breastfeeding periods throughout their reproductive 
years. It is important to integrate HIV services into these periods in order to 
improve maternal health and reduce the risk of mother-to-child transmission 
both for incident and subsequent pregnancies. 
Early infant diagnosis 
The major goal of PMTCT programmes is to reduce vertical transmission, and 
the global scale-up of ART has been the primary contributor to reduction in 
vertical transmission. Therefore, EID results are an important metric for 
assessing whether PMTCT efforts are being effective. As such, it is impossible 
to evaluate this goal without first achieving high EID testing coverage 
throughout the vertical transmission risk period. Serological assays used for 
adult testing are not reliable for infants given that maternal HIV antibodies 
can persist in infants up to 18 months. Therefore, EID seeks to establish the 
presence of HIV infection in children less than 18 months old through DNA 
polymerase chain reaction (PCR) testing, and is critical to reduce infant 
morbidity and mortality through timely ART initiation for those infants that 
test positive (260–262).  
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Early on, when ART was not provided to all women for life, research found that 
infants of mothers on ART were more likely to complete EID (263), it was 
therefore hoped that universal ART would translate to higher completion rates 
of EID but this has not materialised (198). It is imperative that there be high 
coverage of EID testing up to the end of the breastfeeding period for HIV-
exposed infants (HEI), however, testing rates remain low in the countries with 
the highest HIV-burden (198).  
Most studies documenting uptake across the PMTCT cascade have been 
undertaken as cohort studies (11,228,229) of mothers without links to exposed 
infants. Many studies are implemented drawing on paper-based registers in 
which data are not consistently entered and which often lack unique identifiers 
meaning that not all available data can be utilised. Lack of links between 
mother-baby pairs also means that identifying exposed infants in child 
registers is impossible (99). 
Ninety percent of HEI should be tested by eight weeks according to the World 
Health Organisation global targets, but EID uptake in many sub-Saharan 
African countries is suboptimal, with only half of HEI in 21 priority countries 
reported to have been tested in 2015 (26,110,198,227,264). Based on national 
data, only 35.1% of infected mothers intended to access EID services in South 
Africa (110). In Malawi, only 43% of exposed infants were enrolled in follow 
up before 2 months (227).    
Retention of HEI in the postpartum period and ascertainment of HIV status at 
the end of their risk period remains a major gap for reasons including health 
system barriers that result in fragmented services for mother-baby pairs and a 
lack of focus on critical healthcare needs for HEI (265,266). Some authors 
point to concentration on the birth or 6-week EID test to the detriment of the 
rest of the risk period up to the end of breastfeeding (6-month and 18-month 
test which are just as important) as a major reason for this gap (28,264). Lack 
of knowledge regarding EID and infant ART, lack of psychosocial support, fear 
of disclosure of own and/or child's HIV status, the perception of health care 
workers as authority figures, and intent to shorten the life of the child have 
also emerged as reasons for low EID testing rates (267). One study found that 
counterintuitively longer distance from the clinic improved EID uptake but 
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might be explained by the tendency of patients to seek care further away from 
home in order to avoid being recognised at clinics in their own 
neighbourhoods and the decreased fear of social stigma by seeking care 
outside of one’s community (268). Another factor is emotional intimate 
partner violence which reduces the likelihood of EID completion (269). 
Maternal postpartum ART adherence continues to be a facilitator of high EID 
testing completion rates (268,269). 
Innovations like point-of-care EID tests (270) and use of mobile technology 
interventions like the HITSystem (271,272)  have significantly improved EID 
uptake and encouragingly, data from Zambia shows that EID completion rates 
have improved steadily between 2006 and 2016 probably due to increased 
attention and funding (273).  
However, with more than 50% of infant HIV infections happening in the 
postpartum period (198), this reflects the relatively high coverage of 
interventions in the antenatal period and the need for greater attention to 
postpartum women and their exposed infants. Especially as HIV-exposed 
uninfected infants experience a myriad of challenges including higher 
mortality (274–276). 
2.3.3. Influences on engagement in care under Option B+   
Several authors have suggested ways to conceptualise adherence and 
engagement in care for pregnant and postpartum women (48,62). The WHO 
considers five dimensions that can help conceptualise the multiple factors at 
play for patient adherence, health system factors, socioeconomic factors, 
therapy-related factors, patient-related factors, and condition-related factors 
(62). Myer et al (48) suggest a framework for conceptualising pregnant and 
postpartum women’s engagement in care which considers structural factors, 
social and economic conditions, health systems and services, individual-level 
factors and biological and medication conditions (Figure 2.4). I use this 
framework to collate the various influences on engagement in care for 




Figure 2.4: Conceptual model for the determinants of engagement 
in care for pregnant and postpartum women (Myer et al (48)) 
 
 
Structural, social, and/or economic contexts 
These are factors that play a distal role as determinants of engagement and 
include factors such as mobility, poverty, gender, and societal norms. Male 
partner involvement in all the levels of the PMTCT cascade (especially ANC 
visits, HIV testing and treatment) has been identified as a potential barrier to 
women’s long-term retention in care. This is particularly pertinent in 
patriarchal societies where women are heavily reliant on their partners for 
approval or financial support in order to attend health services (277–279). 
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More broadly, family and community have been identified as barriers to 
engagement in HIV care (280–283). Social support, infant testing and 
disclosure to a partner (284) have a positive effect on retention. Perceived and 
experienced stigma is still an issue (283,285) and often prevents disclosure 
(249,279,286,287) with An et al reporting that fear of a positive result is strong 
enough that some women opted out of ANC services altogether rather than 
know their status (288). Mothers also reported fear of stigma related to giving 
their child medication and from their status being disclosed if they did not 
breastfeed their infant (289). Women that disclose their HIV status receive 
more support and are better engaged in care (290). However, women are less 
likely to disclose in situations where disclosure is viewed as too risky with the 
potential repercussions including violence, segregation or loss of social 
support (249,279,286,287). Women who have not disclosed their HIV status 
might also find it harder to remain engaged in care in the postpartum period 
once the cover of frequent clinic visits for ANC ceases and the convenient 
explanation is no longer available to them (245).  
Furthermore, clinics may not be well adapted for the increased mobility that 
often accompanies pregnancy (for example, in many countries expectant 
mothers move back to their natal home because of the help they can receive in 
early childcare but later move back to their own homes to resume their lives) 
(18,102). After delivery, many women return to previous economic activities 
and place of residence which may come with their own stresses which may 
undermine HIV care engagement. Some women report feeling overwhelmed 
in this period and may become too busy with other activities to remain engaged 
in care (245,251,252). In South Africa, where labour migration is very 
common, this might include moving to metropolitan areas either to find or to 
resume work.  
Poverty also plays a major role in engagement in care (291–293). Several 
logistics are involved in continued engagement such as funds for 
transportation to the clinic, and availability of food to aid in taking medication. 
Studies have identified a lack of transport as a barrier to engagement in care 
(234,245,255,282–284,294). Moreover, as patients are usually advised to take 
their medication with food (10), some patients have reported a lack of food as 
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a significant barrier to adequate adherence and continued engagement in care 
(255).  
Health systems and services 
These are the factors that shape access to ART and include concepts such as 
access, availability, quality of care and model of care. Regarding the model of 
care, women must navigate ANC, and HIV clinics in settings where these are 
not fully or well-integrated (295). Moreover, even in settings with better 
integrated clinics, transitioning back into general population HIV clinics in the 
postpartum period can be challenging (296). Integration of ANC and HIV care 
significantly improves ART uptake during pregnancy and has become the 
standard of care in most of sub-Saharan Africa (297–301). Some countries 
continue integrated maternal and child healthcare into the postpartum period 
which has been shown to improve engagement in the postpartum period 
(302–304). However, there is a hurdle of moving mothers from PMTCT 
programmes to routine care postpartum and the potential LTFU during this 
transition period. There is little available evidence to guide decisions on when 
women should be transferred back to routine ART care. As a result, decisions 
in many countries are based on various other practices. In South Africa, this 
transition happens 6-10 weeks postpartum (256), in Malawi this ranges from 
6 weeks to 12 months (17,257), while in Mozambique, the United Republic of 
Tanzania and Zimbabwe this transition occurs up to two years postpartum 
(296,305) showing the heterogeneity in country implementation. Some 
settings offer a one-stop shop where ANC, postnatal care (PNC), child health 
care, and ART services are provided at the same facility (249,306). However, 
while women may not have to transfer geographically, they may need to 
transfer to a different part of the same clinic (249,306). This transfer period 
may come with higher susceptibility to disengagement from care (256,307–
309). Furthermore, if a child tests positive, mothers must navigate both their 
own and their infant’s clinic visits. If child and maternal care are not 
integrated, then the difficulty of juggling multiple clinic appointments might 
undermine women’s continued engagement in care (238,255).  
Regarding access and availability, infrastructure plays a significant role in 
engagement in care. Settings where roads can be washed away or made 
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impassable by rain for example make engagement in care a trickier prospect. 
Stockouts of ARVs also significantly affects adherence and engagement in care 
and stockouts increased in some sites following Option B+ roll-out (296). 
Furthermore, where patients are expected to pay for some services at health 
facilities, this has been shown to be detrimental to engagement in care 
(282,283). Distance to the facility and related transportation costs also played 
a significant role in LTFU among pregnant women (234,245,255,282–
284,294). 
Regarding quality of care, some studies have focused on the testing experience 
for pregnant women (288,310–312), including eliciting the contents of 
counselling sessions (310). Women appreciated the knowledge garnered from 
these HIV testing and counselling sessions (288). Healthcare workers (HCWs) 
also reported improved confidentiality as testing became routine which led to 
less stigma (288). One study also reported improved diffusion of the testing 
message for pregnant women into the community (288), as more mothers 
became knowledgeable and consequently shared this knowledge with other 
pregnant women. On the other hand, the routine nature of the HIV testing 
offer to pregnant women has also been identified as an early barrier to long-
term engagement in care for some pregnant women. For example, some 
studies have shown that women may feel coerced to test, leading to subsequent 
disengagement from care for some of them in the future (288,310–312).  Some 
mothers expressed discomfort in voicing their opinions regarding testing and 
counselling to practitioners (255,313). Several studies noted that the patient-
practitioner relationship was not viewed as equal by patients or providers 
(288,294,313). Few women discussed health decisions in terms of exerting 
control over their own bodies and perceived the HCW as the health-related 
decision maker (288). A role HCWs may not relish but one which nonetheless 
has been thrust upon them by “a unilateral ‘moral economy’, which requires 
the compliance of patients who are newly initiated on treatment” (314–316). 
Many women reported feeling that testing was compulsory, sometimes 
interpreting the HIV test as an order from the Health Ministry (288). A 
supportive relationship with providers often translated to more autonomous 
decision making on the mothers’ part (288). Maltreatment from clinic staff 
was a barrier to adherence and retention in care (237,317), suggesting, that the 
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patient-provider relationship plays a pivotal role in PMTCT service use (313). 
Omission of pre-test counselling also influenced women’s ability to opt-out of 
HIV testing (313). With the need to initiate pregnant women on treatment 
immediately after they tested positive, feeling ready played a major role in 
acceptance of ART (237), with readiness influenced by previous knowledge of 
HIV status, patient-provider relationship and the partner relationship (237). 
Patients and HCWs expressed concerns with the speed of the initiation process 
which they feared would make it difficult for patients to digest a positive result 
(286). With regards to women who never returned for a clinic visit following 
ART initiation, some studies suggest that rapid ART initiation might leave 
patients overwhelmed and underprepared for the realities of lifelong 
treatment thereby making them less likely to return for follow-up clinic visits 
(239). In particular, studies have reported mixed results with regards to 
disengagement from care for women who initiate ART on the same day 
(42,43,203), with some women wanting to first discuss their diagnosis with 
their partner, get a CD4 count and get a confirmatory test at another facility. 
HCWs feared that some women were only initiating treatment to please them 
and that they would not take the treatment properly at home (239). 
Consequently, they were worried about LTFU and drug resistance. Fear of 
breach of confidentiality also played important roles in LTFU (286,313) with 
some women concerned about referrals to other facilities having established 
trust where they initiated ART (313). Facility type and size have also been 
reported as affecting engagement in care (318) although there have been 
mixed results with regards to facility size (249,318). Studies suggest that public 
facilities are a risk factor for disengagement compared to private facilities 
(318), hospitals have higher attrition than health centres (203), and urban 
facilities contribute to disengagement when compared to those located in rural 
settings (318). Finally, long lines, limited clinic hours and slow service 
contributing to long waiting times at the clinic have also been reported as 
barriers to engagement in care (245,319).  
Other studies have identified several concerns throughout the Option B+ 
cascade. Specifically, there is fear of the potential adherence to old messaging 
around PMTCT and the subsequent problems that might arise as a result of 
starting ART with high CD4 (320). Postpartum women also need other 
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services including reproductive health services such as contraceptives for 
those not looking to get pregnant and safe conception for those who are. 
Unplanned pregnancy contributes to mother-to-child transmission and 
maternal engagement in care (321,322). Up to 70% of pregnancies between 
2012 and 2016 were unplanned in African cohorts living with HIV (323–325). 
Multiple hypotheses have been postulated to explain better engagement 
during pregnancy compared to the postpartum period. Healthcare messaging 
on ART adherence has focused heavily on the health of the baby and 
prevention of transmission (235) and women report being motivated to 
remain in care and adherent for the sake of their unborn baby (237).  
Many studies also found a significant number of mothers eligible under old 
guidelines who inexplicably slipped through the cracks (297,326–329) it is 
therefore plausible that this may also happen in Option B+ programmes. 
However, there were also good, contrasting results from South Africa (110) 
where a better resourced health care system likely played a role in the good 
performance of Option A compared to other countries. Questions remain 
regarding how a better resourced health system translates to an Option B+ 
programme. PMTCT is only effective if mothers and exposed infants remain in 
care and on therapy for the duration of MTCT risk (214) something more likely 
to happen with the simplified care continuum offered by Option B+ and 
supported by early findings from Malawi (36). Simplification of eligibility 
criteria could mean an improvement or, conversely, the increasing numbers of 
mothers being initiated could mean that more mothers slip through these 
cracks; supported by retention statistics from a number of studies showing 
that retention rates decline as Option B+ programmes age (34,36,227,318). 
Option B+ is a balancing act especially in scenarios in which poor adherence 
with consequent early virologic failure or high rates of loss to follow-up is 
common (193). ‘Particularly pertinent consideration for resource-constrained 
nations that are balancing ART costs with other critical health expenditures’ 
(31).  
Individual-level factors 
These include psychological, social, interpersonal, and economic factors that 
are proximal determinants of engagement in care among pregnant and 
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postpartum women. Young age is consistently reported as a risk factor for 
disengagement from care (69,249,305,317,330–332). Adolescents and young 
women have also been shown to have poorer adherence, worse HIV treatment 
outcomes, higher rates of vertical transmission and LTFU 
(11,17,50,203,333,334). This is possibly linked to poor health seeking 
behaviour as evidenced by late presentation at ANC and a higher likelihood of 
unplanned pregnancies (35,69,332,335). Young people may have lower 
impulse control (336), poorer grasp of the concept of actions and 
consequences, and poor ability for long-term risk benefit analyses (337) which 
also probably play an important role in this phenomenon. 
Studies have also reported that several other individual level factors play an 
important role in engagement in care. The continuum of acceptance and denial 
plays a role in engagement in care (338). The process of acceptance of an HIV 
status is influenced by various events and experiences that are unique to each 
individual (338). Women who were newly diagnosed at their first ANC visit 
had worse adherence and treatment outcomes (66,331,332) with denial 
possibly partly explaining the mechanism of this observation. Women who had 
previous knowledge of their HIV status at their first ANC visit had had more 
time to move through the process of denial and acceptance (338). Women also 
spoke about feeling healthy when asked to initiate ART, with perceived lack of 
need for treatment undermining their engagement (239,339). Women with 
less education also had worse engagement in care (66,317). Some women 
attributed attrition to several factors including mothers’ lack of knowledge 
regarding the benefits of ART for their own health, ignorance or 
irresponsibility, and that mothers only cared about the baby’s health and not 
their own (245). Religious beliefs were also an important predictor of 
engagement in care (249).  Mothers also expressed several motivating factors 
for remaining in care. Chief among these was the desire to have a healthy baby 
(238), mothers also wanted to remain healthy for themselves and in order to 
see their children grow up (239,240,251,319,340,341). Some women report 
that continuing on ART gives them hope for the future (280). Other motivators 
included stigma avoidance usually expressed as a desire to maintain their 
appearance, keep their status hidden and not be identifiable as HIV positive if 
their health deteriorated and they started to experience symptoms (239). 
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However, a fear of being seen at the clinic was a deterrent probably speaking 
to the setting with high social cohesion where social standing and social 
inclusion are often perceived as more important than individual wellbeing 
(342).   
Regarding psychological factors, research is starting to emerge suggesting that 
postpartum depression is a risk factor for disengagement from care (343–
345). Alcohol and substance abuse are also known to be associated with poor 
adherence and engagement and are prevalent among WLHIV (343–345). 
Other life stressors such as partner violence, crime, loss of employment, food 
and housing security can also disrupt treatment (17,346–348). Migration and 
travel can also disrupt treatment (349). This is particularly pertinent in South 
Africa where labour migration emerged due to the apartheid regime and 
quickly became an important source of income for families in the homelands 
and is still common even now (349,350). Furthermore, fitting clinic visits into 
their schedule when they were back at work was difficult as it often meant they 
had to disclose their HIV status to their employer (245). 
Biological and medical considerations 
This looks at factors related to physiologic changes associated with HIV and 
pregnancy, obstetric and medical conditions, and anything related to disease 
management including the use of ART. Late presenters who are at a more 
advanced disease stage when they first enter HIV treatment programmes are 
more vulnerable to disengagement usually because they are experiencing 
symptoms including physical wasting (250,282,351) and also have higher 
mortality risk (352). The proportion of people initiating ART at an advanced 
disease stage has declined since the advent of ART in sub-Saharan Africa 
(258). Furthermore, pregnant women are generally healthier and are usually 
asymptomatic when they initiate ART (258,259). Nonetheless, some studies 
have reported more advanced disease as a risk factor for disengagement with 
patients being too weak/sick to take ART or attend clinic visits. Feeling healthy 
has also been reported as a risk factor for disengagement from care 
(240,252,283). Readiness to start ART is a concept that features heavily with 
regards to engagement in care (237) and is influenced by many factors 
including coercive testing, and previous knowledge of HIV status.  
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Women who initiate ART during pregnancy have higher disengagement rates 
than women who initiate during the breastfeeding period (17,204,250,318). 
This may point to the multiple pregnancy related symptoms like nausea and 
fatigue which are similar to the profile of side effects that patients might 
experience once they initiate ART. This might also explain why primigravida 
mothers disengage from care more frequently than more experienced mothers 
(69). With the novelty of the transitions of a first pregnancy, mothers are 
perhaps more likely to mistake pregnancy symptoms for ART side effects. 
However, one study reported higher gravida as barrier to engagement in care 
(305). Apart from ART side effects (238,251,289,317,319,353,354), pill size 
(238), beliefs that ART is dangerous (355), a lack of understanding of HIV 
(17,341), and doubts about the effectiveness of ART (354) have also been 
reported as barriers to optimal engagement in care. There have been some 
contrasting findings, some women have reported feeling more motivated 
because of noticeable improvements in their health following ART initiation, 
for example one study reported optimal engagement where mothers perceived 
benefits of lifelong treatment including falling ill less frequently and prolonged 
life (289), findings echoed in another study, where women also felt that they 
would acclimatize to the treatment (239). Women who initiated ART late in 
pregnancy were also reported to have higher risk of attrition (69,317,332). 
Their late attendance of ANC probably speaks to poor seeking behaviour which 
has been reported as a risk factor for disengagement from care 
(35,69,332,335).  
Finally, the role of pregnancy in motivating initiation was important as this 
played a part in postnatal attrition with some women reporting loss of 
motivation after protecting the baby (289). Some mothers also expressed 
challenges with postnatal adherence (245,289) with some mothers reporting 
the pregnancy was a way to hide their status as they could easily explain that 
the reason for all the medication and frequent clinic visits was the pregnancy, 
but this option disappeared once the baby was delivered (245,257). Some 
women also mentioned treatment fatigue (289) and grappling with the fact 
that ART was a lifelong commitment (239,255,339) as reasons for 
disengagement from care.  
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Figure 2.5: Determinants of engagement in care under Option B+ 
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2.4. Loss to follow-up and maternal treatment outcomes 
2.4.1. The problem of LTFU 
Usually, most HIV treatment programmes are most interested in retention and 
survival statistics. As such patients who become LTFU are censored and it is 
assumed that this censoring is uninformative and random (12,356). However, 
it is well established from early treatment programmes that this was not true 
(for example, patients LTFU had higher mortality). Therefore, the proportion 
of patients LTFU became an outcome of interest independent of retention and 
survival (58,61). As LTFU reflects patients not retained in care, it is 
increasingly used as a measure of the effectiveness on treatment programmes 
(57,61,165,357,358).  
One study reported that the  combination of outcomes that make up LTFU 
underestimate retention and death rates by as much as five-fold while default 
rates are overestimated (90). Understanding true outcomes among patients 
who are LTFU is important in order to accurately monitor and report on 
indicators for national ART programmes and better target tracing efforts. 
Accurate mortality estimates are also important as these are used as 
parameters for projections in software programmes such as the UNAIDS 
Spectrum package (91,92,359).  
Furthermore, LTFU threatens the effectiveness of ART. A 2013 systematic 
review of ART patients in Africa estimated LTFU at 82%, 76%, 68% and 65% 
at 6, 12, 24, and 36 months respectively (199). While there was substantial 
variation in retention, given that ART is only effective if patients are retained 
and adherent, these numbers illustrate that retention is a substantial threat to 
ART effectiveness (61). For pregnant and breastfeeding women, this is two-
fold as ART is not only for the health benefit to the mother but also a means to 
curtail vertical transmission.  
Studies have reported increases in attrition as programmes expand and 
increasingly, more programme losses can be attributed to LTFU (13,57,360). 
One study reported an inverse relationship between LTFU rates and mortality, 
with the contribution of unascertained mortality decreasing as LTFU 
increased, and the proportion of attrition attributable to LTFU increasing with 
each additional year on ART (13). With estimates of programme attrition as 
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high as 40% after 3 years, LTFU is a considerable barrier to the achievement 
of the long-term goals of ART programmes (61).  
Finally, in October 2017 the UNAIDS announced the 90-90-90 targets which 
aim to have 90% of people living with HIV know their status, 90% of those who 
know their status remain on ART, and 90% of those on ART achieving viral 
suppression by 2020 (41,97). As part of this initiative, improved HIV testing 
and linkage to care following an HIV diagnosis were identified as points of 
intervention. However, with this goal increasingly being met, programmes 
must now start looking at how best they can restructure themselves to allow 
patients to live productive lives. The gap in achieving the second 90 consists 
of people that do not link to care following an HIV diagnosis as well as people 
that initiate ART but are lost from care. In South Africa, it was estimated that 
in 2018 more than 50% of the diagnosed and untreated population had 
previously been on ART, a proportion which had been steadily increasing over 
the past few years (Johnson LF; SA AIDS conference, 2019) (Figure 2.6). Given 
the successes in testing and treatment scale-up as a result of universal ART 
combined with high rates of LTFU in most ART populations, understanding 
people who start ART but do not remain retained in care is of increasing 
importance to ART programmes. However, this group has received less 
attention than linkage to treatment in the context of the UNAIDS targets (41).     
Figure 2.6: South Africa's progress towards the UNAIDS 90-90-90 




2.4.2. Results from tracing studies 
It is important to estimate the “true default” rate, which is loss to follow-up 
excluding those who have died or transferred out of the area and are receiving 
treatment in another health facility elsewhere. Most ART programmes do this 
by tracing patients lost to follow up. However, this is often done inconsistently 
more so in national governmental programmes (52,90,361) even with tracing 
policies in place. In addition, whereas some programmes try to trace all 
patients LTFU, some trace a random sample of patients and others trace a non-
random sample (15). Wilkinson et al (15) in their systematic review of tracing 
studies reported a summary mortality estimate of 38.8% for patients LTFU, 
which was a reduction compared to a similar review done earlier by Brinkhof 
et al (14) which reported a summary mortality estimate of 42%. More recent 
studies have reported further reductions in mortality with Zürcher et al (16) 
finding that 32.4% of patients traced had died and Chammartin et al (362) 
reporting that 21.8% of patients that were LTFU had died four years after their 
last clinic visit. 
Wilkinson et al also reported a summary estimate of 18.6% for self-transfers 
and 28.6% for patients that stopped ART (“true default”) (15). Many of the 
studies included in these systematic reviews were done in the early stages of 
sub-Saharan African ART programmes when a large number of those initiating 
ART were much sicker. Scale up and decentralisation of these programmes 
also meant that ART could be provided closer to home (15) which potentially 
increased the rate of self-transfers in order to continue treatment at locations 
that were more convenient. This probably explains why LTFU is directly 
proportional to ART programme size (360) and may also explain why LTFU is 
higher at centralised health facilities compared to primary healthcare facilities 
(363). In 2017, Zürcher et al in their systematic review reported that 23.9% of 
LTFU patients successfully traced had transferred, representing an increase 
from the estimate reported by Wilkinson (16). However, an individual patient 
meta-analysis conducted in 2018 reported a reduction in both self-transfers 
and ART stoppage four years after a last clinic visit, with estimates of 14.8% 
and 22.6% respectively (362).  
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It is possible now that the percentage of those deceased has changed owing to 
growing ART access and coverage, leading to more healthy asymptomatic 
patients initiating ART. Wilkinson et al found a significant reduction in deaths 
– from 50% to 30% – identified by tracing studies when they compared studies 
before and after 2007 (15). Zürcher et al also reported that mortality following 
LTFU appeared to decrease each calendar year, while ART stoppage and self-
transfer appeared to be increasing (16). One study reported that mortality 
associated with LTFU is inversely related to the proportion of patients lost 
(364). As the proportion of patients LTFU from a treatment programme 
increase, the proportion of LTFU attributable to mortality decreases. 
Furthermore, few studies have specifically traced mothers LTFU from PMTCT 
programmes (17,19,102). This population is different from the populations 
that have previously been traced in a number of ways; firstly, with Option B+, 
many mothers are initiating ART while asymptomatic which potentially 
increasing their risk of LTFU. In addition, adequate adherence drops 
postpartum (89) and childbirth can be a risk factor for default (365) which 
could be because of a myriad of reasons. For example, the added burden of 
travelling to the clinic with a young infant, postpartum depression or out-
referral after delivery (245,257,366). Consider also that new mothers are often 
quite mobile (18,102). Because of this, we can postulate that they are more 
likely to self-transfer especially in situations where health facilities are not 
transfer friendly.  
2.5. Data sources 
The majority of PMTCT programmes and studies reviewed were implemented 
as clinical cohorts and relied heavily on paper-based registers and physical 
patient files (11,99,228,229). These paper-based registers suffer from several 
deficiencies. Firstly, these registers suffer from general data quality issues, 
such as incompleteness and duplicate records. These registers are also harder 
to store often getting lost or having torn or illegible pages. These issues limit 
the accuracy of results based on routinely collected data (99).  Furthermore, 
the sheer number of registers complicate patient follow-up. In some settings, 
HIV test results, ART clinic visits, pregnancy data, and outcomes of tracing are 
recorded across several separate registers meaning information is often 
duplicated. Sometimes multiple versions of the same register exist at some 
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clinics which constitutes a high volume of paperwork and a significant 
workload for clinic staff, probably explaining the high levels of missing data. 
Finally, the lack of unique identifiers in these registers makes collating of all 
pertinent patient information difficult. Lack of unique identifiers also 
complicates tracking of women’s outcomes throughout the PMTCT cascade. 
For example, it is hard to track patients as they move from one facility to 
another or in the case of postpartum women, when they transfer their 
treatment from ANC to the adult ART clinics. Some studies employed active 
patient tracing to mitigate loss to follow-up (201,367,368). However, this is 
also significantly impeded by data quality issues (17,369). Data linked across 
multiple clinics is recommended by the WHO (370) and could also help to 
catch silent transfers and identify patients who are highly mobile. However, 
these linked data systems are a rarity in sub-Saharan Africa (18,371). 
Investigating retention using other data sources is therefore an important 
consideration especially as data triangulation using multiple sources improves 
the accuracy of estimates and data quality as well (372).  
2.5.1. The role of community cohorts in estimating outcomes 
among ART patients 
Community cohort studies provide an opportunity to investigate engagement 
in Option B+ at a population level (20). These community cohorts collect 
demographic, behavioural and health information (including in and out 
migrations from the surveillance site) regularly using HDSS and have unique 
identifiers for each individual. Furthermore, they include information linking 
infants to their mothers making their identification simpler. Some of these 
community cohorts have also started linking clinical data from nearby clinics 
allowing the utilisation of more data (103,104). This linkage provides the 
opportunity to look at outcomes among mothers who are lost to follow-up from 
the HIV clinic where they initiated treatment, something which other clinic-
based PMTCT cohort studies are unable to do (99). Finally, with the 
availability of verbal autopsies in some sites, presumptive causes of death for 
all patients found to have died can give an indication of predominant causes 
of death in mothers LTFU. Such an endeavour will allow for accurate 
estimation of Option B+ coverage rates in other settings with the availability 
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of population-wide estimates on undocumented transfers between clinics, 
deaths, outcome misclassifications and genuine ART discontinuation.  
2.6. Summary 
Whereas PMTCT programmes in sub-Saharan have come a long way since 
their inception, there are still improvements that could be made to support 
maternal engagement in HIV care. Pregnant and postpartum women have 
worse engagement in care. However, little is known about what happens to 
these women after they become LTFU. Furthermore, given that many mothers 
report protecting their unborn child as a major contributing factor to their 
starting treatment (237,251,319,340), little research has investigated how 
infant outcomes affect mothers’ continued engagement in care in the 
postpartum period (373). By contributing to these research gaps, the work of 
this thesis will improve our understanding of pregnant and postpartum 
women’s engagement in HIV care and provide recommendations for future 
practice to improve engagement in care in this group.  
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Table 2.3: Manuscripts reviewed for retention and engagement in care statistics for pregnant and postpartum 
women  
 




Retention definition N Percent 
retained 
(%) 





Facility visit 12 months after 
ART initiation 
31186 12mo: 60 
Ahoua (375) 2020 Mozambique Retrospective 
cohort 
ANC aggregated data No facility visits for 30 days 
or more prior to expected 
12-month visit date 
31186 12mo: 74 




Not defined in paper 248 96 
Pellowski 
(108) 
2019 South Africa Prospective 
cohort 
Routine facility data 
and self-report 
Not defined in paper 260 80 
Cichowitz 
(377) 




No gap in care greater than 
90 days 
650 24mo: 41 
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Watt (378) 2019 Tanzania Prospective 
cohort 
Routine facility level 
data and patient 
surveys 
In care 6 months 
postpartum with a VL<200 
200 6mo: 79 
Etoori (35) 2018 Eswatini Prospective 
cohort 
Review of facility 
registers and patient 
files 
No gap in visits 0f 4.5 
months or more 




Hauser (379) 2018 Malawi Retrospective 
cohort 
Routine facility 
registers and patient 
files 
No gap greater than 60 days 
following a missed 
appointment 
490 3mo: 73 
Langwenya 
(43) 
2018 South Africa Prospective 
cohort 
Routinely collected 
clinic, pharmacy and 
laboratory records 
VL within a week before or 
after delivery 
628 68 




Any visit after leaving 






2018 Uganda Retrospective 
cohort 
Routine facility data No gap greater than 60 days 
following a missed 
appointment 
518 24mo: 46 
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Atanga (249) 2017 Cameroon Prospective 
cohort 
Facility level data on 
refill appointments 
No gap of 90 days or more 
following a missed 
appointment 
277 1st appt: 92, 
3mo: 88, 
6mo: 85, 
12mo: 77  
Hoffman 
(317) 
2017 Malawi Case-control Review of facility 
records 
No gap of 60 days or more 




2017 Malawi Randomised 
control trial 
Record review of 
facility registers and 
patient files 
No gap of 60 days or more 
after a missed appointment 






2017 Malawi Cluster 
randomised 
trial 
Record review of 
facility registers and 
patient files 
No more than 14 days late 
for drug refills and attended 
12-month postpartum visit 
396 12mo: 69 
Phiri (201) 2017 Malawi Randomised 
control trial 
Record review of 
facility registers and 
patient files 
No gap of 60 days or more 
after a missed appointment 
1269 1st appt: 85, 
24mo: 65 




registers and forms 
Medication refill +/- 5 days 
of scheduled visit (30-day 
refills) 





2017 Nigeria Cluster 
randomised 
trial 
Record review of 
facility registers and 
patient files 
Full: Attended six-month 
postpartum visit (±30 days) 
and did not missed any 
previous scheduled visit by 
more than 30 days; Partial: 
Attended six-month 
postpartum visit (±30 days) 
but missed ≥1 previous 
scheduled visit by more 
than 30 days 
247 6mo: 68 
Sam-Agudu 
(383) 
2017 Nigeria Prospective 
cohort 
Record review of 
facility registers and 
patient files 
At least 3 visits between 










Facility visit 15 months 
postpartum 
185 18mo: 98 




At least one CD4, VL, or lab 
record after being 
considered LTFU 
788 62* 




No gap of 60 days or more 




Koss (202) 2017 Uganda Cross-
sectional 
follow-up of a 
random 
sample of 
women in a 
randomised 
trial 




Attended the clinic in the 90 
days preceding the 
interview 
200 48mo: 68 
Miller (385) 2017 Uganda Retrospective 
cohort 
Record review of 
facility registers and 
patient files 
At least one clinic visit 12 
months after pregnancy 
detection 
373 12mo: 84 
Muhumuza 
(386) 




No gap of 90 days or more 
without a visit 


















registers and case 
report forms 
Medication possession ratio 
or exhausted pill supply 
following last visit 
1113 12mo: 68 
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Ford (330) 2017 Zimbabwe Retrospective 
cohort 
Record review of 
facility registers and 
patient files 
No gap 90 days or more 
without a visit 




Foster (387) 2017 Zimbabwe Cluster 
randomised 
trial 
Record review of 
facility registers and 
patient files 
Visited the clinic at 12 
months postpartum 
348 12mo: 66 
Joseph (388)  2017 Zimbabwe Cluster 
randomised 
trial 
Record review of 
facility registers and 
patient files 
Having had an ART refill 
visit a minimum of 335 days 
post-ART initiation and on-
time attendance (before, on 
or up to 14 days after the 
next scheduled date) for at 
least 75% of scheduled ART 
refill visits, up to and 
including the 12-month visit 
AND no gap in care >90 
days. 
547 1st appt: 96, 
6mo: 69, 
12mo: 63 
Mitiku (203) 2016 Ethiopia Retrospective 
cohort 
Record review of 
facility registers and 
patient files 
No gap of 90 days or more 
without a visit 






Chan (42) 2016 Malawi Retrospective 
cohort 
Record review of 
facility registers and 
patient files 
Clinic visit within 2 months 
of last dispensed drugs 
running out 
813 1st appt: 56, 
3mo: 48, 
6mo: 47  




No gap greater than 60 days 
following a missed 
appointment 




Landes (250) 2016 Malawi Retrospective 
cohort 
Review of standard 
ART monitoring 
tools 
No gap of 60 days or more 
after a missed appointment 
2955 1st appt: 87, 
3mo:85 




60 days or more late for a 
scheduled appointment 
14397 6mo: 69 
Llenas-
Garcia (204) 




No gap in visits of 180 days 
or more 
308 1st appt: 60, 
12mo: 42 
Woelk (389) 2016 Rwanda Retrospective 
cohort 
Record review of 
facility registers and 
patient files 
At least one visit in each 
period 6wk, 3, 6, 9, and 12 
months postpartum 














HIV databases  
VL around time of delivery 620 94* 
Schnack (66) 2016 Uganda Observational 
cohort 
Facility level data on 
refill appointments 
and pill counts 
 124 1st appt: 64 
Dzangare 
(305) 
2016 Zimbabwe Retrospective 
cohort 
Record review of 
facility registers and 
patient files 
Not defined in paper 148 1st appt: 93, 
6mo: 77 
Kim (391) 2015 Malawi Quasi-
experimental  
Routine facility level 
data 
Not defined in paper 810 6mo: 80 
Schwartz 
(109) 
2015 South Africa Pilot 
intervention 
Record review of 
facility registers and 
patient files 
No gap of more than 6 
weeks after a missed 
appointment 
50 12mo: 76 
Kamuyango 
(70) 
2014 Malawi Retrospective 
cohort 
Record review of 
facility registers and 
patient files 
No gap of 60 days or more 
after a missed appointment 
190 12mo:97 
Koole (392) 2014 Malawi Retrospective 
cohort 
Record review of 
facility registers and 
No gap of 60 days or more 
after a missed appointment 
586 6mo: 85 
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patient records plus 
patient interviews 
Price (354) 2014 Malawi Retrospective 
cohort 
Record review of 
facility registers and 
self-reported 
On ART at the time of the 
interview 




2014 Malawi Retrospective 
cohort 







No gap of 60 days or more 
after a missed appointment 
5357 6mo: 76 




No gap of 3 weeks or more 
after a missed appointment 
2930 1st appt: 91, 
3mo: 87, 
9mo: 83  
Van Lettow 
(257) 




No gap of 2 months or more 
without ART 




2013 Uganda Randomised 
control trial 
Record review of 
facility registers and 
patient files 
VL 6-12 months post ART 
initiation 
85 89* 
(* Cohort may contain some pregnant and breastfeeding WLHIV who initiated ART under Option B or A) 
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3. Research methods 
 
This chapter begins by introducing the context for this PhD research, including 
an overview of the study setting, details of the MRC/Wits Rural Public Health 
and Health Transitions Research Unit activities in the Agincourt HDSS and 
details of the health services offered in the HDSS. Methods for the collection 
of quantitative data and other specific information about the datasets are 
outlined. Statistical analysis methods are then presented. The second part of 
this chapter describes the methods used during the implementation of a 
qualitative study that I designed and implemented in in the second year of my 
research. I describe the data collection procedures and outline the methods 
used to analyse the data generated.  
3.1. Context   
3.1.1. Overview of the study setting 
The research for this PhD was conducted in the Agincourt sub-district located 
in Bushbuckridge local municipality of Ehlanzeni district in the Mpumalanga 
province, in rural north-east South Africa. The Agincourt HDSS located in this 
area is run by the MRC/Wits Rural Public Health and Health Transitions 
Research Unit under the auspices of the School of Public Health at the 
University of the Witwatersrand. The HDSS has been tracking demographic 
and health events in the Tsonga or Shangaan people since 1992. Mozambicans 
comprise about 30% of the population and have culturally assimilated, 
primarily speaking Shangaan. They arrived as refugees in South Africa in the 
1980s following the Mozambican National Resistance (RENAMO) – 
Mozambique Liberation Front (FRELIMO) civil war in Mozambique (350). At 
the time of this study, the HDSS covered an area of approximately 475 square 
kilometres, with an approximate population of 115,000 people living in 17,000 
households located in 31 contiguous villages (394). The Agincourt HDSS is 
bordered by Kruger National Park to the east and is adjacent to the 
Mozambique border (Figure 3.1).  
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Figure 3.1: A map showing the regional location of the Agincourt 
health and demographic surveillance system (Source: Kahn et al 
(395)) 
 
3.1.2. Historic context 
It is important to consider the historical context in order to better understand 
the nature of the HIV epidemic and national responses to it in a given setting. 
In South Africa, the National Party government introduced apartheid in 1948. 
As part of this system, legislation was enacted that included forced 
resettlement, movement restrictions for black South Africans, and separate 
development with the establishment of “homelands” or “Bantustans”. 
Restriction of access to land, together with forced resettlement resulted in 
black South African settlements that were densely populated, but 
agriculturally and economically inhospitable (396). As a result, many of the 
inhabitants of these settlements were forced to migrate for work. Various laws 
were passed to restrict their movement. The pass system, for example, 
restricted free movement to those with employment, entrenching the 
separation of families because women and children often did not have the legal 
right to travel with their partners (396).  
Gazankulu was a homeland situated in northeast South Africa. The Agincourt 
sub-district is situated in what was formally Mhala district of Gazankulu, the 
inhabitants of which belong to the Shangaan-speaking Tsonga ethnic group 
(396). 
3.1.3. Current socioeconomic context 
Located within a former Bantustan, the area still carries remnants of the 
Apartheid legacy of underdevelopment and inadequate education. Despite 
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improvements in the social situation following the collapse of Apartheid, and 
the move to more democratic governance, there are still issues with access to 
electricity, water and tarred roads (20). Because homelands were often found 
in areas of little industrial and agricultural activity or potential, lack of gainful 
employment opportunities has led to high unemployment rates. As a result, 
there are high rates of labour migration with reliance on remittances as an 
important income source (350). Formal employment involves mostly migrant 
men working in the mining sector, in construction and security firms in larger 
towns and on nearby agricultural and game farms (350). For many families, 
social benefits/allowances are a crucial source of income especially the “old 
age” pension and the “child support grant”. 
This political history has influenced current demographic patterns, including 
migration, that influence ART access patterns today. Whereas it was hoped 
that black South Africans would move and assimilate into economic centres 
and cities following the end of Apartheid, labour migration has remained the 
norm for most. Continued separation due to labour migration has had severe 
psycho-social impacts, especially with regards to alcoholism and violence 
(350). Sexually transmitted infections (STIs) are also highly prevalent and 
have been proliferated by behavioural traits that are more commonly found 
among migrant communities, such as the development of sexual networks at 
workplaces due to spousal separation. This has been exacerbated by the 
intersection of a weak health system and other social conditions like poverty 
in which HIV/AIDS thrived and became entrenched, bred by protracted 
colonialism and Apartheid, which a social and political transition period was 
unable to curtail.  
The Agincourt HDSS had an estimated population of 115,000 residents in 
2018, with 52% of them being female. Children under 5 years of age accounted 
for 10% of the population, with children and young adults 5-19 years of age 
making up 31% of the population. There were 2042 births recorded in 2017 
and the crude birth rate (CBR) was estimated at 18 live births per 1000 people. 
The age-specific fertility rate was estimated at 60 births per 1000 women aged 
15-19 and peaked at approximately 90 births per 1000 women in the 25-29 
years age group. There were 542 deaths (52.3% males) recorded in the 
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Agincourt HDSS in 2017, giving a crude death rate of 6 deaths per 1000 people. 
The Agincourt HDSS recorded 3049 total in-migrations and 4533 total out-
migrations in 2017 (397).  
Antenatal care (ANC) attendance is estimated at >95%. Estimates of HIV sero-
prevalence in antenatal clinics in the province rose from 2% in 1992 to 35% in 
2005 (396). In 2010, HIV prevalence among people 15 years of age or older 
was estimated at 19.4% in the Agincourt HDSS. Prevalence was characterised 
by a large gender difference (10.6% for men and 23.9% for women) and peaked 
at ages 35-39 among both men (45.3%) and women (46.1%), with 5.5% of 
women 15-19 years old estimated to be HIV infected (398). 
3.1.4. Health services overview  
The Agincourt HDSS includes eight government-run health facilities within its 
borders. Five of these facilities are primary healthcare (PHC) clinics and three 
are designated as community health centres (CHCs). These centres act 
primarily as referral centres for patients that require specialised healthcare 
services. The objective of this is two-fold, to make modern healthcare services 
available to rural populations and to reduce overcrowding at regional and 
district hospitals. The clinics offer ANC services, delivery, and child clinic 
services as well as offering STIs and tuberculosis screening and treatment. The 
facilities also offer HIV counselling and testing services, PMTCT and HIV care 
and treatment services for PLHIV. There has also been a push by the 
Department of Health to improve health services for other chronic diseases 
such as diabetes and hypertension and these services are now being 
implemented in most clinics. There are three government hospitals located 
near the Agincourt HDSS, Matikwana and Mapulaneng hospitals located 
about 5 kilometres outside the HDSS, and Tintswalo hospital located 
approximately 24 kilometres away (Figure 3.2).   
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Figure 3.2: Maps of Agincourt HDSS showing health facilities 
within the site and the surrounding area (Source: Lippman et al (399))  
 
Note: Lillydale clinic and Bhubezi CHC merged in 2016, Thulamahashe is 
















3.1.5. HIV services 
 
HIV counselling and testing 
The HIV/AIDS and STI national strategic plan of 2007 emphasised a push to 
establish “a national culture in which all people in South Africa regularly seek 
voluntary testing and counselling for HIV” (400). The plan proposed 
interventions including the development of high-profile campaigns utilising 
peer influence to promote testing and disclosure, expansion of access to HIV 
testing beyond formal healthcare settings, and development of clear, 
consistent HIV prevention messaging. In 2009, as part of his World AIDS day 
address, President Jacob Zuma launched a new HIV counselling and testing 
(HTC) campaign. As part of the HTC campaign, the President publicly tested 
for HIV, being among 20 million South Africans to learn their status over the 
next 20 months (401). This represented a substantial increase in national 
testing rates (402).   
In line with national policy on provider-initiated counselling and testing 
(PICT), facilities in Agincourt offer HCT to adults who do not know their HIV 
status if they have not tested in the past year, as part of any clinical care or 
screening, in cases of sexual assault or domestic violence, and as part of 
medical male circumcision. This is repeated annually for those who were HIV 
negative when they last tested, with more frequent testing for those with new 
sexual partners or those engaging in unprotected sex (402). HCT should be 
offered to all pregnant and breastfeeding women with unknown HIV status or 
those who tested HIV-negative 3 or more months prior. Children aged 12 years 
or older may consent to a test if they are considered by the health worker as 
sufficiently mature to understand the benefits, risks, and social implications 
of the HIV test result. In all other cases, a parent or caregiver must give 
consent.   
The policy also stipulates that all patients receiving PICT or client-initiated 
counselling and testing (CICT) should provide verbal consent for HIV testing. 
HCT follows the Department of Health testing algorithm (Figure 3.5). A group 
session outlines the benefits of HCT to the patient, including in the context of 
PMTCT, if the patient is pregnant. Individual sessions should include an 
assessment of whether the information communicated in the group session 
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was understood, answering any questions, clarifying any misunderstanding, 
and addressing any concerns. Pregnant and breastfeeding women who test 
negative are considered part of the PMTCT programme and should retest every 
3 months until breastfeeding cessation, unless HIV infection is diagnosed. All 
patients receive post-test counselling regardless of their result, which covers 
risks for HIV transmission, safe sex and condom use, contraception and family 
planning, HIV testing for sexual partners and children, repeat HIV testing for 
those who are HIV-negative, and PMTCT including safe infant feeding and 
infant prophylaxis. All patients who test for HIV are recorded in the HCT 
register. For those who test positive, details including full names, age, sex, and 




Figure 3.5: Algorithm for HTC using rapid antibody test for 
adolescents and adults including pregnant and breastfeeding 
women (Source: National consolidated guidelines (402)) 
 
As part of PICT, all HIV-exposed neonates should receive an HIV polymerase 
chain reaction (PCR) test at birth, ten and eighteen weeks, and a rapid HIV 
antibody test at 18 months or older (Figure 3.6). Children should also be tested 
if they present with severe illness, are suspected to be HIV infected, are 
diagnosed with tuberculosis (TB), the mother’s HIV status is unknown, the 
father or sibling tests HIV-positive, the  mother, father or sibling dies, they are 
a suspected victim of sexual assault and if they are being considered for 
fostering or adoption. Parents can also request for the child to be tested.    
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Figure 3.6: Testing algorithm for routine testing in children <18 
months of age 
 
Depending on the size of the facility, testing is done in a separate room in the 
same building or in a different building within the clinic compound. However, 
for pregnant women, HCT is integrated into ANC.  
Antiretroviral therapy (ART) 
A national HIV treatment programme was first proposed in South Africa in 
late 1999 by the National Department of Health but did not materialise until 
2004 following legal action by the Treatment Action Campaign (TAC) against 
the South African government (403). In November 2003, the South African 
Department of health proposed a plan to provide HIV/AIDS care and 
treatment in at least one service point in every health district in 2004, with the 
aim to expand the programme and achieve equitable access within local 
municipal areas by 2008. In total, 22500 new health workers would be 
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recruited over the five-year period, including 1100 new doctors (404). To begin 
with, ART was only offered to those with a CD4 count less than or equal to 200 
cells/µl with the aim of achieving universal treatment coverage for all new 
AIDS cases by the end of 2008. By March 2005, the target of at least one 
service point per district had been met, but ART was largely provided through 
hospitals, most of which were tertiary facilities. On 1 December 2009, World 
AIDS day, then president Jacob Zuma announced new interventions to 
improve ART access to all HIV-positive infants, pregnant women, people with 
TB and HIV co-infection and PLHIV with CD4 counts less than or equal to 350 
cells/µl (402). With the launch of a massive HIV counselling and testing 
campaign, and in anticipation of large numbers of new patients identified by 
the campaign, it was also announced that accreditation would be abandoned 
and that all public healthcare facilities would be equipped to provide ART.  In 
2013, a fixed-dose combination (FDC) of tenofovir (TDF), emtricitabine 
(FTC)/lamivudine (3TC), and efavirenz (EFV) was introduced to simplify and 
streamline ART (402). On July 23, 2014, the Minister of Health announced 
the threshold for ART initiation would increase to CD4 less than or equal to 
500 cells/µl (402). This came into effect in January 2015. Furthermore in 
2015, use of viral load for monitoring treatment success and early 
identification of treatment failure became the standard treatment and third-
line drugs were introduced for patients failing second-line regimens. On 22 
August 2016, all health facilities were instructed to move to universal test and 
treat starting on the 1st of September 2016 (93) (Figure 3.7).  
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Figure 3.7: The South African National treatment programme timeline showing major milestones 
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Most health facilities in Agincourt have been providing ART since 2010 (405). 
Patients who test HIV-positive are now eligible to initiate ART as soon as they 
are ready (402). According to national guidelines, at the time of diagnosis, the 
healthcare provider should involve the patient in the decision-making process 
regarding ART initiation and explain the entire treatment plan (402). In the 
case of pregnant women, they can initiate ART during ANC, usually on the 
same day. Non-pregnant patients are referred to HIV/ART services. Services 
are usually provided at the same facility but in some cases, the patient can be 
referred to another facility on request. In such instances, the sending facility 
makes an appointment directly with the receiving facility on behalf of the 
patient and provides the patient with an appointment date and referral letter. 
Most patients receive FDC as their first ART regimen. If FDC is 
contraindicated for pregnant women, they are considered high-risk 
pregnancies and are referred to HIV/ART services where they are usually 
offered AZT twice daily until a three-drug ART regimen can be initiated.  
Patients should receive a viral load (VL) test at 6 and 12 months after ART 
initiation and annually thereafter (10). Pregnant women should receive VL 
tests more frequently usually every 3 months until breastfeeding cessation. 
Patients with suspected non -adherence (e.g. multiple missed appointments) 
or treatment failure (VL>1000 copies/mL) should receive step-up adherence 
counselling. This includes re-education about the importance of adherence, 
evaluation of support structures, advice on methods to improve adherence like 
pillboxes, encouragement to participate in a support group, a mental health 
assessment and in some cases home visits where spot pill counts can be done. 
Clinically stable patients defined as those receiving ART for at least one year, 
with no adverse drug reactions requiring monitoring, no current illnesses or 
pregnancy, a good understanding of lifelong adherence, and two consecutive 
undetectable viral load results are offered differentiated models of care (10). 
These include greater spacing between pill refill visits of up to 6 months, “fast-
track” appointments, health worker run adherence clubs and Central Chronic 
Medicines Dispensing and Distribution programme (CCMDD) which allows 
patients to collect their treatment at multiple distribution points. 
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Prevention of mother-to-child transmission of HIV 
On July 23, 2014, the Minister of health announced that the PMTCT 
programme would adopt the Option B+ approach and this was implemented 
from January 2015. The PMTCT programme should be fully integrated into 
ANC. HIV testing, ART, HIV care and treatment, labour and skilled delivery 
services should all be offered through a one-stop shop approach.  
In South Africa, 4% of pregnant women who test negative at their first ANC 
visit seroconvert during the pregnancy (402). Women newly diagnosed with 
HIV receive several tests including CD4 count, Hepatitis B antigen, 
haemoglobin, creatinine and are assessed for ART eligibility and readiness. 
They are initiated on treatment following a specific treatment initiation 
algorithm (Figure 3.8).  





For women already on ART with a confirmed pregnancy, a VL test should be 
done at the same visit of the confirmed pregnancy, with the results of the VL 
test used to indicate which interventions the mother requires (Figure 3.9).   
Figure 3.9: Algorithm for the management of pregnant women 




All HIV-positive pregnant and breastfeeding women should receive a VL test 
every 3 months until breastfeeding cessation. All pregnant women are 
encouraged to deliver their baby at a health facility. 
HIV-exposed infants for mothers on ART also receive nevirapine (NVP) at 
birth and then daily for 6 weeks. Infants whose mother did not receive ART 
are given NVP as soon as possible and then daily until the mother has been on 
ART for 12 weeks. Infants whose mother is diagnosed with HIV while 
breastfeeding or whose mother had their latest VL>1000 copies/mL receive 
NVP and AZT immediately. If the infant then tests HIV-negative by PCR, AZT 
is stopped and NVP continued until the mother has been on ART for 12 weeks. 
All infants who test HIV-positive are initiated on ART immediately.  
Home-Based Carers organisations 
Community home-based care for people who had advanced AIDS was first 
proposed in an effort to mitigate the impact of the HIV epidemic. In 2000, 
home-based carers were recognised as de facto healthcare sector labour force 
with the government initiating a non-governmental organisation-based 
contracting system to provide community-based services (406). In 2010, in 
order to formalise the community-based care sector, home-based care was 
recognised by the South African National Department of Health as a primary 
healthcare strategy to reduce pressures on hospitals and other healthcare 
resources (407). Under a programme to re-engineer primary healthcare, 
home-based care was expanded (408). Since it was first proposed, many of 
these volunteer caregivers have organised themselves into non-profit 
organisations that are affiliated with specific villages. They recruit and train 
community health workers to assist families with homecare, participate in 
income-generating activities including agriculture (Figure 3.10) and receive 
donations from various charities (409,410). Home-Based Carers are 
sometimes HIV-positive patients themselves, with experience of engaging 
with HIV services (usually referred to as “expert clients”), these groups are 
seen to have their hand on the pulse of their community and to be most 
knowledgeable about most inhabitants of their villages.  
These organisations provide comprehensive services ranging from health 
education to palliative care. Home-based care also includes preventative, 
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therapeutic, rehabilitative, long-term maintenance, and other social services 
with the aim of empowering patients to take ownership of their health. In some 
clinics, home-based care workers are utilised in routine tracing and adherence 
monitoring through pills counts and direct observation of treatment taking. 
These organisations are not formally employed healthcare cadres and receive  
a stipend rather than remuneration from the Department of Health (411). 
There were sixteen home-based carer organisations operating in the Agincourt 
HDSS at the time of this research. 
Figure 3.10: Images of Lillydale home-based carers compound 





Routine patient tracing 
All health facilities in Agincourt routinely trace HIV patients who are LTFU, 
defined in this setting as being more than 90 days late for a scheduled 
appointment in accordance with national policy (412). In practice, each health 
facility manager is responsible for ensuring that there is a functioning paper-
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based or electronic appointment system, such that clinical files for patients 
who are expected the following day are retrieved from the filing room. Files for 
patients who do not attend a scheduled visit should be kept aside for further 
action. A list of patients who did not attend a scheduled appointment should 
be generated every week, either through the facility’s appointment register or 
through querying the facility-level electronic database (TIER.Net). If a patient 
has not attended the facility within 5 working days to follow-up on a missed 
scheduled appointment, the patient’s name should be registered in the facility 
tracing register to be traced. 
This list is signed off by the facility manager and transferred to the person 
responsible for tracing patients, usually a designated nurse, community health 
worker (CHW) or the ward-based outreach team (WBOT) lead. The delegated 
nominee will extract contact information including addresses and telephone 
numbers (which should be updated at every clinic visit) of the individuals on 
the list (and their treatment supporter where available) from the patient files 
and enter this information into the facility tracing register. The facility 
telephone is then used to contact all the individuals who were added to the 
tracing register that week, with the date the phone call was attempted and the 
outcome of the phone call, and patient outcomes recorded in the register when 
obtained. Six facilities receive assistance with telephone tracing from a non-
profit organisation called Right-to-Care (RtC)2. Three calls should be 
attempted within 14 days after each patient’s missed visit. Patients who are 
alive, and who have not transferred to another clinic are encouraged to return 
to treatment. Self-transfers are further investigated usually through a phone 
call to the facility they have transferred to. The names of patients who cannot 
be reached after three attempts by phone are transferred to a list of those to be 
traced through outreach and home visits.  
Patient consent for a home visit should be verified in the patient file. WBOTs, 
CHWs and home-based carers (HBCs) linked to the facility are involved to 
physically trace defaulters. Details of each home visit, including the outcome 
of the visit, are reported to the facility manager. Each outreach tracing effort 
 
2  See https://www.righttocare.org/ [accessed 27 August 2020] 
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should be marked in the facility tracing register, indicating the date and 
outcome of the tracing visit.  
Patients who return to the facility after tracing are actively referred for 
psychosocial support to either a social worker, psychologist, peer support or 
other support groups. Patients in differentiated care models are returned to 
normal care if they cannot be found after 30 days of tracing. They can return 
to differentiated care if they meet the criteria in the future.   
Patients who have not reported back to the clinic for 90 days since their last 
scheduled visit and do not have a tracing outcome e.g. transferred out, died or 
stopped treatment are registered as LTFU. Before this entry is made, one more 
attempt at phoning or visiting the patient should be made. Information from 
this entire exercise is in principle fed back into the patients’ electronic record. 
3.1.6. MRC/Wits Agincourt unit activities 
 
Annual demographic surveillance  
The Agincourt HDSS was initiated in 1992. A baseline census was conducted 
in 20 villages chosen for their rural living conditions, limited access to public 
services, underperforming primary care clinics and communities of 
Mozambican refugees displaced by the civil war (413,414). Following the 
baseline demographic surveillance survey and three update rounds that 
occurred up to 1998, the site has conducted annual surveys since 1999. An 
annual update of the HDSS household rosters is made of every birth, death 
and migration within the HDSS households. A household roster showing 
current members (based on the previous year’s census) is printed onto each 
census form before the annual update. Trained fieldworkers visit each 
household and interview the most knowledgeable adult available. During the 
visit, individual-level information on all household members is checked and 
updated and any events that have occurred since the last census round are 
recorded. Fieldworkers also record maternity histories of all in-migrant 
women aged 15-55 years, as well as residence histories and other pertinent 
data modules built into the census. Census updates are supported by 
geographic information system (GIS) based maps to guarantee that every 
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household is covered. Maps are kept updated by recording global positioning 
system (GPS) coordinates for every new dwelling each year.  
For each death, a verbal autopsy should be conducted to establish a probable 
cause of death. A structured interview is conducted with people who were 
closely related to or cared for the deceased during the final illness and could 
report on symptoms and signs they observed during this period. The interview 
is conducted using a World Health Organisation validated tool, in the local 
language. Until 2010, two medical doctors independently reviewed the data to 
assign a cause of death based on international classification of diseases (ICD-
10) conventions (415), with a third doctor used in the event of a lack of 
consensus. The cause was coded ‘undetermined’ if this failed to yield any 
agreement (20,416). Since 2011, causes of death are assigned using the 
InterVA-4 probabilistic model (106). The database is stored in Microsoft SQL 
server in a relational database. Starting in 2017, the HDSS migrated from 
paper-based census forms to electronic forms administered on tablets.  
Ethics approval was obtained from the Human Research Ethics Committee 
(Medical) of the University of the Witwatersrand, Johannesburg, South Africa, 
for surveillance activities in the Agincourt HDSS (Appendix 11.2.1). Informed 
verbal consent is obtained at every surveillance visit from the household head 
or another eligible adult present (417). The person giving consent is noted in 
the household roster, with pertinent details and the date recorded by the 
fieldworker. 
Point-of-contact Interactive Record Linkage (PIRL) 
In parallel to demographic surveillance, chronic care HIV patient visit logs are 
collected by study fieldworkers in the eight health facilities that provide ART 
in the HDSS area. Fieldworkers also log other chronic care (diabetes and 
hypertension) patient visits. This work started in April 2014 at seven 
government facilities and was extended in 2015 to include one additional 
health facility. In addition to logging patient visits, these records are linked to 
the Agincourt HDSS demographic surveillance records using a procedure 
named Point-of-contact Interactive Record Linkage (PIRL) (103,104).  
This approach uses a probabilistic search algorithm to identify possible 
matches in the HDSS database for patients who visit any of the clinics. Possible 
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matches are subjected to a review in the presence of the patients whose records 
are being linked. This allows for any uncertainty to be resolved during a brief 
interaction where names of other household members or other unique 
information is used as a key attribute to adjudicate between possible matches. 
This also allows for ethical and privacy concerns to be addressed as informed 
consent is sought at the time of record linkage and given their participation in 
the process, individuals become fully aware of how their data are being used 
and can have any issues clarified.  
Ethics approval was obtained from the Human Research Ethics Committee 
(Medical) of the University of the Witwatersrand, Johannesburg, South Africa, 
for linkage of Agincourt HDSS demographic surveillance records and 
individual clinic records (Appendix 11.2.1). Informed written consent is 
obtained at every record linkage event from the individual whose records are 
being linked. 
3.2. Fieldwork operations 
Between August 2017 and December 2018, I undertook fieldwork in the 
Agincourt HDSS that aimed to determine the true outcomes of patients that 
had disengaged from HIV care and explore their experiences with HIV 
treatment in this setting through IDIs. As part of this fieldwork, I recruited and 
trained two teams of fieldworkers (quantitative team of four fieldworkers and 
a qualitative team of five fieldworkers). The quantitative team was trained on 
the aims of the study, the data that were required from the clinics, how to 
approach clinic staff during fieldwork, and data entry procedures. The 
qualitative team was trained on how to approach potential study participants, 
obtain informed consent, and conduct interviews using the study topic guide.  
The fieldwork was split into three different trips equating to approximately 6 















1 19/08/2017 4 months • Interviewed, hired, and trained four 
quantitative fieldworkers to perform the 
comprehensive record review 
• Created a Microsoft Access database to 
capture data from the record review 
• Liaised with clinics, RtC and HBCs to 
gain access to pertinent data 
• Supervised the collection of all data 
from the comprehensive record review 
in 8 clinics  
2 05/01/2018 1 month • Interviewed, hired and trained five 
qualitative fieldworkers  
• Handed lists of patients requiring 
supplementary tracing to the respective 
clinics  
• Supervised 31 IDIs. This involved daily 
debriefings to gain an understanding of 
the fieldworkers experiences each day 
3 25/11/2018 1 month • Revisited all the clinics to check 
TIER.Net, speak to RtC representatives 
and HBCs in an attempt to locate a last 
group of patients who remained LTFU 
after supplementary tracing.  
 
3.3. Quantitative research methods 
This section provides an overview of the quantitative research methods used. 
It includes information on the record review and tracing study (through which 
most of the data used in this research were generated) as well design of data 
collection tools, fieldworker recruitment and training, data collection and 
management, preparation of the data, ethical considerations for this work and 
analysis methods.   
3.3.1. Record review and tracing study 
Study design  
The study was an observational cohort study of PLHIV who initiated ART after 
record linkage began in 2014 and were considered LTFU on August 15, 2017 
to ascertain their treatment and vital status following disengagement from 
HIV services at eight clinics located within the Agincourt HDSS. All HIV-
positive adults (18 years or older3) who had declared residency in the HDSS 
 
3 Girls aged 14-17 were excluded due to ethical concerns as they are minors under South African law 
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and who had enrolled in HIV care since record linkage began in 2014 were 
eligible for the study. I only considered patients who had enrolled after record 
linkage began to account for survivor bias. Considering patients who initiated 
treatment before record linkage began would include only patients who had 
survived up to that point and exclude patients who had died, a group that 
would have different characteristics that merit investigation. 
Loss to follow-up was defined using the South African definition which is all 
patients who are more than 90 days late for a scheduled clinic appointment 
(412). For those without the date of the next scheduled clinic visit documented 
in their file, they were assumed to be on a month-long refill schedule and their 
next scheduled visit was set to 28 days after their last actual clinic visit. I used 
the PIRL database to identify and extract a list of patients who met the 
eligibility criteria and were more than 90 days late for a scheduled clinic 
appointment as of August 15, 2017 (the date of data extraction). These patients 
were recruited into a cohort and followed up until December 2018 to ascertain 
their treatment and vital status (Figure 3.11).   
The treatment and vital status of patients deemed LTFU was ascertained via: 
(i) Record review: I recruited, trained and supervised fieldworkers who 
compared the lists of patients LTFU against (a) TIER.Net (b) patient 
clinic files, (c) logbooks kept by RtC and HBCs. I then reviewed the 
PIRL database for duplicate patients (the same HDSS resident linked 
to multiple clinic records, which probably indicated a silent transfer). 
Finally, I reviewed residency and vital status from the demographic 
surveillance data collected by the HDSS. This was done on a case-by-
case basis.  
(ii) Supplementary tracing: For all patients for whom a satisfactory 
outcome could not be established, I conducted additional tracing in 
collaboration with HBCs. List of these patients were separated by 
clinic and given to the sisters-in-charge at each clinic. The sisters then 
liaised with HBCs to conduct physical tracing.  
(iii) A final attempt was made to search TIER.Net at clinics in the vicinity 
of patient’s homes to find any that might have transferred unofficially 
and who the record review and supplementary tracing had missed. 
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Figure 3.11: Record review and tracing flow chart 
 
Data collection 
All the data were entered either at the clinic or at the HBC compound. 
Fieldworkers worked in a room within the clinic designated by the clinic staff 
as available and without disruptions to their work. In order to collect data from 
clinic files, the fieldworkers retrieved individual files from the filing rooms at 
each clinic, with the permission of clinic staff (Figure 3.12). Files were returned 
to their rightful place once the pertinent data had been retrieved and entered. 
In order to collect data from TIER.Net, fieldworkers had to work around the 
schedule of the clinic data clerk in order not to disrupt their work. 
Fieldworkers received instructions on how to query the database and then 
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were signed into the database as a visitor with read-only rights. Permission to 
access RtC data was obtained from the province programme manager. 
Fieldworkers queried logbooks kept by RtC linkage officers.   
Figure 3.12: Fieldworkers retrieving files from Belfast Clinic (left), 







At each clinic, I obtained permission from the sister-in-charge before we 
commenced work. The fieldworkers worked in pairs. For the first 1-3 days at 
each clinic, one pair retrieved data from TIER.Net while the other pair 
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retrieved data from physical patient files. After this was completed, the 
fieldworkers reviewed RtC logbooks kept by RtC linkage officers if there was a 
RtC presence in the clinic (not all clinics were assisted by RtC). Finally, the 
fieldworkers reviewed HBC logbooks as well as physical tracing forms (Figure 
3.13) if these were available.  
Figure 3.13: Images showing examples of forms used by 
community outreach teams like HBCs (these were from Lillydale HBC, 







Data entry and management 
I designed a Microsoft Access database to collect data from the record review. 
This database contained a table for each data source (TIER.Net, patient clinic 
files, HBC, RtC). Each table had a Visual Basic front-end data entry form 
(Appendix 11.3.1). The forms included skip patterns and basic data checks like 
date validity and consistency (for example the tracing date could not happen 
before the last visit date in the PIRL database) to streamline data entry and 
make it more intuitive. Each clinic had a separate database. I recruited and 
trained four fieldworkers on how to use the database for data entry.  
I populated the tables and forms with the Patient IDs, file numbers, health 
facility, date of HIV diagnosis, ART initiation date, and the last visit date 
according to the PIRL database for all the patients that were LTFU. 
Additionally, fieldworkers received a list containing the patient ID, file 
number, first name, last name and date of birth of these patients. Names were 
not added to the database to ensure the data remained anonymised. The name 
lists were given to the fieldworkers at the beginning of the day and retrieved at 
the end of each workday. I personally kept the name lists during fieldwork and 
these lists were shredded at the end of the fieldwork.  
All eight health facility databases were stored on password-protected 
fieldwork laptops. At the end of each day, these laptops remained in either my 
possession or that of the Agincourt data supervisor until the next workday. 
Once data collection had ended at a clinic, the databases for that clinic 
(TIER.Net, patient files, RtC, and HBC) were transferred to my password 
protected laptop and deleted from the fieldwork laptops. I applied edit checks 
on the data. These included checks for missing data and any other 
inconsistencies. Where these were identified, I retrieved and entered the data 
into the database on my computer.  
At the end of data entry, I extracted the tables from each database and 
imported them into Stata. I then merged data from the different tables into 
one dataset for each clinic. All eight clinic datasets were then appended to form 
one dataset for analysis.   
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3.3.2. Statistical analysis methods 
All statistical analyses were conducted in Stata 15 (418) and R (419). Analyses 
for paper C included all patients who were more than 90 days late for a 
scheduled clinic appointment as well as a sample of patients recorded as still 
in care to act as a comparison group. Paper A and B included all patients that 
were LTFU excluding 57 patients who did not have an ART initiation date. 
Patients who had not yet initiated ART were excluded from analyses as they 
often did not have a next scheduled visit specified and as such it was 
impossible to determine whether they were LTFU or just visited the clinics less 
frequently. Furthermore, this population would not be comparable to patients 
who had potentially accrued some benefits from taking ART in terms of 
reductions in morbidity and mortality.  
The linkage rate for clinic and HDSS records for our cohort of patients was 
88%. The probabilistic algorithm for finding matches is not perfect and 
unfortunately in 12% of cases, even in the presence of the patient, the records 
of those reporting residence in the HDSS could not be linked to the HDSS 
dataset. There are various reasons that could explain this. It is possible that 
patients misunderstood the question regarding their residency, or that they 
thought that there might be some incentives for answering in the affirmative, 
or that they were genuine residents whose record could not be retrieved for a 
myriad of reasons including differently spelled names, or they had migrated 
into the HDSS after the last census round. It is impossible to differentiate the 
different groups, so to minimise bias, patients whose records had not been 
linked were included in all analyses. The implications of this choice are 
considered in further detail in the discussion chapter.  
All CD4 data were retrieved from patient clinic records (TIER.Net or patient 
files). All other clinical data were retrieved from the PIRL database, if any data 
were missing, this was cross-checked in the clinic records. Demographic data 
such as age and sex were retrieved from the PIRL database and cross-checked 
in the clinic and HDSS records. All socioeconomic data were retrieved from 





Table 3.2: Definition of terms used  
Term Definition 
The last appointment The last scheduled appointment for each patient as of 




The treatment status of the patient as recorded in 
TIER.Net during the comprehensive record review. 
The final outcome The outcome ascertained for each patient through the 
record review and tracing process. 
Data error A situation in which a patient was found still in care and 
<90 days late for their last appointment. Some data 
errors occurred because visit dates had not been 
properly entered in the PIRL database. Patients 
categorised as a data error were excluded from our 
analyses. 
Deceased A patient was considered to have died if they were 
reported as deceased in their patient file or in TIER.Net 
or if they were reported to have died through HDSS 
surveillance data.  
Re-engagement A patient was considered to have re-engaged in care if 
they were found to be still in care at the same clinic 
where they initiated treatment but were >90 days late 
for their last appointment (had previously been LTFU). 
Transfer out A patient was considered to have transferred if they had 
either reported taking treatment at another clinic (for 
clinics outside the Agincourt HDSS), if their ART 
initiation clinic had communicated with and 
ascertained their transfer to another clinic, or if there 
was record of them collecting treatment at another 
clinic within the Agincourt HDSS. 
Migration A patient was classified as having migrated out of the 
study site if they were recorded as having migrated 
through the Agincourt HDSS demographic 
surveillance, this migration event happened after their 
last clinic visit date and there was no proof that they 
were taking treatment at another facility. 
Stopped ART  A patient was considered alive and not on ART if they 
had been found and had reported that they had stopped 
ART, denied their HIV status or refused to return to the 
clinic. 
Alive with ART status 
unknown 
A patient was considered alive with ART status 
unknown if additional tracing yielded no definitive 
outcome, but they were found to still be alive through 
the most recent Agincourt HDSS demographic 
surveillance, with a surveillance date after their last 
clinic visit and there was no proof that they were taking 
treatment at any facility. 
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Source of resolution A source of resolution was the data source from which 
the final outcome for each patient was ascertained. 
Origin health facility The health facility at which a patient initiated ART and 
was recorded as LTFU 
Destination health 
facility 
The health facility to which a patient transferred their 
care after being recorded as lost to follow-up  
 
A descriptive analysis of outcomes following loss to follow-up was conducted 
for paper A, with outcomes stratified by sex, clinic variables such as baseline 
CD4 and pregnancy status at ART initiation in order to compare Option B+ 
women to the rest of the treatment population. With regards to the reasons for 
ART initiation, whereas specific reasons for ART initiation such as CD4 and 
presence of opportunistic infections were listed for the general population, this 
was not always consistently done and so non-PMTCT patients were all grouped 
together. A descriptive analysis of sources of resolution was also conducted 
with possible sources being through record review, through demographic 
surveillance data (migrations, deaths, alive with treatment status unknown), 
through subsequent updates to visit data in the PIRL database, through 
supplementary tracing, identification as duplicates in the PIRL database (one 
person matching to multiple clinic records), and through a search of patient 
records in clinics in close proximity to the patient’s residence. A descriptive 
analysis for causes of death was conducted for all patients for whom verbal 
autopsy data was available.   
For paper A, competing risk survival analysis methods were used to estimate 
the cumulative incidence of death, transfer, migration, ART stoppage and re-
engagement following LTFU. As we suspected that many deaths leading to loss 
to follow-up would occur closely after a last clinic visit, follow-up time began 
on the date of each patient’s last recorded clinic visit to account for any 
outcomes that might have occurred before patients would have been 
categorised as LTFU. These cumulative probabilities were used to produce 
status plots stratified by sex, pregnancy status at ART initiation and baseline 
CD4.  
Factors associated with mortality following LTFU were determined using a 
Cox regression model with all other outcomes considered as right censored. 
All models accounted for clustering at the clinic level with robust standard 
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errors. Bivariate analyses were conducted using an a priori list of variables, 
with all variables with p<0.1 included in the multivariable model. A 
parsimonious model was achieved using Wald tests. A similar analysis was 
conducted in paper B for factors associated with transferring to another facility 
following LTFU. However, in this model all variables with p<0.2 were included 
in the multivariable model.  
For paper C, to assess the degree and direction of misreporting of patient 
outcomes in TIER.Net, each patient was assigned a treatment status based on 
their current TIER.Net status (still in care, deceased, transferred out, lost to 
follow-up) and this was compared to their final outcome. A misclassification 
was defined as any instance where the patient’s TIER.Net treatment status did 
not match their final outcome. The variables produced from these two sources 
were cross-tabulated. A Pearson’s chi-square test was used to compare 
whether TIER.Net treatment status and the final outcome varied by age, sex, 
pregnancy status at ART initiation, ART initiation year, baseline CD4, time on 
ART, clinic visit schedule (used as a proxy for patient stability), health facility, 
and time since the patient’s last scheduled visit.  
To visualise this data, TIER.Net treatment status and the final outcome were 
aggregated by ART initiation status and reason, and time since the last missed 
appointment using the collapse command in Stata. These collapsed datasets 
were imported into R where the ggplot package was used to plot bar graphs of 
these data.  
As patients recorded as LTFU in TIER.Net were the most likely to be 
misclassified, a binary outcome variable was created to identify whether a 
patient was recorded as LTFU in TIER.Net. Logistic regression was used to 
assess the factors associated with being recorded as LTFU in TIER.Net. 
Logistic regression was also used to assess the factors associated with being 
misclassified in TIER.Net, with a binary outcome variable being created to 
indicate whether TIER.Net had misclassified a patient’s treatment status. 
Because we could not find a TIER.Net record for every patient, all cases where 
an electronic record could not be found were excluded from these analyses. 
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For paper B, an undocumented transfer was defined as one where the origin 
health facility was unaware and therefore did not have this recorded as a 
patient outcome within its system. Patients’ village of residence was 
ascertained through health facility and Agincourt HDSS records. A mid-point 
GPS coordinate of the village was used as each patient’s residence. I also 
obtained decimal degree coordinates for origin and destination health 
facilities by querying Google Maps. Geographic distances were calculated (i) 
between patients’ residence and both their origin and destination health 
facility, and (ii) between the origin and destination clinic. Kruskal-Wallis test 
was used to compare median distances disaggregated by age, sex, pregnancy 
status at ART initiation, type of transfer (documented or undocumented), ART 
initiation year, baseline CD4 count, time on ART, clinic visit schedule, health 
facility, and time since the patient’s last scheduled visit. Using ArcMap® 10.3.1 
(420), the health facility coordinates were imported to shapefiles with a WGS 
1984 coordinate system. I then used ArcMap to spatially visualise the locations 
of destination health facilities.  
The Circlize package in R (419,421) was also used to visualise the main 
corridors of movement between facilities. I created a matrix containing the 
transfer flow data with the input data calculated using Stata. Separate flow 
matrices were created for Option B+ women, other women, and men’s 
transfers as well as for documented and undocumented transfers. Each health 
facility was then allocated a circle segment with all transfers outside the HDSS 
aggregated under other facilities. I then created a data frame to store 
information on each segment of the circle plot. The circlize command was then 
used to plot the circle plots.  
3.3.3. Ethical considerations 
Permissions were obtained from the Mpumalanga Department of Health to 
collect and process data from the clinics. The district manager sent a letter to 
the PHC manager for the Bushbuckridge Department of Health. The PHC 
manager then sent a letter to each clinic explaining the study and its aims and 
objectives and authorising the data collection process. Ethical approval was 
obtained for the LSHTM, the University of Witwatersrand and the 
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Mpumalanga department of health ethical review boards for the collection and 
use of these quantitative datasets (Appendix 11.2.2). 
Fieldworkers who entered the clinic data were trained on the importance of 
protecting patient confidentiality. 
The name lists did not contain any sensitive information about HIV status or 
receipt of ART in case they inadvertently fell into the wrong hands. Separate 
lists were generated for each clinic, handed to fieldworkers at the beginning of 
a workday and retrieved at the end of the day. All lists remained in my 
possession throughout the duration of fieldwork. The database used for data 
collection as well as datasets generated from these databases only included ID 
numbers (Patient ID, file number) without names. During fieldwork, the 
databases were stored on password-protected laptops which were kept by me 
or the Agincourt data supervisor at the end of each workday. At the end of data 
collection these databases and datasets generated from them were stored in 
independent files on a secure laptop with password restricted access and 
deleted from the fieldwork laptops. All name lists were shredded at the end of 
data collection. 
The supplementary tracing component was intentionally nested into routine 
care as patients must give consent to be physically traced at their homes. As 
such, HBCs would have first consulted patient files to make sure they had 
consented to tracing before a supplementary tracing visit was attempted.     
3.4. Qualitative research methods 
This section provides an overview of the aims of the qualitative research and 
methods used, the objectives and design of the data collection tools, fieldwork 
recruitment and training, piloting, sampling and recruitment, data collection, 
preparation of the data and analysis of results. 
3.4.1. Aims and overview 
The overall aim of the qualitative study conducted for this thesis was to 
investigate patients experiences of HCT, HIV treatment including 
interruptions and re-engagement in care, and pregnant and breastfeeding 
women’s experiences with infant testing with a view to understanding if any of 
their experiences with HIV care and treatment were linked to interruptions or 
re-engagement in care. Data were generated through IDIs with HIV-positive 
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patients and structured observations of public areas at health facilities in the 
Agincourt HDSS to achieve this aim.  
The use of qualitative methods in this thesis allowed for a broader 
understanding of engagement in care in this setting. Fieldwork took place from 
January to February 2018. The design of data collection tools, fieldwork 
procedures and final analysis of results was done in collaboration with local 
fieldworkers and scientists. The fieldworkers helped to improve the data 
collection tools based their knowledge of the context which enhanced the 
relevance of the work. For example, they played a role in translating the IDI 
topic guide into Shangaan.  
3.4.2. Objectives and design of the data collection tools 
 
In-depth interviews 
In-depth interviews were chosen as a data collection method to enable a 
private and detailed discussion of their personal experiences of the HIV care 
and treatment programme. This allowed us to explore personal challenges 
faced while using the programme, barriers and motivators to remaining 
engaged with the programme. Interviews with non-pregnant women and men 
aimed to explore their HIV testing experience, ART treatment and follow-up, 
and any interruptions during treatment. I also aimed to understand re-
engagement in care in this setting to get a better understanding of the barriers 
and facilitators to re-engagement in care following treatment interruptions. 
These interviews were undertaken to understand how experiences among 
pregnant and breastfeeding women differed from those of PHIV who received 
their services outside of PMTCT. For pregnant and breastfeeding women 
infant testing was explored as an additional topic. Since research has shown 
that many pregnant women initiate ART for the sake of the baby(237), I 
hypothesised that infant testing and the results from infant testing could play 
a major role in their disengagement from care.  
The topic guide (Appendix 11.3.4) for the IDIs was divided into six sections 
reflecting the study objectives: life history (serving as an ‘ice-breaker’ and a 
way to build rapport), testing experience, ART treatment and follow-up, loss 
to follow-up, re-engagement in care, and infant testing. Fieldworkers were 
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encouraged to ask questions in the third person to ease anxiety around the 
discussion of sensitive topics. 
Observations 
Observations were conducted to enhance my understanding of how the health 
system may potentially affect participants engagement in care. Observations 
also helped me to understand how programmes actually operate in relation to 
standard operating procedures, guidelines and protocols issued by the 
national Department of Health. Furthermore, observations also helped to 
improve the IDI topic guide. For example, some questions about attitudes 
towards breastfeeding were added to the IDI topic guide after observing 
aggressive campaign posters against bottle-feeding in one clinic (Figure 3.14).   
Observations were recorded in a fieldwork notebook and in some cases, 
photographs were taken with the permission of clinic staff.  
Figure 3.14: Posters observed in one clinic campaigning against 
bottle-feeding 
  
3.4.3. Fieldworker recruitment and training 
Five Shangaan-speaking female fieldworkers were recruited. These 
fieldworkers were recruited from an existing pool of qualitative fieldworkers 
who were usually contractually employed by the Agincourt HDSS. There were 
no men available at the time of fieldwork. Four of the selected fieldworkers had 
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prior experience of conducting qualitative research in the Agincourt HDSS and 
this mostly included IDIs (the fifth had prior quantitative fieldwork 
experience). Fieldworkers had some knowledge of the HIV care and treatment 
services available in the clinics, but training revised the basics of HIV 
transmission, prevention, care and treatment. 
Training was conducted over a week and included a discussion on the aims of 
the study, discussions on approaching potential participants for the study, how 
to ensure that participants’ consent was truly informed, protecting anonymity 
and confidentiality, other ethical concerns (Figure 3.15). The training 
approaches included practical sessions and group discussions to facilitate 
learning. I designed all the fieldwork training tools which included PowerPoint 
slides, printing information sheets, and exercises to improve interviewing 
techniques. I also delivered the training sessions. Training sessions were 
interactive, and fieldworkers were encouraged to be at ease and to share their 
experiences from other projects. The fieldworker with no prior qualitative 
experience benefitted a lot from these sessions giving her an idea of what to 
expect and how to handle different scenarios during the interview process.  
All the data collection tools, and the information sheet (Appendix 11.3.3 and 
Appendix 11.3.4) were translated by the fieldworkers. This allowed them to 
become more familiar with the tools and gave them a chance to practice what 
translation would best be suited to asking the questions so that respondents 
clearly understood them. Translations were shared with the Agincourt HDSS 
















One day of training included the review, practice, and piloting of the topic 
guide. One fieldworker interviewed another while the rest watched with 
feedback being shared throughout the process. I observed these sessions and 
discussed difficulties encountered and potential refinements with the team.  
3.4.5. Sampling and recruitment 
Participants were recruited purposively for interview from the Agincourt 
HDSS community by fieldworkers to ensure a sample of patients with varying 
engagement in care profiles. For example, patients might have recently 
transferred their care to a new health facility, might have recently re-engaged 
in care, or might have currently been disengaged from care. The sample was 
chosen to ensure that patients with all these different treatment outcomes 
were included. In order to recruit patients who were currently disengaged from 
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care or who had previously disengaged from care, I utilised the PIRL database 
to identify patients that met these criteria.  
It was expected that patients currently disengaged from care would be hard to 
recruit as other studies have demonstrated previously (422). Many of these 
patients have been lost to the health system and are difficult to locate through 
the clinics. Furthermore, it was feared that an approach from the clinic could 
influence participation, firstly if potential participants mistook the researchers 
for clinic or healthcare system staff, secondly if they feared that this was an 
attempt to coerce or re-engage them into care and they were not ready, and 
finally if clinic staff were biased in who they approached to participate. These 
were people whose experiences I was particularly interested in eliciting 
because they have been under-represented in research on HIV treatment 
experiences. Therefore, I decided to utilise all data available through the 
potential participants’ HDSS records. Potential recruits’ HDSS records were 
used to retrieve the location of their home which was then located on maps 
showing all the dwellings in the HDSS. They were then contacted and were 
informed of the aims of the study and asked if they would be willing to 
participate. They were not coerced to participate but given an opportunity to 
share their opinions. The study was not framed as an HIV study but more as 
one to understand their experiences with using the healthcare system. If they 
agreed to participate, an appointment would then be scheduled.  
3.4.6. Data collection procedures 
 
In-depth interviews 
Thirty-one IDIs were conducted in total: 20 with women who were pregnant 
or breastfeeding when they initiated ART, 6 with non-pregnant women, and 5 
with men. A summary of the IDI sample size and recruitment procedures is 
provided in table 3.3 and basic demographic characteristics of all the 














IDIs 20 HIV+ women who 
were pregnant or 
gave birth since 
2015 (Option B+) 
Purposive to ensure 
diversity in terms of age, 
parity, clinic attended, and 
treatment outcomes (11 
reengaged, 3 transferred, 6 
not in care). All community 
recruits.  
IDIs 6 HIV+ women who 
had not been 
pregnant since 
2015 
Purposive to include as 
many treatment outcomes 
as possible (2 reengaged, 4 
transferred). All community 
recruits. 
IDIs 5 HIV+ men Purposive to include as 
many treatment outcomes 
as possible (2 reengaged, 3 
transferred). All community 
recruits.  
 
All interviews were conducted in Shangaan. All IDIs were audio-recorded 
following written consent from each participant. To begin with, three IDIs 
were conducted and transcribed into English. These three transcripts were 
manually open coded by myself with regular discussions with my supervisor 
(AW), and advisor (JR) to get a sense of the data that was being generated. 
Information garnered from this process was used to improve the topic guide 
and brief/support the fieldworkers in order to improve their interviewing 
technique. After each IDI, I held a debriefing session with the fieldworker 
involved to discuss how the interview went and identify any obstacles or ways 
to improve the process. Fieldworkers also made detailed field notes about the 







Table 3.4: Summary of characteristics of participants and non-
participants 














20 6 5 12 10 8 
 
N (%) N (%) N (%) N (%) N (%) N (%) 
Age 
19-24  7 (35.0) 1 (16.7) 1 (20.0) 5 (41.7) 0 (0.0) 1 (12.5) 
25-29  6 (30.0) 0 (0.0) 0 (0.0) 4 (33.3) 2 (20.0) 2 (25.0) 
30-34  5 (25.0) 0 (0.0) 0 (0.0) 2 (16.7) 3 (30.0) 0 (0.0) 
35+  2 (10.0) 5 (83.3) 4 (80.0) 1 (8.3) 5 (50.0) 5 (62.5) 











Single 3 (15.0)  1 (16.7) 4 (80.0) 7 (58.3) 3 (30.0) 3 (37.5) 
Married 4 (20.0) 1 (16.7) 0 (0.0) 1 (8.3) 1 (10.0) 0 (0.0) 
Informal 12 (60.0) 1 (16.7) 1 (20.0) 1 (8.3) 2 (20.0) 2 (25.0) 
Separated or Divorced 1 (5.0) 1 (16.7) 0 (0.0) 1 (8.3) 1 (10.0) 3 (37.5)) 
Widowed 0 (0.0) 2 (33.3) 0 (0.0) 0 (0.0) 2 (20.0) 0 (0.0) 
Unknown 0 (0.0) 0 (0) 0 (0.0) 2 (16.7) 1 (10.0) 0 (0.0) 
Education status 
No formal education 0 (0.0) 1 (16.7) 0 (0.0) 1 (8.3) 1 (10.0) 0 (0.0) 
Primary  3 (15.0) 2 (33.3) 2 (40.0) 6 (50.0) 4 (40.0) 6 (75.0) 
Secondary 15 (75.0) 1 (16.7) 3 (60.0) 2 (16.7) 3 (30.0) 1 (12.5) 
Tertiary 2 (10.0) 1 (16.7) 0 (0.0) 1 (8.3) 0 (0.0) 0 (0.0) 
Unknown 0 (0.0) 1 (16.7) 0 (0.0) 2 (16.7) 2 (20.0) 1 (12.5) 
Parity 
0 0 (0.0) 1 (16.7) 
    
1 to 2 17 (85.0) 0 (0.0) __ __ __ __ 
3 to 4 3 (15.0) 2 (33.3) __ __ __ __ 
5+ 0 (0) 3 (50.0) 
    
Self-reported treatment status  
In care 13 (65.0) 5 (83.3) 4 (80.0) __ __ __ 
Not in care 7 (35.0) 1 (16.7) 1 (20.0) __ __ __ 
Clinic treatment status 
Re-engaged 11 (55.0) 3 (50.0) 2 (40.0) 5 (41.7) 3 (30.0) 1 (12.5) 
Transferred 3 (15.0) 3 (50.0) 3 (60.0) 2 (16.7)  7 (70.0) 6 (75.0) 
Not in care 6 (30.0) 0 (0.0) 0 (0.0) 5 (41.7) 0 (0.0) 1 (12.5) 
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Timing of HIV diagnosis 
Newly diagnosed 12 (60.0) 5 (83.3) 2 (40.0) 5 (41.7) 6 (60.0) 8 
(100.0) 
Previously diagnosed 8 (40.0) 1 (16.7) 3 (60.0) 7 (58.3) 4 (40.0) 0 (0.0) 
EID done 
Yes 14 (70.0) __ __ __ __ __ 
No 4 (20.0) __ __ __ __ __ 
Incomplete (<18 months) 2 (10.0) __ __ __ __ __ 
Infant’s HIV status at the time of the interview 
Negative  15 (75.0) __ __ __ __ __ 
Positive 1 (5.0) __ __ __ __ __ 
Unknown 4 (20.0) __ __ __ __ __ 
Reason for non-participation 
Not at home __ __ __ 3 (25.0) 3 (30.0) 5 (62.5) 
Migrated  __ __ __  5 (41.7) 5 (50.0) 2 (25.0) 
Could not be found __ __ __ 1 (8.3) 1 (10.0) 0 (0.0) 
Refusal __ __ __ 3 (25.0) 1 (10.0) 1 (12.5) 
 
Observations 
I conducted observations at all the clinics and at some of the HBC compounds. 
In instances where I was observing HBCs, I was accompanied by a fieldworker 
who was fluent in Shangaan to assist with translating questions and answers. 
I kept fieldnotes and in some instances with the permission of clinic staff or 
HBCs also took some photographs. Observations did not follow any systematic 
or predetermined format but were done informally, and all observation notes 
were recorded in English.  
3.4.7. Data preparation and analysis 
Audio recordings from IDIs were translated and transcribed directly into 
English by the qualitative fieldworkers. The translated transcripts were 
uploaded to Nvivo11.  
Preliminary analysis was conducted in the field to identify emerging themes 
from the data generated. Information from the debriefing sessions and 
fieldworker notes was used to modify the remaining interviews with probes 
added to add more clarity or to explore new emerging concepts. Probes 
included questions on infant testing counselling sessions at the clinics 
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including when during the pregnancy these sessions occurred and the content 
of these sessions. 
The final analysis stage aimed to explore maternal engagement in care and 
infant outcomes in detail. Only the 20 IDIs conducted with HIV+ women who 
had given birth since 2015 were extensively analysed (while the IDIs 
conducted with men and non-pregnant women generated interesting findings, 
the themes did not align with my objectives and were therefore excluded). I 
analysed the data generated thematically drawing on the principles of 
inductive coding to identify themes. I coded all the transcripts with the aid of 
Nvivo11. The coding framework was continually refined as more transcripts 
were analysed to capture new codes as they emerged. Codes were then grouped 
and conceptualised to identify themes. Two themes were considered for 
further analysis those relating to women’s engagement in care and those 
relating to infant testing. As mentioned in chapter two, practice theory 
(83,85,87) was identified as an appropriate theoretical framework with which 
to present and relate the findings. Participants’ accounts and social practices 
were presented in relation to engagement in care and infant testing, the main 
social practices of interest. Interpretations were built by exploring 
relationships between the engagement in care, infant testing and other social 
practices mentioned by the participants and considering the meanings they 
gave to these practices and the competences they described in relation to 
enacting them. 
3.4.8. Ethical considerations for the qualitative research 
Ethical approval for the qualitative study was received from the LSHTM, the 
University of Witwatersrand and the Mpumalanga Department of Health 
ethical review boards (Appendix 11.2.2). Members of the HDSS give consent 
to be approached at home using contact information provided to the HDSS 
team and to be invited to participate in relevant studies with the 
understanding that they have the right to refuse to participate. As the 
population of the HDSS is studied all year round, it was not unusual for HDSS 
staff to approach participants at the homes and as a result of this, patient 
confidentiality was kept. Interviews took place in private at a location of the 
participant’s choosing.  
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All IDI participants were informed about the study before commencing the 
interviews. They were informed of their right to refuse to participate and that 
their refusal would not affect the services they received through the healthcare 
system or result in any loss of benefits regarding medical treatment. They were 
also advised that all discussions were confidential and that they could refuse 
to answer any questions or leave the interview at any time. Written informed 
consent was obtained for all the IDIs. 
Interviews were transcribed on password protected fieldwork computers. All 
transcripts were also individually password protected. All documentation was 
labelled with codes. Interviews were labelled with a number, followed by the 
status of the patient, the initial of the first name of the fieldworker and the date 
of the interview. For example, the fourth interview was with a patient who had 
re-engaged in care and the label was 04RE24/01/2018. The list of all people 
that were approached to participate as well as all participants was kept in a 
password protected Excel spreadsheet on my personal laptop which also has 
password-restricted access. Published quotations by participants were 
anonymised and documented observations were not linked to the participants. 
Audio recordings were stored on a secured Agincourt HDSS server and deleted 
from the recorders after transcription. Translations, notes and other outputs 
were also stored on the secure server. I also kept transcripts and fieldnotes on 





4. Paper A: Outcomes after being 
lost to follow-up differ for 
pregnant and postpartum women 
when compared to the general 
HIV treatment population in 
rural South Africa 
 
Introduction to the paper: 
This paper (A) utilises data from the record review and tracing study described 
in chapter 3 to investigate objective 1. The paper provides estimates of the 
outcomes for patients that were considered to be lost to follow-up through the 
linked clinic-HDSS dataset. This paper was conceived as a means to explore 
LTFU among pregnant WLHIV (particularly under Option B+) which has not 
been widely researched. As such, outcomes are disaggregated by sex and 
pregnancy status at ART initiation. I disaggregated the outcomes in order to 
compare these groups with the rationale that any differences observed might 
explain why pregnant and postpartum women disengage from care at higher 

















Background: Undetermined attrition prohibits a full understanding of the 
coverage and effectiveness of HIV programmes. Outcomes following loss to 
follow-up (LTFU) among antiretroviral therapy (ART) patients may differ 
according to their reasons for ART initiation.  
Setting: We compare the true outcomes of adult patients previously identified 
as LTFU by reason for ART initiation in eight health facilities in north eastern 
South Africa. 
Methods: Adult HIV patient records were linked to health and demographic 
surveillance system (HDSS) data from 2014 to 2017.  
Outcomes of adults categorised as LTFU (>90 days late for the last scheduled 
clinic visit) were determined through clinic and routine tracing record reviews, 
consultation of HDSS data, and supplementary tracing. 
We calculated the proportion of patients per outcome category and performed 
competing risk survival analysis to estimate the cumulative incidence of death, 
transfer, migration, ART interruption and re-engagement following LTFU. 
Results: Of 895/1017 patients LTFU with an outcome ascertained, 120 
(13.4%) had died, 225 (25.1%) re-engaged, 50 (5.6%) migrated out of the 
HDSS, 75 (8.4%) were alive and not on treatment, and 315 (35.1%) transferred 
their treatment. These outcomes varied by sex and pregnancy status at ART 
initiation. Mortality was less likely among pregnant women, patients with 
higher baseline CD4, and more likely among older patients.  
Conclusion: Patient survival and transfers to other facilities are considerably 
higher than those suggested in earlier studies. Outcomes differ for women who 
were pregnant or postpartum when initiating ART, with this population less 




As HIV programmes in sub-Saharan Africa have expanded, emphasis has been 
put on initiating patients on antiretroviral therapy (ART) as early as possible 
in the course of HIV infection (5,6). Eligibility for ART has changed since the 
adoption of Option B+ which made all pregnant and postpartum women 
eligible for ART as soon as they tested HIV positive and “Treat all” which 
extended this eligibility to all people living with HIV (PLHIV) (9). Although 
ART initiation rates among people diagnosed with HIV have increased 
(360,423,424), many programmes have experienced high attrition rates, 
especially among women who initiate ART for prevention of mother-to-child 
transmission of HIV (PMTCT) (11). Many of these patients are classified as lost 
to follow-up (LTFU), a general term for unknown outcomes of patients who 
have not returned for a scheduled clinic visit. LTFU is often an amalgamation 
of “silent” (undocumented) clinic transfers, treatment interruptions or 
stoppages, and deaths (15,51,52,55,56), which are challenging to accurately 
document using routine reporting mechanism (16,102,367).  
Misclassification of patients as being LTFU can lead to as much as a five-fold 
underestimation of retention and deaths (425). Understanding true outcomes 
among patients who are reported as LTFU is important in order to accurately 
monitor and report on indicators for national ART programmes and better 
target tracing efforts (52). Accurate mortality estimates are also important for 
parameterising epidemic projections in software programmes such as the 
UNAIDS Spectrum package (91). 
A systematic review of HIV patient tracing studies conducted in sub-Saharan 
Africa from 2001 to 2012 reported that 39% of patients documented as LTFU 
in clinic records had died, 18.6% had self-transferred to other HIV clinics, and 
28.6% had stopped ART but were still alive (15). An earlier review covering 
studies in sub-Saharan Africa undertaken between 2004 and 2008 reported 
that 42% of patients documented as LTFU in HIV clinics had died (14). 
These two reviews were conducted in the earlier stages of sub-Saharan African 
ART programmes when ART patient profiles included a higher proportion 
with severe immunosuppression at treatment initiation and before universal 
ART for HIV positive pregnant women (Option B+) had been introduced 
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(259). In addition, decentralisation of ART programmes means ART can be 
provided closer to patients’ homes (15), which may have increased the number 
of “silent” transfers taking place within these programmes. Furthermore, the 
proportion of pregnant and postpartum women in ART programmes has 
increased since the adoption of Option B+. This population differs from the 
general adult population on ART in several ways that are likely to impact the 
true outcomes among those LTFU, yet few studies have traced women LTFU 
from PMTCT programmes (17). Firstly, ART initiation eligibility criteria for 
pregnant women have included higher CD4 counts in many settings over the 
past decade, such that on average they are more likely to initiate treatment 
while still asymptomatic (258). In addition, childbirth is a risk factor for 
default from treatment programmes (89,365) for reasons including 
postpartum depression or out-referral from PMTCT programmes after 
delivery (245,257,366).  
With recent randomised control trials of universal test and treat showing 
modest and mixed results regarding reducing HIV incidence (94,96,426), it is 
imperative that we understand outcomes among non-adherent patients 
including those LTFU. This will help to develop and direct innovative ways to 
identify and reach those who have truly disengaged from care. In this context, 
we conducted a tracing study in Agincourt in rural north-eastern South Africa 
to ascertain the true outcomes of patients who were LTFU, disaggregated by 
whether they were pregnant or postpartum when initiating ART (PMTCT) or 
not, to better understand the outcomes of this group and compare them to the 




The Agincourt Health and Demographic Surveillance System (HDSS) is 
located in Mpumalanga province in rural north-eastern South Africa. 
Established in 1992, the site is approximately 475 square kilometres and has 
conducted annual demographic surveys within the HDSS population to 
capture births, deaths and migrations since 1999 (20,413). In 2013, HIV 
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prevalence in the HDSS population aged 15 years or older was estimated at 
19.4% (398). 
The HDSS also collects verbal autopsy (VA) data to ascertain probable causes 
of death (105). In brief, a structured interview was conducted with people who 
were closely related to or cared for the deceased during the final illness and 
could report on symptoms and signs they observed during this period. The 
interview was conducted using a locally validated tool, in the local language. 
Until 2010, two medical doctors independently reviewed the data to assign a 
cause of death based on international classification of diseases (ICD-10) 
conventions (415), with a third doctor used in the event of a lack of consensus. 
The cause was coded ‘undetermined’ if this failed to yield any agreement 
(20,416). Since 2011, causes of death are assigned using the InterVA-4 
probabilistic model (106).  
There are five primary health facilities and three secondary community health 
centres located within the Agincourt HDSS, all of which offer HIV services 
including testing and treatment. All health facilities routinely trace patients 
that are late for a scheduled appointment, with some clinics receiving tracing 
support from two non-profit organisations, Right-to-Care (RtC) (6 facilities) 
and Home-Based Carers (HBC) (7 facilities). Routine tracing is described in 
detail elsewhere (412). Briefly, tracing procedures are triggered once a patient 
is more than five working days late for a scheduled visit and usually involves 
two steps, three phone calls and a home visit if the phone calls do not yield a 
satisfactory outcome. Patients are considered LTFU if they have not returned 
to the clinic 90 days after their scheduled visit. 
In 2014, an initiative was started to identify registered HDSS residents when 
they visited local health facilities. The point-of-contact interactive record 
linkage (PIRL) matches chronic care (HIV, diabetic and hypertensive) patient 
information at the health facility to their HDSS record. This is done in the 
presence of the patient to resolve any indecision about their identity in the 
event of multiple resident matches (104).  
4.3.2. Record review and tracing study 
Using the PIRL database, we identified patients who were more than 90 days 
late for a scheduled HIV clinic appointment on August 15, 2017 at any of the 
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eight health facilities located in the Agincourt HDSS. Patients were included 
in the cohort if they were 18 years or older, had ever declared residency in the 
HDSS, and had enrolled in HIV treatment after PIRL was established at the 
health facilities. 
Patients who had not yet initiated ART were excluded from our analyses as 
they did not have a next scheduled visit and as such it was impossible to 
determine whether they were LTFU or just visited the clinics less frequently. 
Furthermore, this population would not be comparable to patients who had 
potentially accrued some benefits from taking ART. 
Patients were followed up to ascertain whether they were still alive and still on 
treatment. Trained fieldworkers conducted a thorough record review, on a 
case-by-case basis, to resolve each patient outcome by comparing the list of 
patients LTFU against (i) TIER.Net (the electronic medical records database 
for health facilities in South Africa) (100) (ii) paper-based patient clinic files, 
and (iii) logbooks kept by RtC and HBC. The PIRL database was also reviewed 
for duplicate patients who were then considered silent transfers. Residency 
and vital status were also checked in the HDSS demographic surveillance 
database.  
Home-Based Carers conducted a further home visit for all patients without an 
outcome resolution (i.e. no definitive outcome after the record review and for 
whom routine tracing had not previously been done). For all patients 
remaining LTFU, searches were undertaken in TIER.Net databases of clinics 
in close proximity to their residence to capture any further silent transfers 
(Figure 4.1).  
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A patient was considered to have died if they were reported as deceased in their 
patient file or in TIER.Net or if they were reported to have died through HDSS 
surveillance data.  
A patient was considered to have re-engaged in care if they were found to still 
be in care at the same clinic where they initiated treatment but were >90 days 
late for their last appointment.  
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A patient was defined as having transferred if they had either reported taking 
treatment at another clinic, if the clinic at which they initiated ART had 
communicated with and ascertained their transfer to another clinic, or if there 
was a record of them collecting treatment from another clinic within the 
Agincourt HDSS.  
Patients were defined as having migrated if they were recorded as such 
(movement outside the study area) through the HDSS, the migration event 
happened after their last clinic visit and there was no evidence of them taking 
treatment at another clinic.  
A patient had stopped ART if they had been found and reported that they 
stopped ART, denied their HIV status or refused to return to the clinic.  
A patient was alive with ART status unknown if additional tracing yielded no 
definitive outcome, but they were found to still be alive through the most 
recent demographic surveillance round, with a surveillance date after their last 
clinic visit.  
A data error was a situation where a patient was <90 days late for their next 
scheduled appointment but was erroneously classified as LTFU.  
4.3.4. Statistical analyses 
Counts and proportions were calculated for socio-demographic, baseline 
clinical characteristics, patient tracing outcomes, and verbal autopsy causes of 
death. A Pearson’s chi-square test was used to compare categorical variables.  
Competing risk survival analysis methods were used to estimate the 
cumulative incidence of death, transfer, migration, ART stoppage and re-
engagement following loss to follow-up (LTFU). Follow-up time began on the 
date of each patient’s last recorded clinic visit as we suspected that some 
outcomes especially deaths would occur closely following a last visit and before 
patients would have been categorised as LTFU. Using these cumulative 
probabilities, status plots were produced stratified by sex, pregnancy status at 
ART initiation and baseline CD4.  
A Cox regression model was used to determine the factors associated with 
death, with all other outcomes considered to be right-censored. Bi-variate 
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analyses were conducted with a priori selected variables that had been shown 
to be associated with death in previous studies (14,427–429). All variables with 
p<0.1 were included in the multivariable Cox regression model. A 
parsimonious model was achieved using Wald tests. All analyses were 
conducted using Stata 15 (418). All models accounted for clustering at the 
clinic level and utilised robust standard errors.  
4.3.5. Ethics 
Ethical approval was obtained from the London School of Hygiene and 
Tropical Medicine, the University of Witwatersrand and the Mpumalanga 
Department of Health. 
4.4. Results 
4.4.1. Population characteristics 
Over the study period, 4089 patients were added to the PIRL database and 
met the inclusion criteria. Of these 4089, 1325 (32.4%) met the LTFU criteria 
and were eligible for inclusion in the record review and tracing study. Of these 
1325 patients, 166 (12.5%) did not have an ART initiation date. Further 
investigation of these 166 patients found 46 (27.7%) had initiated ART after 
record linkage, 59 (35.5%) had not yet initiated ART and 61(36.7%) had 
initiated ART before record linkage began. These 61 patients and the 59 non-
ART patients were excluded from further analyses. Of the remaining 1205 
patients, 188 (15.6%) were misclassified as LTFU due to data errors (missed 
clinic visits in the PIRL database) and were excluded from further analysis 
(Figure 4.2).  
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Figure 4.2: Number of patients that were eligible at each stage 
and the number of patients excluded at each stage 
 
 
Of 188 patients who were categorised as data errors, 39 (20.7%) returned early 
(before their next scheduled visit), 58 (30.9%) returned on the exact date of 
their next scheduled visit, 30 (16.0%) were between 1 to 7 days late for their 
next scheduled visit, and 61 (32.4%) were more than 7 days late for their next 
scheduled visit and were a median of 43 days late (IQR: 27, 58). These 61 
probably indicate the utility of routine tracing as tracing procedures would 
have in theory been performed for them. The 91 patients that were late for their 
scheduled visit, were late for a median of 27 days (IQR: 6, 55). The remaining 
1017 patients were 91 to 1188 days late (Figure 4.3). 
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Figure 4.3: Histogram and kernel density plots of the distribution 
of days late for a missed appointment disaggregated by 
pregnancy status at ART initiation 
 
Of the 1017 remaining patients, 280 (27.5%) initiated ART for PMTCT, 767 
(75.4%) were females and 849 (83.5%) linked to an HDSS record (Table 4.1). 
Pregnant women were younger with a median age of 29 years (IQR: 25, 33) 
compared to non-pregnant women, 33 years (IQR: 28, 42) and men, 41 years 
(IQR: 34, 48). Of 280 patients who initiated ART for PMTCT, 52 (18.6%) had 
a baseline CD4 <200 cells/ µL compared with 193 of 487 (39.6%) non-
pregnant women and 146 of 250 (58.4%) men. None of the patients who 
initiated ART for PMTCT with baseline CD4 <200 cells/ µL were categorised 
as WHO stage III/IV compared to 53 of 193 (27.5%) non-pregnant women and 
45 of 146 (30.8%) men. Furthermore, 5.0% of women who initiated treatment 
for PMTCT had a CD4 less than 100 cells/µL compared to 21.8% of non-
pregnant women and 34.4% of men. The main reason for ART initiation for 























90 270 450 630 810 990 1170





















90 270 450 630 810 990 1170






















90 270 450 630 810 990 1170

















90 270 450 630 810 990 1170




Table 4.1: Patient demographic and clinical characteristics, and 









1017 280 487 250 
 
N (%) N (%) N (%) N (%) 
Age 
    
18-29 333 (32.7) 150 (53.6) 157 (32.2) 26 (10.4) 
30-44 484 (47.6) 124 (44.3) 226 (46.4) 134 (53.6) 
45-59 141 (13.9) 6 (2.1) 70 (14.4) 65 (26.0) 
60+ 58 (5.7) 0 (0) 33 (6.8) 25 (10.0) 
Missing 1 (0.1) 0 (0) 1 (0.2) 0 (0) 
ART reason 
    
CD4 549 (54.0) 0 (0) 376 (77.2) 173 (69.2) 
PMTCT 280 (27.5) 280 (100.0) 0 (0) 0 (0) 
WHO stage 77 (7.6) 0 (0) 45 (9.2) 32 (12.8) 
Test and treat 43 (4.2) 0 (0) 23 (4.7) 20 (8.0) 
TB 39 (3.8) 0 (0) 17 (3.5) 22 (8.8) 
Missing 29 (2.9) 0 (0) 26 (5.3) 3 (1.2) 
ART start year 
    
2014 211 (20.8) 58 (20.7) 101 (20.7) 52 (20.8) 
2015 414 (40.7) 105 (37.5) 212 (43.5) 97 (38.8) 
2016 350 (34.4) 107 (38.2) 157 (32.2) 86 (34.4) 
2017 42 (4.1) 10 (3.6) 17 (3.5) 15 (6.0) 
Time on ART 
    
≤3 months 325 (32.0) 89 (31.8) 136 (27.9) 100 (40.0) 
3-6 months 190 (18.7) 70 (25.0) 88 (18.1) 32 (12.8) 
6-12 months 228 (22.4) 70 (25.0) 114 (23.4) 44 (17.6) 
12-24 months 219 (21.5) 39 (13.9) 120 (24.6) 60 (24.0) 
>24 months 55 (5.4) 12 (4.3) 29 (6.0) 14 (5.6) 
Baseline CD4 
    
<100 206 (20.2) 14 (5.0) 106 (21.8) 86 (34.4) 
100-199 185 (18.2) 38 (13.6) 87 (17.9) 60 (24.0) 
200-349 261 (25.7) 71 (25.4) 129 (26.5) 61 (24.4) 
350-499 193 (19.0) 74 (26.4) 95 (19.5) 24 (9.6) 
500+ 145 (14.3) 64 (22.9) 64 (13.1) 17 (6.8) 
Missing 27 (2.6) 19 (6.8) 6 (1.2) 2 (0.8) 
Baseline WHO stage 
   
I 722 (71.9) 261 (93.2) 329 (67.6) 132 (52.8) 
II 143 (14.1) 17 (6.1) 73 (15.0) 53 (21.2) 
III 129 (12.7) 2 (0.7) 70 (14.4) 57 (22.8) 
IV 10 (1.0) 0 (0) 6 (1.2) 4 (1.6) 
Missing 13 (1.3) 0 (0) 9 (1.8) 4 (1.6) 
Refill schedule 
    
1 month 672 (66.1) 188 (67.1) 322 (66.1) 162 (64.8) 
2 months 233 (22.9) 68 (24.3) 102 (20.9) 63 (25.2) 
3 months 79 (7.8) 20 (7.1) 44 (9.0) 15 (6.0) 
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>3 months 33 (3.2) 4 (1.4) 19 (3.9) 10 (4.0) 
Health Facility 
    
Agincourt 272 (26.7) 74 (26.4) 141 (28.9) 57 (22.8) 
Belfast 186 (18.3) 64 (22.9) 80 (16.4) 42 (16.8) 
Cunningmore 58 (5.7) 16 (5.7) 32 (6.6) 10 (4.0) 
Justicia 120 (11.8) 42 (15.0) 42 (8.6) 36 (14.4) 
Kildare 117 (11.5) 25 (8.9) 62 (12.7) 30 (12.0) 
Lillydale 166 (16.3) 32 (11.4) 81 (16.6) 53 (21.2) 
Thulamahashe 25 (2.5) 9 (3.2) 12 (2.5) 4 (1.6) 
Xanthia 73 (7.2) 18 (6.4) 32 (7.6) 18 (7.2) 
Time since last appointment 
  
≤1 year 526 (51.7) 130 (46.4) 255 (52.4) 141 (56.4) 
1-2 years 369 (36.3) 117 (41.8) 176 (36.1) 76 (30.4) 
>2 years 122 (12.0) 33 (11.8) 56 (11.5) 33 (13.2) 
AHDSS outcome 
   
Still in HDSS 505 (49.7) 142 (50.7) 237 (48.7) 126 (50.4) 
Deceased 74 (7.3) 6 (2.1) 42 (8.6) 26 (10.4) 
Migrated 270 (26.5) 99 (35.4) 125 (25.7) 46 (18.4) 
Not linked 168 (16.5) 33 (11.8) 83 (17.0) 52 (20.8) 
Final Outcome 
    
Deceased 120 (11.8) 10 (3.6) 60 (12.3) 50 (20.0) 
Transferred out 315 (31.0) 82 (29.3) 176 (36.1) 57 (22.8) 
Stopped ART 75 (7.4) 28 (10.0) 20 (4.1) 27 (10.8) 
Migrated 49 (4.8) 21 (7.5) 22 (4.5) 6 (2.4) 
Reengaged 225 (22.1) 54 (19.3) 110 (22.6) 61 (24.4) 
Alive: ART 
unknown 
111 (10.9) 45 (16.1) 45 (9.2) 21 (8.4) 
LTFU 122 (12.0) 40 (14.3) 54 (11.1) 28 11.2) 
 
4.4.2. Sources of resolution 
Of the 1017  patients LTFU, 895 (88.0%) were resolved, with 536 (59.9%) of 
these occurring through record review, 155 (17.3%) through demographic 
surveillance data (23 migrations, 21 deaths, 111 alive), 72 (8.0%) through 
subsequent visit data in the PIRL database, 53 (5.9%) through supplementary 
tracing, 57 (6.4%) identified as duplicates in the PIRL database (one person 
matching to multiple clinic records), and 22 (2.5%) through a search of patient 
records in clinics in close proximity to the patient’s residence. 
4.4.3. Patient outcomes 
Of 1017 patients LTFU, 120 (11.8%, 95% C.I: 9.9-13.9) had died , 315 (31.0%, 
C.I: 28.1-33.9) had transferred to another facility, 75 (7.4%, C.I: 5.8-9.1) had 
stopped ART, 49 (4.8%, C.I: 3.6-6.3) had migrated, 225 (22.1%, C.I: 19.6-24.8) 
re-engaged in care, 111 (10.9%, C.I: 9.1-13.0) were alive with an unknown 
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treatment status and 122 (12.0%) remained LTFU. These outcomes differed 
(all p<0.001) by sex, age, baseline CD4 count, time on ART, clinic visit 
schedule, health facility, time since a missed appointment, and ART initiation 
reason. Women who initiated treatment while pregnant or postpartum were 
less likely to have died (3.6% (C.I: 1.7-6.5) compared to 14.9% (C.I: 12.4-17.7)) 
and more likely to have migrated (7.5% (C.I: 4.7-11.2) compared to 3.8% (C.I: 
2.5-5.4)), to be alive with their ART status unknown (16.1% (C.I: 12.0-20.9) 
compared to 8.9% (C.I: 7.0-11.2)) or stopped ART (10.0% (C.I: 6.7-14.1) 
compared to 6.4% (C.I: 4.7-8.4)) (Table 4.2 & Figure 4.4). 
Figure 4.4: Outcome estimates and confidence intervals 
disaggregated by pregnancy status at ART initiation 
 
Most deaths occurred in the groups where baseline CD4<200 cells/µL (Figure 
4.5). Men were at highest risk of mortality, and pregnant women were at the 
lowest risk (Figure 4.6). Men and pregnant women also had higher risks of 
being alive and not in care compared to non-pregnant women (Figure 4.6). 
The mortality risk appeared to be similar for all CD4 categories for pregnant 




Figure 4.5: Status of patients by baseline CD4 and years since 
their last clinic visit 
 
Figure 4.6: Status of patients by sex, pregnancy status at ART 































































0 1 2 3 4
Years
CD4>500
Deceased Alive/Not on ART Migrated Transferred






























































0 1 2 3 4
Years
Men
Deceased Alive/Not on ART Migrated Transferred
Reengaged Alive/unknown ART LTFU(Unresolved)
154 
 




Deceased Transferred out Stopped ART Migrated Reengaged Alive: ART 
unknown 
Still LTFU All LTFU 
 
120 315 75 49 225 111 122 1017 
 
N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
 
Sex (p<0.001) 
        
Female 70 (9.1) 258 (33.6) 48 (6.3) 43 (5.6) 164 (21.4) 90 (11.7) 94 (12.2) 767 (75.4) 
Male 50 (20.0) 57 (22.8) 27 (10.8) 6 (2.4) 61 (24.4) 21 (8.4) 28 (11.2) 250 (24.6) 
Age (p<0.001) 
        
18-29 17 (5.1) 117 (35.1) 24 (7.2) 25 (7.5) 61 (18.3) 46 (13.8) 43 (12.9) 333 (32.7) 
30-44 55 (11.4) 147 (30.4) 37 (7.6) 21 (4.3) 116 (24.0) 50 (10.3) 58 (12.0) 484 (47.6) 
45-59 27 (19.1) 38 (26.9) 11 (7.8) 2 (1.4) 35 (24.8) 13 (9.2) 15 (10.6) 141 (13.9) 
60+ 21 (36.2) 13 (22.4) 3 (5.2) 1 (1.7) 12 (20.7) 2 (3.4) 6 (10.3) 58 (5.7) 
Missing 0 (0) 0 (0) 0 (0) 0 (0) 1 (100) 0 (0) 0 (0) 1 (0.1) 
ART reason (p<0.001) 
       
Non-PMTCT 110 (14.9) 233 (31.6) 47 (6.4) 28 (3.8) 171 (23.2) 66 (8.9) 82 (11.1) 737 (72.5) 
PMTCT 10 (3.6) 82 (29.3) 28 (10.0) 21 (7.5) 54 (19.3) 45 (16.1) 40 (14.3) 280 (27.5) 
ART start year (p=0.251) 
       
2014 28 (13.3) 58 (27.5) 14 (6.6) 18 (8.5) 50 (23.7) 19 (9.0) 24 (11.4) 211 (20.7) 
2015 41 (9.9) 149 (36.0) 33 (8.0) 16 (3.9) 82 (19.8) 44 (10.6) 49 (11.8) 414 (40.7) 
2016 46 (13.1) 100 (28.6) 24 (6.9) 14 (4.0) 82 (23.4) 41 (11.7) 43 (12.3) 350 (34.4) 
2017 5 (11.9) 8 (19.0) 4 (9.5) 1 (2.4) 11 (26.2) 7 (16.7) 6 (14.3) 42 (4.1) 
Time on ART (p<0.001) 
       
≤3 months 54 (16.6) 89 (27.3) 29 (8.9) 13 (4.0) 47 (14.5) 41 (12.6) 52 (16.0) 325 (32.0) 
3-6 months 18 (9.5) 62 (32.6) 13 (6.8) 8 (4.2) 31 (16.3) 30 (15.8) 28 (14.7) 190 (18.7) 
6-12 months 25 (11.0) 79 (34.6) 12 (5.3) 17 (7.5) 42 (18.4) 25 (11.0) 28 (12.3) 228 (22.4) 
12-24 months 16 (7.3) 76 (34.7) 17 (7.8) 9 (4.1) 75 (34.2) 13 (5.9) 13 (5.9) 219 (21.5) 
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>24 months 7 (12.7) 9 (16.4) 4 (7.3) 2 (3.6) 30 (54.5) 2 (3.6) 1 (1.8) 55 (5.4) 
Baseline CD4 (p<0.001) 
       
<100 50 (24.3) 64 (31.1) 8 (3.9) 4 (1.9) 38 (18.4) 13 (6.3) 29 (14.1) 206 (20.2) 
100-199 32 (17.3) 46 (24.9) 16 (8.6) 8 (4.3) 41 (22.2) 19 (10.3) 23 (12.4) 185 (18.2) 
200-349 19 (7.3) 69 (26.4) 23 (8.8) 12 (4.6) 63 (24.1) 43 (16.5) 32 (12.3) 261 (25.7) 
350-499 11 (5.7) 72 (37.3) 16 (8.3) 14 (7.3) 36 (18.6) 20 (10.4) 24 (12.4) 193 (19.0) 
500+ 8 (5.5) 53 (36.5) 11 (7.6) 10 (6.9) 41 (28.3) 12 (8.3) 10 (6.9) 145 (14.3) 
Missing 0 (0) 11 (40.7) 1 (3.7) 1 (3.7) 6 (22.2) 4 (14.8) 4 (14.8) 27 (2.6) 
Baseline WHO stage (p=0.017) 
       
I 65 (9.0) 230 (31.8) 55 (7.6) 38 (5.3) 159 (22.0) 88 (12.2) 87 (12.0) 722 (71.0) 
II 21 (14.7) 42 (29.4) 12 (8.4) 6 (4.2) 34 (23.8) 11 (7.7) 17 (11.9) 143 (14.1) 
III 26 (20.1) 39 (30.2) 7 (5.4) 4 (3.1) 28 (21.7) 9 (7.0) 16 (12.4) 129 (12.7) 
IV 5 (50.0) 1 (10.0) 1 (10.0) 0 (0) 2 (20.0) 0 (0) 1 (10.0) 10 (1.0) 
Missing 3 (23.1) 3 (23.1) 0 (0) 1 (7.7) 2 (15.4) 3 (23.1) 1 (7.7) 13 (1.3) 
Refill schedule (p<0.001) 
       
1 month 84 (12.5) 210 (31.2) 48 (7.1) 30 (4.5) 143 (21.3) 77 (11.4) 80 (11.9) 672 (66.1) 
2 months 24 (10.3) 71 (30.5) 21 (9.0) 14 (6.0) 43 (18.4) 24 (10.3) 36 (15.5) 233 (22.9) 
3 months 9 (11.4) 30 (38.0) 3 (3.8) 5 (6.3) 18 (22.8) 9 (11.4) 5 (6.3) 79 (7.8) 
>3 months 3 (9.1) 4 (12.1) 3 (9.1) 0 (0) 21 (63.6) 1 (3.0) 1 (3.0) 33 (3.2) 
Health Facility (p<0.001) 
       
Agincourt 27 (9.9) 66 (24.3) 15 (5.5) 11 (4.0) 110 (37.1) 21 (7.7) 22 (8.1) 272 (26.7) 
Belfast 16 (8.6) 52 (28.0) 13 (7.0) 12 (6.4) 32 (17.2) 29 (15.6) 32 (17.2) 186 (18.3) 
Cunningmore 11 (19.0) 21 (36.2) 8 (13.8) 1 (1.7) 7 (12.1) 5 (8.6) 5 (8.6) 58 (5.7) 
Justicia 20 (16.7) 30 (25.0) 13 (10.8) 7 (5.8) 14 (11.7) 11 (9.2) 25 (20.8) 120 (11.8) 
Kildare 16 (13.7) 50 (42.7) 10 (8.5) 8 (6.8) 14 (12.0) 9 (7.7) 10 (8.5) 117 (11.5) 
Lillydale 19 (11.4) 51 (30.7) 9 (5.4) 7 (4.2) 37 (22.3) 24 (14.5) 19 (11.4) 166 (16.3) 
Thulamahashe 3 (12.0) 4 (16.0) 1 (4.0) 0 (0) 7 (28.0) 6 (24.0) 4 (16.0) 25 (2.4) 




Time since last appointment (p<0.001) 
      
≤1 year 48 (9.1) 146 (27.8) 40 (7.6) 16 (3.0) 171 (32.5) 51 (9.7) 54 (10.3) 526 (51.7) 
1-2 years 53 (14.4) 134 (36.3) 26 (7.0) 19 (5.1) 46 (12.5) 44 (11.9) 47 (12.7) 369 (36.3) 
>2 years 19 (15.6) 35 (28.7) 9 (7.4) 14 (11.5) 8 (6.6) 16 (13.1) 21 (17.2) 122 (12.0) 
AHDSS outcome (p<0.001) 
       
Still in HDSS 17 (3.4) 177 (35.0) 52 (10.3) 7 (1.4) 141 (27.9) 111 (22.0) 0 (0) 505 (49.7) 
Deceased 70 (94.6) 4 (5.4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 74 (7.3) 
Migrated 22 (8.1) 86 (31.8) 19 (7.0) 34 (12.6) 58 (21.5) 0 (0) 51 (18.9) 270 (26.5) 
Not linked 11 (6.5) 48 (28.6) 4 (2.4) 8 (4.8) 26 (15.5) 0 (0) 71 (42.3) 168 (16.5) 
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Figure 4.7: Status of patients who were pregnant at ART 
initiation stratified by baseline CD4 count and years since their 
last clinic visit 
 
Figure 4.8: Status of non-pregnant female patients stratified by 
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4.4.4. Causes of death 
We managed to ascertain the probable cause of death for 58 (48.3%) of 120 
deaths through verbal autopsy data from the HDSS. HIV/AIDS was indicated 
as the main cause of death for 10 (17.2%) deaths and acute respiratory 
infection for 11 (19.0%) deaths. Other causes included tuberculosis, malaria, 
cardiovascular disease, and neoplasms. These causes of death varied by ART 
initiation reason (Table 4.3).  








Primary cause N (%) N (%) N (%) N (%) 
Acute respiratory infection 
(including pneumonia) 
2 (20.0) 6 (10.0) 3 (6.0) 11 (9.2) 
HIV/AIDS related death 0 (0) 8 (13.3) 2 (4.0) 10 (8.3) 
Pulmonary tuberculosis 1 (10.0) 0 (0) 4 (8.0) 5 (4.2) 
Malaria       0 (0) 3 (5.0) 0 (0) 3 (2.5) 
Oral neoplasms 0 (0) 0 (0) 1 (2.0) 1 (0.8) 
Digestive neoplasms 1 (10.0) 0 (0) 4 (8.0) 5 (4.2) 
Reproductive neoplasms 0 (0) 2 (3.3) 0 (0) 2 (1.7) 
Severe malnutrition 0 (0) 1 (1.7) 0 (0) 1 (0.8) 
Diabetes mellitus 0 (0) 0 (0) 2 (4.0) 2 (1.7) 
Acute cardiac disease 0 (0) 1 (1.7) 3 (6.0) 4 (3.3) 
Stroke 0 (0) 2 (3.3) 0 (0) 2 (1.7) 
Other and unspecified cardiac 
disease 
0 (0) 2 (3.3) 1 (2.0) 3 (2.5) 
Asthma      0 (0) 2 (3.3) 0 (0) 2 (1.7) 
Acute abdominal condition 0 (0) 1 (1.7) 0 (0) 1 (0.8) 
Pregnancy induced hypertension 0 (0) 1 (1.7) 0 (0) 1 (0.8) 
Obstetric haemorrhage 1 (10.0) 0 (0) 0 (0) 1 (0.8) 
Pregnancy related sepsis 0 (0) 1 (1.7) 0 (0) 1 (0.8) 
Anaemia of pregnancy 1 (10.0) 1 (1.7) 0 (0) 2 (1.7) 
Accidental exposure to smoke fire 
and flames 
0 (0) 1 (1.7) 0 (0) 1 (0.8) 




Total 10 60 50 120 
 
4.4.5. Factors associated with death 
Of 120 deaths, 48 (37.2%) occurred before the patient's next visit date, 42 
(32.6%) occurred after the patient's next scheduled visit date but before they 
would have met the criteria for LTFU, 30 (23.3%) occurred after the patient 




Figure 4.9: Timing of deaths disaggregated by sex and pregnancy 
status at ART initiation 
 
In multivariable competing risk regression, being pregnant at ART initiation 
(aHR: 0.36, 95% C.I: 0.15-0.87), and longer time on ART (12-24 months aHR: 
0.44, 0.23-0.85) were associated with lower hazard of death following LTFU. 
Older age (≥60 years aHR: 8.86, 3.90-20.14) and lower CD4 at ART initiation 
(<100 cells/µL aHR: 3.77, 2.31-6.15; 100-199 cells/µL aHR: 2.35, 1.49-3.69) 














Table 4.4: Factors associated with death  
 




    
Female Reference  __ 
  
Male 2.10 (1.57, 2.81) <0.001 
  
Age 
    
18-29 Reference  __ Reference __ 
30-44 2.68 (1.30, 5.51) 0.007 2.37 (0.98, 5.75) 0.056 
45-59 4.73 (3.13, 7.15) <0.001 2.96 (1.44, 6.08) 0.003 




    
Non-PMTCT Reference  __ Reference __ 
PMTCT 0.17 (0.07, 0.43) <0.001 0.36 (0.15, 0.87) 0.022 
ART start year 
    
2014 1.29 (0.82, 2.04) 0.268 
  
2015 Reference  __ 
  
2016 1.20 (0.67, 2.14) 0.536 
  
2017 1.28 (0.83, 1.97) 0.258 
  
Time on ART 
    
≤3 months Reference  __ Reference __ 
3-6 months 0.56 (0.31, 0.99) 0.048 0.76 (0.46, 1.25) 0.276 
6-12 months 0.74 (0.49, 1.13) 0.167 0.82 (0.56, 1.20) 0.307 
12-24 months 0.53 (0.31, 0.91) 0.023 0.44 (0.23, 0.85) 0.015 
>24 months 0.91 (0.41, 2.05) 0.828 0.60 (0.23, 1.56) 0.297 
Baseline CD4 
    
<100 4.26 (3.11, 5.82) <0.001 3.77 (2.31, 6.15) <0.001 
100-199 2.57 (1.60, 4.12) <0.001 2.35 (1.49, 3.69) <0.001 
200-349 Reference  __ Reference __ 
350-499 0.78 (0.39, 1.55) 0.483 1.11 (0.53, 2.36) 0.776 
500+ 0.82 (0.24, 2.79) 0.756 1.13 (0.35, 3.67) 0.840 
Baseline WHO stage 
    
I Reference  __ Reference __ 
II 1.71 (0.98, 3.00) 0.061 0.86 (0.40, 1.86) 0.706 
III 2.70 (1.77, 4.14) <0.001 1.36 (0.94, 1.96) 0.102 
IV 6.64 (3.08, 14.32) <0.001 3.14 (1.14, 8.59) 0.026 
Refill schedule 
    
1 month Reference  __ 
  
2 months 0.83 (0.37, 1.86) 0.647 
  
3 months 0.93 (0.49, 1.75) 0.824 
  
>3 months 0.74 (0.22, 2.42) 0.615 
  
Health Facility 
    
Agincourt Reference  __ Reference __ 
Belfast 1.03 (0.97, 1.09) 0.345 0.80 (0.61, 1.05) 0.108 
Cunningmore 3.14 (2.98, 3.31) <0.001 3.39 (2.92, 3.94) <0.001 
Justicia 2.10 (1.98, 2.24) <0.001 1.70 (1.55, 1.86) <0.001 
Kildare 1.90 (1.84, 1.95) <0.001 1.08 (0.78, 1.50) 0.639 
Bhubezi 1.26 (1.19, 1.34) <0.001 0.96 (0.73, 1.28) 0.810 
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Thulamahashe 0.93 (0.91, 0.95) <0.001 1.59 (1.15, 2.22) 0.005 
Xanthia 1.75 (0.70, 1.80) <0.001 1.98 (1.64, 2.38) <0.001 
Time since last 
appointment 
    
≤1 year Reference  __ Reference __ 
1-2 years 1.57 (1.03, 2.39) 0.037 1.75 (1.10, 2.78) 0.018 
>2 years 1.65 (0.73, 3.75) 0.228 0.81 (0.39, 1.67) 0.564 
 
4.5. Discussion 
We describe the treatment outcomes of HIV patients enrolled in care between 
April 2014 and August 2017 who had become LTFU in a rural South African 
setting as determined through a comprehensive record review and tracing 
study. Using multiple data sources and methods, we managed to ascertain the 
outcomes of 88% of the patients LTFU, a figure that is higher than most studies 
included in a recent systematic review of tracing studies in sub-Saharan Africa 
(15). We found that 31% of patients LTFU had transferred to another facility, 
22% had re-engaged in care, and 12% of patients had died. These percentages 
varied by sex, reason for ART initiation and baseline CD4 cell count. The 
differences for pregnant and postpartum women are particularly pertinent 
given that they represent the first iterations of treatment as prevention and 
could provide an indication for what to expect with the move to test and treat 
for all PLHIV. 
The proportion of patients reported as LTFU who had died in our study was 
substantially lower than the 42% and 39% reported in earlier systematic 
reviews of tracing studies from sub-Saharan Africa (14,15). Even if all the 
patients remaining LTFU after record review and tracing had died, mortality 
in our study would only rise to 24%. This lower percentage of deaths compared 
to the previous reviews is likely to be due to a healthier cohort of patients 
initiating treatment. We found that pregnant women were less likely to have 
died, an encouraging trend if it does translate to the general ART treatment 
population as less immunocompromised people begin to initiate ART. 
Mortality following LTFU may decrease further as universal test and treat 




In competing risk survival analysis, being pregnant at ART initiation, higher 
baseline CD4 and longer time on ART were protective against death, while 
older age was found to be associated with a higher hazard of death following 
LTFU. Our findings suggest baseline CD4 cell count, WHO stage, and older 
age remain accurate measures for determining which patients are at highest 
risk for death (357,429,430), and these characteristics could be used to help 
prioritise tracing interventions. Whereas mortality risk appeared to wane with 
increasing CD4 at baseline for non-pregnant women and men, mortality 
appeared to be similar for all CD4 categories for women who initiated 
treatment for PMTCT. This may reflect the fact that their mortality risk was 
more influenced by other factors such as pregnancy related complications than 
by HIV (431,432). This could also be due to the fact that pregnant women were 
healthier in terms of WHO staging compared to non-pregnant women and 
men, given the same CD4 at baseline, also reflected by the lower proportion of 
pregnant patients with a baseline CD4 <100 cells/µL. This discrepancy could 
also be related to temporary declines in CD4 count during pregnancy (433).  
Patients lost early on in treatment were at higher risk of death and this 
remained statistically significant even when controlling for baseline CD4, 
indicating that a longer duration on ART prior to attrition may reduce the risk 
of death. This protective effect appeared to be strongest for those who had been 
on ART 12-24 months before they became LTFU. This suggests that in settings 
with limited resources, tracing should be considered most urgent for newly 
ART-initiated patients who drop out of care. On the other hand, it might also 
indicate that some patients are still initiating treatment too late. In this study, 
11% of non-pregnant patients had a CD4 cell count >500 cells/µL (compared 
to 23% of pregnant women), reflecting the fact that universal test and treat was 
not adopted in South Africa until September 2016 (93,434). Men were 
disproportionately over-represented in the <200 cells/µL baseline CD4 
category despite South African guidelines for ART initiation with CD4<500 
cells/µL having been in effect since January 2015 (435). Men especially appear 
to be harder to reach and come into care later, similar to findings from other 




However, as the proportion of LTFU attributable to mortality dwindles, other 
outcomes are likely to become more prevalent. In our study, transfer to 
another facility accounted for 31% of patients who were reported as LTFU, 
which is higher than a previous systematic review (15). Other studies have 
suggested transfers become more common as programmes expand and offer 
ART closer to patients’ homes (15,441,442). Women were more likely to have 
transferred their care to another clinic. For pregnant women, this could reflect 
the higher mobility common during pregnancy and childbirth (102,443,444). 
Furthermore, given that the majority of these transfers were not reported to 
the sending facility  similar to previous studies (15,16), these types of transfers 
could potentially lead to the spread of drug resistance in situations where ART 
experienced patients are offered regimens that have lost any therapeutic value 
due to drug resistance (445). Silent transfers may also lead to over-estimates 
of the number of people newly initiating ART and the number of people who 
have ever initiated ART. The current system of transferring patients could be 
improved by better referral systems, patient education, regular information 
exchange between clinics, and provider training (364). 
We found that 7.4% of patients had stopped treatment, with this being more 
common for women who initiated ART while pregnant, which adds to findings 
from previous studies that suggest that feeling healthy contributes to attrition 
for pregnant women (240,339). This figure is lower than the 28.6% of 
treatment interruptions reported in a recent systematic review (15). This may 
suggest that interventions to reduce interruptions, including routine tracing, 
are working well in this setting, further supported by the number of re-
engagements in care that were observed in our study.  
Our data showed that pregnant women and the general treatment cohort still 
differ significantly especially with regards to immune system markers such as 
CD4. However, with the advent of test and treat, these groups may increasingly 
become similar in this regard and hence outcomes for pregnant women living 
with HIV could represent what treatment programmes may expect to see in 
the future with regards to patients that become LTFU especially those of a 
similar age. With ART programmes in sub-Saharan Africa maturing, and with 
less immunologically compromised patients initiating ART, patients that 
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become LTFU will be less likely to have died, while ART cessation or 
interruption and re-engagement in care are likely to become more common. 
Treatment programmes will increasingly need to reallocate resources to deal 
with improving the clinic transfer process and invest in tracing and 
psychosocial support to get patients back in care or else risk having high 
community viral load which may increase the probability of onward 
transmission. We showed that 6% of patients who were late for a scheduled 
appointment returned before they officially became categorised as LTFU. 
These patients in theory would have received the routine tracing intervention 
offering further evidence of its utility, in line with a previous study that has 
highlighted how early active tracing of patients LTFU may improve patient 
outcomes and retention in care (55).  
Furthermore, given that most resolutions came through record review of 
tracing logbooks and clinic records, this study demonstrates that routine 
patient tracing still has utility for improving the completeness and accuracy of 
patient records. The availability of these data within the clinics suggests that 
routinely-collected data, especially those from the two organisations that 
assist in patient tracing needs to be better collated, integrated and recorded in 
order to ensure that patient outcomes are reflected in their clinic files and on 
TIER.Net. This study also demonstrates the utility of other data sources such 
as HDSS data. Given the push to integrate national ID numbers in patient 
profiles, clinics operating within similar health and demographic surveillance 
sites should consider liaising with these sites to improve the capture of deaths 
and migrations. Policy makers should also consider using South Africa’s 
national death registry within clinics as this has been shown to be useful in 
other studies (446,447). 
This study had several limitations. Firstly, the record review was cross-
sectional; we only consulted clinic records at one point in time, whereas, some 
of these records might have subsequently been updated. Furthermore, we only 
consulted HBC and RtC logbooks that were afforded to us and it is possible 
that we might have missed some with information on patients we were trying 
to find. The observational nature of the study limited our ability to assess 
predictive factors and causality. We failed to ascertain the outcomes for 12% 
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of our cohort and this might introduce some downward bias to our estimates. 
Finally, as we only resolved cause of death in 48.3% of patients found to have 
died, this data should be interpreted with caution. As we attempted to trace all 
adult patients LTFU, rather than a sample, these results are likely to be 
generalisable to other rural sub-Saharan settings. A strength of this study is 
the utilisation of multiple data sources. 
4.6. Conclusions 
Our study offers evidence for the growing utility for routine patient tracing. 
The different distribution of outcomes among Option B+ women suggests that 
different programme mortality and attrition correction factors will be needed 
as universal test and treat becomes more established. Higher mortality among 
men emphasises the importance of programmatic efforts to reach men earlier 
and treatment programmes need to improve transfer procedures to make it 
more conducive for patients to move between clinics.  
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5. Paper B: Getting on with their 
lives: Understanding clinic 
transfers among HIV patients 
considered lost to follow-up in 
rural South Africa  
 
Introduction to chapter: 
This paper (B) utilises data from the record review and tracing study described 
in chapter 3 to examine objective 1. In this chapter, I comprehensively 
investigate transfer of care to another facility following LTFU. Transfers 
represented the most common outcome for patients considered LTFU through 
the PIRL database. The paper includes comparisons by sex and pregnancy 
status at ART initiation in order to examine transfers for Option B+ women in 
comparison to other adults on ART. The paper also presents factors that 










Investigating transfers is important for accurate estimates of retention and 
informing interventions to support patients. We investigate clinic transfers for 
adults lost to follow-up (LTFU) from eight HIV care facilities in the Agincourt 
health and demographic surveillance system (HDSS), South Africa.  
Using linked clinic and HDSS records, outcomes of adults more than 90 days 
late for their last scheduled clinic visit were determined through clinic and 
routine tracing record reviews, HDSS data, and supplementary tracing. 
Factors associated with transferring to another clinic were determined 
through Cox regression models. We also graphically and geospatially visualise 
these transfers. 
Transfers were more common for women, patients living further from the 
clinic, and patients with higher baseline CD4. Transfers to clinics within the 
HDSS were more likely to be undocumented and were more common for 
women pregnant at ART initiation. Transfers outside the HDSS appeared to 
cluster around economic hubs, suggesting labour migration.  
Patients transferring to health facilities within the HDSS may be shopping for 
better or more convenient care, whereas those who transfer out of the HDSS 
may be migrating for work. Treatment programmes should facilitate transfer 
processes for patients, ensure continuity of care among those migrating, and 




In 2016, the South African government launched the “test and treat” strategy 
providing antiretroviral therapy (ART) to all people living with HIV (PLHIV) 
regardless of CD4 count (93,95). By 2018, approximately 68% of  the estimated 
7.2 million PLHIV in South Africa were on ART (24,448). 
Although ART expansion has improved life expectancy (174,449), several ART 
programmes in sub-Saharan Africa have reported higher rates of loss to 
follow-up (LTFU) among patients who initiated ART in more recent years 
(114,450,451). Increasing patient numbers have placed pressure on health 
systems, leading to longer waiting times and shorter counselling consultations 
for patients, which may increase LTFU (102,452). Asymptomatic or less 
severely ill patients initiating ART may not see the merits of remaining 
engaged in care (452,453), and higher rates of asymptomatic disease are linked 
to increased LTFU among women who initiate ART for prevention of mother-
to-child transmission (PMTCT) compared to the general population (89,454). 
High rates of LTFU present multiple challenges, including mortality and HIV 
transmission risk (56,455–457).    
Misclassification of patients as LTFU may lead to biased estimates of death 
and retention. One study reported a five-fold underestimation of death and 
retention rates and an overestimation of attrition due to LTFU (425). As more 
healthy people initiate ART, less LTFU will be attributable to mortality (14,15). 
“Silent transfers” whereby sending facilities are unaware of the transfer, so it 
is unreported, majorly contribute to LTFU (15,90). This is exacerbated by 
decentralised ART provision in sub-Saharan Africa, reliance on paper-based 
registers, a lack of unique identifiers and poorly implemented electronic 
databases, making patients’ movement between clinics difficult to track and 
document (99). Silent transfers might also be driven by patient practices, such 
as “clinic shopping” as programmes expand, and ART becomes increasingly 
available (15,53). One South African study reported an increase in transfers 
from 1.4% among patients enrolled in care between 2002-2004 to 8.9% for 
patients enrolled in 2009, following ART expansion (442).  
Previous studies reported high mortality immediately following clinic 
transfers and return migration, attributed to patients with severe illness 
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moving closer to home to be cared for in the expectation of death 
(405,428,458–460), or to better equipped facilities which could handle 
severely ill patients (428). However, evidence now shows a reduction in 
mortality for migrants following ART rollout (460).  A similar trend may occur 
for clinic transfers more broadly. Patients can actively seek better quality care, 
hoping for improved outcomes (428,461). Whereas historically, migration 
selection effect has favoured participation of healthy individuals (462), studies 
are reporting increased participation in migration by physically healthier 
PLHIV (463). This has important implications for their continuity of care and 
consequently the potential transmission of HIV (464–466).  
Recent research into patient mobility shows evidence of continued HIV care 
among patients considered LTFU after ART initiation (18,102). However, it is 
pertinent to understand how this mobility affects retention and the 
preventative benefits of ART (467), and contributes to silent transfers and 
over-estimation of LTFU.  
We undertook a record review and patient tracing study in rural north-eastern 
South Africa to understand the outcomes of patients considered LTFU, from a 
network of eight public sector ART facilities. We utilised routinely collected 
data from the Agincourt Health and Demographic Surveillance System 
(HDSS), linked to patient records from health facilities, to track patients’ 
movement between health facilities. In this paper, we describe mobility of 
residents of the HDSS who initiated ART and who were recorded as LTFU, 
using geographic information system (GIS) mapping techniques and circular 




The Agincourt HDSS comprises 115,000 residents in 31 villages, located in 
Mpumalanga province, South Africa where HIV prevalence is 14.1% across all 
ages (20,468,469).  
There are five primary health facilities (Belfast, Cunningmore, Justicia, 
Kildare and Xanthia) and three secondary community health centres 
(Agincourt, Bhubezi and Thulamahashe) within the HDSS. All health facilities 
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routinely trace patients who are late for a scheduled clinic appointment, in 
conjunction with two non-profit organisations, Right to Care (RtC) and Home-
Based Carers (HBC). Health facility staff contact patients by phone, with a 
home visit organised if necessary. Patients are classified LTFU 90 days after 
their scheduled visit if they have not returned or do not have an outcome 
ascertained through tracing.  
Demographic surveillance 
Fertility, mortality and migration data are collected annually from residents, 
based on a comprehensive household registration system, in operation since 
1992 (20,413,414,470). Fieldworkers visit each household and interview the 
most knowledgeable adult available to obtain information on demographic 
events occurring since the last census (471). 
Point-of-contact interactive record linkage (PIRL) 
Since 2014, HIV patient visits to ART clinics in the area are logged by 
fieldworkers and linked to the HDSS using Point-of-Contact Interactive 
Record Linkage (PIRL) (103,104). In brief, a fieldworker conducts a short 
uptake interview with patients in the clinic waiting area. Consenting patients 
are asked for personal identifiers, used to search the HDSS database using a 
probabilistic algorithm. Matches are confirmed in interaction with the 
patients, and names of household members are used as a key attribute to 
adjudicate between possible matches. 
5.3.2. Record review and tracing study 
Through the PIRL database, we identified HDSS residents aged 18 years or 
older, enrolled after record linkage was established and more than 90 days late 
for a scheduled ART clinic appointment (LTFU) on August 15, 2017 (data 
extraction date). 
Trained fieldworkers conducted a thorough record review on a case-by-case 
basis, comparing LTFU patients ( against (a) TIER.Net (the South African 
national HIV treatment electronic database (100)) (b) patient clinic files, and 
(c) logbooks kept by RtC and HBC. The PIRL database was reviewed for 
duplicate patients (different clinical records linking to the same individual in 
the HDSS database, which was taken as evidence of silent transfers), and 
residency and vital status were extracted from the HDSS database. This was 
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supplemented by an HBC home visit if no outcome could be ascertained and a 
further TIER.Net search at clinics close to patients’ residences to capture 
further silent transfer. Data collection concluded in December 2018. 
5.3.3. Definitions 
A patient was defined as having transferred if they had reported taking 
treatment at another health facility, if the health facility at which they initiated 
ART had communicated with and ascertained their transfer to another health 
facility, or if there was a record of them collecting treatment from another 
health facility within the HDSS. An undocumented transfer was defined as one 
where the sending (origin) health facility was unaware and therefore did not 
have this recorded as a patient outcome within its system.  
Socioeconomic status is an assets-based indicator constructed using 
household assets data collected by the HDSS (469). 
5.3.4. Statistical analyses 
Patient characteristics were summarised using counts and proportions for 
categorical variables and medians and interquartile ranges (IQR) for 
continuous variables. A Pearson’s chi-square test was used to test for 
differences in categorical variables, while a rank sum test was used for 
continuous variables. 
A Cox regression model was used to determine the factors associated with 
transfer to another health facility, with all other outcomes treated as right 
censored. Bi-variate analyses were conducted with variables that were 
hypothesised to have a relationship with health facility transfer. All variables 
with p<0.2 were included in the multivariable Cox regression model. A 
parsimonious model was achieved using Wald tests. All analyses accounted for 
clustering at the clinic level with robust standard errors. These analyses were 
performed in Stata 15 (418). 
Patients’ village of residence was ascertained through health facility and 
Agincourt HDSS records. A mid-point Global Positioning System (GPS) 
coordinate of the village was used to calculate the distance between patients’ 
residence and the health facility where they initiated ART. To assess the 
patterns of movement between health facilities, we obtained decimal degree 
coordinates for origin and destination health facilities by querying Google 
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Maps. Using ArcMap® 10.3.1 (420), the coordinates were imported to 
shapefiles with a WGS 1984 coordinate system. We then used ArcMap to 
spatially visualise the movements between health facilities.  
We calculated geographical distances between the GPS coordinates for 
sending and destination health facilities. We compared the median transfer 
distances using the Kruskal-Wallis test for the equality of populations.  
To visualise movements between health facilities within Agincourt HDSS, we 
used the Circlize package in R (419,421). A matrix of the volume of movements 
between health facilities was calculated for all transfers, stratified by the type 
of transfer (documented versus undocumented), and sex and pregnancy status 
at the time of ART initiation. These matrices were used to visualise flows 
between health facilities.  
5.3.5. Ethics 
Ethical approval was obtained from the London School of Hygiene and 
Tropical Medicine, the University of Witwatersrand and the Mpumalanga 
Department of Health. 
5.4. Results 
5.4.1. Population characteristics 
Over the study period, 1017 patients met the LTFU criteria and were eligible 
for inclusion. Of these 1017 patients, 280 (27.5%) initiated ART for PMTCT, 
737 (72.5%) met the ART initiation criteria for non-pregnant adults. 767 




Table 5.1: Baseline characteristics of patients lost to follow-up and those who transferred, and factors associated 
with transfer to another facility 
 
LTFU Transfers 






DEMOGRAPHIC AND CLINIC 
VARIABLES 
N (%) N (%) HR (95% CI) p-values aHR (95% CI) p-values 
Sex 
      
Female 767 (75.4) 258 (81.9) Reference __ Reference __ 
Male 250 (24.6) 57 (18.1) 0.64 (0.43, 0.94) 0.024 0.76 (0.56, 1.03) 0.078 
Age4 
      
18-29 333 (32.7) 117 (37.1) 1.18 (1.02, 1.37) 0.027 
  
30-44 484 (47.6) 147 (46.7) Reference __ 
  
45-59 141 (13.9) 38 (12.1) 0.89 (0.50, 1.58) 0.681 
  
60+ 58 (5.7) 13 (4.1) 0.84 (0.52, 1.34) 0.457 
  
Missing 1 (0.1) 0 (0) __ __ 
  
ART reason 
      
Non-PMTCT 737 (72.5) 233 (74.0) Reference __ 
  
PMTCT 280 (27.5) 82 (26.0) 0.79 (0.50, 1.26) 0.325 
  
ART start year 
      
2014 211 (20.8) 58 (18.4) 0.71 (0.46, 1.09) 0.122 0.80 (0.55, 1.15) 0.229 
2015 414 (40.7) 149 (47.3) Reference __ Reference __ 
 
4 Age was assessed on August 15, 2017 the date that data was extracted from the PIRL database 
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2016 350 (34.4) 100 (31.7) 0.85 (0.72, 1.01) 0.072 1.02 (0.82, 1.28) 0.827 
2017 42 (4.1) 8 (2.5) 0.47 (0.23, 0.97) 0.042 0.49 (0.22, 1.10) 0.083 
Time on ART 
      
≤3 months 325 (32.0) 89 (28.2) Reference __ Reference __ 
3-6 months 190 (18.7) 62 (19.7) 1.18 (0.84, 1.66) 0.337 1.25 (0.83, 1.89) 0.275 
6-12 months 228 (22.4) 79 (25.1) 1.37 (1.11, 1.70) 0.004 1.31 (1.04, 1.66) 0.024 
12-24 months 219 (21.5) 76 (24.1) 1.54 (1.26, 1.87) <0.001 1.73 (1.46, 2.06) <0.001 
>24 months 55 (5.4) 9 (2.9) 0.83 (0.38, 1.79) 0.637 0.98 (0.46, 2.08) 0.96 
Baseline CD45 
      
<100 206 (20.2) 64 (20.3) 1.29 (1.07, 1.56) 0.008 1.43 (1.15, 1.77) 0.001 
100-199 185 (18.2) 46 (14.6) 0.94 (0.74, 1.18) 0.581 1.02 (0.84, 1.24) 0.857 
200-349 261 (25.7) 69 (21.9) Reference __ Reference __ 
350-499 193 (19.0) 72 (22.9) 1.51 (1.04, 2.19) 0.03 1.52 (1.03, 2.24) 0.037 
500+ 145 (14.3) 53 (16.8) 1.55 (1.12, 2.13) 0.007 1.57 (1.23, 2.01) <0.001 
Missing 27 (2.6) 11 (3.5) __ __ 
  
Baseline WHO stage 
    
I 722 (71.9) 230 (73.0) Reference __ 
  
II 143 (14.1) 42 (13.3) 0.94 (0.73, 1.22) 0.651 
  
III 129 (12.7) 39 (12.4) 1.02 (0.68, 1.52) 0.924 
  
IV 10 (1.0) 1 (0.3) 0.36 (0.37, 3.56) 0.386 
  
Missing 13 (1.3) 3 (0.9) __ __ 
  
Refill schedule 
      
 
5 Blood for a baseline CD4 was drawn on the date of HIV diagnosis  
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1 month 672 (66.1) 210 (66.7) Reference __ 
  
2 months 233 (22.9) 71 (22.5) 0.94 (0.78, 1.13) 0.49 
  
3 months 79 (7.8) 30 (9.5) 1.30 (0.88, 1.93) 0.185 
  
>3 months 33 (3.2) 4 (1.3) 0.46 (0.17, 1.22) 0.117 
  
Health Facility 
      
Agincourt 272 (26.7) 66 (20.9) Reference __ Reference __ 
Belfast 186 (18.3) 52 (16.5) 1.01 (0.97, 1.05) 0.573 1.18 (1.03, 1.35) 0.015 
Cunningmore 58 (5.7) 21 (6.7) 1.71 (1.66, 1.76) <0.001 2.04 (1.75, 2.37) <0.001 
Justicia 120 (11.8) 30 (9.5) 0.86 (0.83, 0.89) <0.001 1.06 (0.86, 1.30) 0.594 
Kildare 117 (11.5) 50 (15.9) 1.80 (1.76, 1.84) <0.001 2.14 (1.92, 2.38) <0.001 
Bhubezi 166 (16.3) 51 (16.2) 1.08 (1.05, 1.12) <0.001 1.55 (1.40, 1.72) <0.001 
Thulamahashe 25 (2.5) 4 (1.3) 0.62 (0.60, 0.63) <0.001 0.62 (0.54, 0.71) <0.001 
Xanthia 73 (7.2) 41 (13.0) 2.61 (2.53, 2.68) <0.001 3.12 (2.96, 3.27) <0.001 
Time since last appointment 
    
≤1 year 526 (51.7) 146 (46.3) Reference __ 
  
1-2 years 369 (36.3) 134 (42.5) 1.18 (1.00, 1.40) 0.051 
  
>2 years 122 (12.0) 35 (11.1) 0.70 (0.43, 1.14) 0.156 
  
Ever been late for a scheduled clinic visit 
    
No 603 (59.3) 184 (58.4) Reference __ 
  
Yes  414 (40.7) 131 (41.6) 1.12 (0.88, 1.41) 0.348 
  
 
Median (IQR) Median (IQR) 
    
Distance to the clinic (KM)6 3.91 (1.06, 6.36) 4.16 (0.65, 7.78) 1.03 (0.99, 1.08) 0.169 1.04 (1.01, 1.08) 0.019 
 




    
Ever migrated outside the HDSS 
     
Permanent resident 710 (69.8) 208 (66.0) Reference __ 
  
Migrant 307 (30.2) 107 (34.0) 1.17 (0.96, 1.43) 0.127 
  
Education     
    
No formal education 47 (4.6) 13 (4.1) 1.19 (0.64, 2.22) 0.58 
  
Some primary 240 (23.6) 76 (24.1) Reference __ 
  
Completed primary 79 (7.8) 29 (9.2) 1.26 (0.76, 2.09) 0.365 
  
Some secondary 5 (0.5) 2 (0.6) 2.27 (0.44, 11.71) 0.329 
  
Completed secondary 204 (20.1) 63 (20.0) 1.09 (0.89, 1.33) 0.397 
  
Completed tertiary 19 (1.9) 6 (1.9) 0.88 (0.38, 2.06) 0.773 
  
Missing 423 (41.6) 126 (40.0) __ __ 
  
Marital status 
      
 Single 385 (37.9) 132 (41.9) Reference __ 
  
Married 56 (5.5) 13 (4.1) 0.61 (0.46, 0.81) 0.001 
  
Separated 75 (7.4) 19 (6.0) 0.64 (0.36, 1.13) 0.125 
  
Informal union 83 (8.2) 27 (8.6) 0.85 (0.58, 1.26) 0.42 
  
Divorced 29 (2.8) 11 (3.5) 1.28 (0.60, 2.71) 0.521 
  
Widowed 46 (4.5) 11 (3.5) 0.85 (0.35, 2.04) 0.711 
  
Missing 343 (33.7) 102 (32.4) __ __ 
  
SES quintile7 
      
1 134 (13.2) 35 (11.1) Reference __ 
  
 
7 SES quintile is an assets-based measure calculated at household level in the Agincourt HDSS 
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2 137 (13.5) 49 (15.6) 1.43 (0.97, 2.11) 0.068 
  
3 129 (12.7) 39 (12.4) 1.28 (0.82, 2.02) 0.275 
  
4 136 (13.4) 40 (12.7) 1.19 (0.82, 1.73) 0.358 
  
5 103 (10.1) 33 (10.5) 1.31 (0.93, 1.85) 0.121 
  





5.4.2. Transfer characteristics 
Of 1017 patients LTFU, 315 (31.0%) had transferred to another facility. The 
proportion of transfers differed by sex (p=0.001), ART initiation year 
(p=0.02), time on ART (p=0.032), baseline CD4 (p=0.027), health facility 
(p<0.001), and time since last clinic appointment (p=0.021) (Figure 5.1). 
Figure 5.1: Stacked bar graphs for variables for which the 
proportion of patients that transferred their care to another 
facility differs statistically 
 
Of 315 transfers, 133 (42.2%) were documented at the sending health facility, 
35 (11.1%) silent transfers were eventually reported to the sending health 
facility, and 147 (46.7%) remained undocumented at the sending health 
facility.  Women were more likely to have transferred, with 82 of 280 (29%) 
women who initiated ART for PMTCT, and 176 of 487 (36%) non-pregnant 
women having transferred compared to 57of 250 (23%) men (p<0.001). 
Undocumented transfers were more common among women who initiated 
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women and (52.6%, n=57) for men (p=0.043). Undocumented transfers were 
more common among patients on shorter ART refill schedules (a proxy for 
care stability, p=0.043). One hundred forty-nine (47.3%) transfers occurred 
on or before the next scheduled clinical appointment, 43 (13.7%) occurred 
after the next scheduled appointment, but before the patient would have been 
considered LTFU, 111 (35.2%) happened after the patient would have been 
considered LTFU, and 12 (3.8%) were missing a transfer date.  
One hundred thirty-one patients (41.6%) transferred to facilities within the 
HDSS, 89 (28.3%) to other health facilities in Mpumalanga province, 37 
(11.8%) to Gauteng province, 25 (7.9%) to other provinces, 7 (2.2%) out of 
Mpumalanga province but with no new facility specified, 23 (7.3%) had 
transferred without any indication of their final destination, and 2 (0.6%) had 
transferred out of the country (1 to Mozambique and 1 to Zimbabwe). 
Transfers outside the HDSS were to economic hubs (Figure 5.2).  
Figure 5.2: Maps of clinics attended for HIV care after 





Men were most likely to transfer to facilities outside the HDSS with 39/57 
(68.4%) transferring to an outside facility, compared to 109/176 (61.9%) non-
pregnant women, and 36/82 (43.9%) women who initiated treatment for 
PMTCT (p=0.006) (Figure 5.3). Undocumented transfers were more common 
for transfers within the HDSS 105/131 (80.1%) compared to 77/184 (41.8%) 
transfers outside the HDSS (p<0.001) (Figure 5.4). The proportion of 
undocumented transfers reduced for transfers in provinces further away with 
transfers to the Eastern Cape, Western cape, Northern Cape, and North West 
provinces all being documented.  
Patients were out of care for a median of 22.5 days (IQR: 1, 245). Women who 
initiated treatment for PMTCT were out of care for a median of 129 days (IQR: 
1, 324), compared to 8 days (IQR: 1, 183) for non-pregnant women and 33 days 
(IQR: 1, 313) for men (p=0.0014). Patients who transferred to a health facility 
within the HDSS were out of care a median of 206 days (IQR: 8, 437) 
compared to 1 day (IQR: 1, 63.5) for those who transferred to health facilities 
outside the HDSS (p=0.0001). Undocumented transfers were out of care 
longer than documented transfers (p=0.0001).  
The median transfer distance was 13.73 kilometres (IQR: 8.97, 88.29). This 
differed statistically by reason for ART initiation (p=0.0392), with women who 
initiated ART for PMTCT having a median transfer distance of 9.99 kilometres 
(IQR: 8.97, 59.47) compared to 17.02 kilometres (IQR: 9.22, 99.99) for non-
PMTCT patients. Median transfer distance also differed by sex (p=0.0414) 
with men transferring further away, ART initiation year (p=0.0087), type of 
transfer (p=0.0001), and health facility (p=0.0001) (Figure 5.5). The transfer 
distance was weakly negatively correlated with health facility distance 
(between village of residence and origin health facility) (coefficient = -0.0718) 
and time spent out of care (coefficient=-0.2457). The median health facility 
distance was higher for transfers to health facilities within the HDSS compared 
to those outside the HDSS (p=0.0001). Distance to the origin and destination 
health facilities was weakly negatively correlated for all transfers (coefficient=-




Figure 5.3: Circle plots to visualise patient transfers in the Agincourt HDSS disaggregated by pregnancy status at 
ART initiation  (largest 50%  for each group)   
 
*The origins and destinations of transfers are represented by the colour-coded circle segments. The length of each segment represents all the movements in and out of the particular health facility and 
therefore longer circle segments represent higher number of transfers to and from that clinic. The inner segment represents movements out of a clinic. Segments closer together represent clinics that 
are geographically close to each other (within reason). The volume of movements is indicated by the width of the flow and the direction of the flow is encoded by the sending facility colour.   
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Figure 5.4: Circle plots to visualise patient transfers in the Agincourt HDSS disaggregated by type of transfer  




Figure 5.5: Box plots of transfer distances disaggregated by ART 
initiation reason, pregnancy status at ART initiation, type of 
transfer, and year of ART initiation 
 
5.4.3. Factors associated with transfer to another clinic 
In multivariable Cox regression, patients on ART for 12-24 months when they 
became LTFU (aHR: 1.73, 95% CI: 1.46-2.06), and patients with baseline CD4 
(<100 cells/µL aHR: 1.43, 1.15, 1.77;  350-499 cells/µL aHR: 1.52, 1.03-2.24; 
≥500 cells/µL aHR: 1.57, 1.23-2.01) were more likely to have transferred to 
another health facility. The hazard of transfer increased with increasing 
distance between a patient’s village of residence and their health facility (aHR: 
1.04, 1.01-1.08) (Table 5.1).  
5.5. Discussion 
Within a cohort of South African patients who had been categorised as LTFU, 
we found evidence of HIV care continuation, with 31% transferring their care 
to another facility. Similar to other studies (15,102), we found high levels of 
undocumented transfer. Women were more likely than men to transfer their 
care, with women who initiated treatment for PMTCT the least likely to have 
their transfer documented at the health facility where they initiated treatment, 
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Mobility during pregnancy and after childbirth are high (102,443,444,456), 
and transfer patterns may reflect this. Longer time on ART, higher baseline 
CD4 and further distance to the health facility from patient residences were 
associated with higher risk of transferring to another facility.  
Most transfers outside the HDSS study area were to economic hubs, including 
agricultural and mining towns, suggesting that these transfers were due to 
labour migration which is common in South Africa (472). As earlier studies 
suggested that PLHIV were moving back home to die (459,473), this migration 
is encouraging, suggesting that PLHIV feel healthy enough to work, and 
countering challenges early in the epidemic, when HIV mortality and 
morbidity disproportionately affected people of working-age (474). In our 
study, patients who initiated ART in later years transferred further away, 
suggesting programme expansion has led to healthier PLHIV initiating 
treatment, who may be more mobile. However, given that patients with 
CD4<100 cells/µL were more likely to transfer this might also show that there 
is still a substantial cohort of sicker patients moving back home to die. 
The weak negative correlation between origin health facility distance and 
transfer distance may suggest “clinic shopping” (102), as patients who 
transferred to another health facility within the HDSS attended an origin 
health facility further from their village of residence. It might also reflect a 
rational decision to move to a closer facility as scale-up increases options. 
However, as patients who transferred to health facilities within the study area 
were more likely to be undocumented and were out of care longer than those 
who transferred outside the HDSS, other mechanisms such as stigma, fear of 
accidental disclosure, fear of healthcare worker reactions on reengaging at the 
same health facility, and a desire for anonymity may influence patients’ 
decision to “shop” around local health facilities (102,245,283,285,289,329). 
Furthermore, as undocumented transfers were out of care longer, they may 
represent a loss of motivation to stay engaged in care. Women who initiated 
treatment for PMTCT were out of care longer, more likely to transfer to a 
health facility within the HDSS and healthier in terms of baseline CD4 and 
WHO staging, therefore “clinic shopping” might be more common for 
healthier, asymptomatic patients or women with young children may be less 
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inclined to migrate outside the HDSS. Longer time out of care could pose 
higher risks for mortality, vertical and horizontal transmission (187,456,457), 
suggesting the need for tailored interventions to address treatment 
interruptions among this population (475,476).  
Undocumented transfers were common, especially for women who initiated 
treatment for PMTCT, less stable patients and transfers to health facilities 
within the HDSS.  Undocumented transfers present several problems 
including the risk of amplification and transmission of HIV drug resistance 
when experienced patients are offered regimens with no therapeutic benefit 
(445). Furthermore, this can lead to over-estimation of the number of people 
newly initiated on ART and ever initiated on ART, biasing ART programme 
indicators. Finally, these undocumented outcomes affect estimations of 
retention in HIV care (15).  
This study adds to extant evidence examining continued care among 
individuals considered LTFU after ART initiation in sub-Saharan Africa 
(14,17,54,477), and particularly transfer to other facilities (18,102). We provide 
detailed comparisons of transfers by reason for ART initiation, on types of 
transfers and factors associated with transferring to another facility. Our use 
of linked demographic surveillance and clinical data to ascertain outcomes for 
patients considered LTFU allowed us to utilise unique HDSS identifiers to 
follow patients between health facilities. However, not all clinic records were 
linked to a demographic surveillance record, which is a limitation to our 
analyses. Although unique identifiers are recommended by the World Health 
Organisation, these are not feasible in many settings (370). Facility-linked 
data improves the ability to follow patients and to monitor their long-term 
outcomes (18,371). Transfers to health facilities further away from the HDSS 
were more likely to be documented. However, we could only check the records 
of health facilities within the study area and might have missed undocumented 
transfers to health facilities outside the HDSS, potentially introducing bias. 
Undocumented transfers should become less prevalent with increased use of 
national IDs at health facilities and as TIER.Net becomes fully networked. The 
use of a centre point for each village to represent residence may introduce 
some bias to our findings. Furthermore, searching for patient outcomes 
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involved time consuming manual procedures and is more feasible as a 
research exercise than within routine clinical follow-up. Other data sources 
like the national reference lab database might improve ascertainment of 
transfers and has been shown to be feasible (102). Finally, given the small 
numbers, these results should be interpreted with caution.  
5.6. Conclusions 
Our findings suggest that an HIV diagnosis may no longer be viewed as a major 
impediment and people are getting on with their lives, with many transfers 
appearing linked to labour migration. We highlight the importance of 
ascertaining undocumented transfers as these individuals stay longer out of 
care, which has implications for onward transmission. As ART programmes 
continue to expand in sub-Saharan Africa, nationally linked treatment 
databases would improve the capture of transfers in highly mobile 
populations, to enable those who wish to transfer to do so, and to ensure 




6. Paper C: Misreporting of patient 
outcomes in the South African 
national HIV treatment database: 
consequences for programme 
planning, monitoring and 
evaluation 
 
Introduction to chapter: 
This paper (C) uses data from the record review and tracing study described in 
chapter 3 to investigate objective 2. This paper was conceived as a means to 
appraise the performance of routine data sources (represented by electronic 
medical records) in accurately reporting patient treatment outcomes. The 
paper compares treatment outcomes ascertained through the record review 
and tracing study to outcomes reported in TIER.Net (South Africa’s national 
HIV treatment database). The rationale for this exercise is to measure the bias 
of relying solely on one data source to measure retention in care. I also 
compare the magnitude of misclassification of treatment outcomes by sex and 
pregnancy status at ART initiation in order to explore whether 
misclassification differs significantly for pregnant and postpartum WLHIV 









Background: Monitoring progress toward global treatment targets using 
HIV programme data in sub-Saharan Africa has proved challenging. 
Constraints in routine data collection and reporting can lead to biased 
estimates of treatment outcomes. In 2010, South Africa introduced an 
electronic patient monitoring system for HIV patient visits, TIER.Net. We 
compare treatment status and outcomes recorded in TIER.Net to outcomes 
ascertained through detailed record review and tracing in order to assess 
discrepancies and biases in retention and mortality rates. 
Methods: The Agincourt Health and Demographic Surveillance System 
(HDSS) in north-eastern South Africa is served by eight public primary 
healthcare facilities. Since 2014, HIV patient visits are logged electronically at 
these clinics, with patient records individually linked to their HDSS record. 
These data were used to generate a list of patients >90 days late for their last 
scheduled clinic visit and deemed lost to follow-up (LTFU). Patient outcomes 
were ascertained through a review of the TIER.Net database, physical patient 
files, registers kept by two non-government organisations that assist with 
patient tracing, cross-referencing with the HDSS records and supplementary 
physical tracing. Descriptive statistics were used to compare patient outcomes 
reported in TIER.Net to their outcome ascertained in the study.      
Results: Of 1074 patients that were eligible for this analysis, TIER.Net 
classified 533 (49.6%) as LTFU, 80 (7.4%) as deceased, and 186 (17.3%) as 
transferred out. TIER.Net misclassified 36% of patient outcomes, 
overestimating LTFU and underestimating mortality and transfers out. 
TIER.Net missed 40% of deaths and 43% of transfers out. Patients categorized 
as LTFU in TIER.Net were more likely to be misclassified than patients 
classified as deceased or transferred out. 
Discussion: Misclassification of patient outcomes in TIER.Net has 
consequences for programme forecasting, monitoring and evaluation. 
Undocumented transfers accounted for the majority of misclassification, 
suggesting that the transfer process between clinics should be improved for 
more accurate reporting of patient outcomes. Processes that lead to correct 
classification of patient status including patient tracing should be 
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strengthened. Clinics could cross-check all available data sources before 
classifying patients as LTFU. Programme evaluators and modelers could 






At the end of 2017, it was estimated that there were 36.9 million people living 
with HIV (PLHIV) worldwide, with 70% of the disease burden situated in sub-
Saharan Africa (24,448). The World Health Organisation’s (WHO) revised 
HIV treatment guidelines in 2015 call for immediate provision of lifelong 
antiretroviral therapy (ART) to all people testing positive for HIV. By the end 
of 2017, 60% of PLHIV in sub-Saharan Africa were on ART (24,448). Whilst 
ART initiation rates have been increasing over time, in order to reduce HIV 
transmission rates and achieve 90-90-90 AIDS elimination goals, there is a 
need for accelerated increases in treatment adherence and retention in care 
(98,478,479). South Africa has the largest population of PLHIV worldwide, 
with an estimated 18.8% of the adult population aged 15-49 years old living 
with HIV, representing 7.2 million people (24,448). By the end of 2018, an 
estimated 68% of PLHIV in South Africa were on ART (24,448).  
The rapid growth in access to ART has accentuated the need for an affordable 
and accurate way to monitor and evaluate treatment programmes (480–482), 
including documenting the number of people alive and on treatment, and 
programme impact on mortality. In the past, the progress of patients on ART 
was mainly monitored through patient cohorts (483) and tallying numbers of 
services rendered to inform resource allocation (482). However, evaluation of 
HIV programmes has proved challenging due to multiple data constraints. 
These include concerns about data reliability (482), and continued use of 
paper registers which often lack unique identifiers, suffer from incompleteness 
(99), and are cumbersome to use with increasing patient numbers and length 
of patient follow-up (100,101). Another major concern is “silent transfers” 
whereby patients change clinics informally and without accompanying 
documentation, a phenomenon which has become more prevalent with the 
expansion of ART programmes (15,484). As a result, there is concern that 
many high-burden countries are ill-equipped to report on the outcomes of 
patients in care and on treatment (480,481,485–487).  
In order to address these concerns, many countries are scaling-up the use of 
electronic patient registers (100). However, challenges persist including 
insufficient linkages between clinics (99), insufficient training of staff who are 
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responsible for entering this information (99), and staff shortages (488–491), 
resulting in some staff responsible for data management being stretched 
across multiple roles (492). This sometimes leads to poor workflow, and staff 
resistance which results in poor change management. Privacy and security 
issues (492) are also a major concern. 
In 2010, South Africa adopted TIER.Net, a three-tiered monitoring approach 
involving paper registers (TIER 1 – recommended for facilities with less than 
500 patients), an offline electronic register (TIER 2 – recommended for 
facilities with 500-2000 patients) and networked electronic medical records 
(TIER 3 – recommended for facilities with more than 2000 patients) (100). 
This allowed for different tiers to be implemented in each facility based on the 
context and resources available at the time of implementation and typically 
involved a phased evolution, beginning with preparation for TIER.Net, 
installation and training, back capturing, live capturing and finally a live site 
able to produce monthly and quarterly reports with staff on-site to manage it. 
In 2014, an estimated 3000 out of 4000 public sector clinics in South Africa 
were using TIER.Net (493,494) in one of the three phases of implementation. 
As of 2017, TIER 3 was still in its pilot phase (495).  
ART patient outcomes have evolved since the start of national HIV treatment 
programmes. In several cohort studies of ART programmes in sub-Saharan 
Africa, there have been reports of higher rates of LTFU among patients who 
initiated ART in later years compared to earlier years (114,450,451). This may 
be explained by patients increasingly initiating treatment while less severely 
ill (453), as well as a negative consequence of patient numbers increasing such 
as facility workloads (452), raising concerns about the sustainability of these 
programmes. Some systematic reviews have shown that the percentage of 
patients LTFU who have died has decreased in later years as eligibility criteria 
have evolved to include less immunologically compromised patients, and as 
the proportion of patients LTFU has increased (14,15). Furthermore, scale-up 
and decentralisation of these programmes means ART can be offered at clinics 
closer to patients’ homes, which may serve as an incentive to self-transfer in 
order to continue treatment at more convenient locations (15,53).  
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Unpublished TIER.Net analyses from 2018 showed LTFU rates to range from 
11%-15% in the first three months and from 27%-34% in the first year of ART 
(Y.Pillay, HIV Think-tank update, March 19, 2019). The high percentages of 
LTFU present many issues. Firstly, if these patients have really stopped ART 
then they have a higher mortality risk (56,455,496), and are more likely to 
transmit HIV (48,187,456,457). Given that patients that are LTFU have poorer 
outcomes, LTFU can also through misclassification bias event rates such as 
mortality downwards (497), leading to biased performance indicators for ART 
programmes. Accurate mortality rates are also important as they are used as 
parameters for projections such as in the UNAIDS spectrum package 
(498,499).  
We compare patient outcomes recorded in TIER.Net to the outcomes 
ascertained through a record review and tracing study for patients deemed lost 
to follow-up in eight public sector health facilities in rural north-eastern South 
Africa. We aimed to assess misreporting in TIER.Net and potential biases in 




The Agincourt Health and Demographic Surveillance System (Agincourt 
HDSS) is located in rural north-eastern South Africa, in Mpumalanga province 
which has the second highest prevalence of HIV at 14.1% (468). HIV 
prevalence among people 15 years of age or older in the HDSS was estimated 
at 19.4% in 2010 (398). The Agincourt HDSS comprises of 31 villages covering 
an area of 475 square kilometres with an estimated population of 115,000 
people (20,469).  
There are five primary health facilities and three secondary community health 
centres located within the Agincourt HDSS. Every HIV-positive patient has a 
clinical file that is opened when they first register at an ART clinic and updated 
at each clinic visit. Following the clinic visit, visit-level information from the 
patient file is entered into the national electronic database, TIER.Net. All 
health facilities routinely trace patients that are late for a scheduled clinic 
appointment. This tracing is done in conjunction with two non-profit 
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organisations, Right to Care (RtC) and Home-Based Carers (HBC). Clinic staff 
must contact all patients first by phone and if this does not yield a satisfactory 
outcome, a home visit is organised. Patients are classified as lost to follow-up 
(LTFU) if they have not returned 90 days after their scheduled visit.  
6.3.2. Demographic surveillance 
Data collection aims to capture all demographic events for the Agincourt 
HDSS population. Fertility, mortality and migration data are based on a 
comprehensive household registration system that has been in operation since 
1992. Following the baseline demographic surveillance survey in 1992 and 
three update rounds until 1998, the site has conducted annual surveys since 
1999 (20,413,414,470). Trained fieldworkers visit each household and 
interview the most knowledgeable adult available. During the visit, individual-
level information on all household members is checked and updated and any 
events that have occurred since the last census round are recorded. Starting in 
2017, data have been collected utilising an electronic data collection system 
using tablets (471). 
6.3.3. Point-of-contact interactive record linkage (PIRL) 
A key element of the data infrastructure for this study consists of HIV patient 
visit logs collected by a study fieldworker in the health facilities that provide 
ART in the area. This work started in April 2014 at seven government facilities 
and was extended in 2016 to include one additional health facility. In addition 
to logging patient visits, these records are linked to the Agincourt HDSS using 
a procedure that we have previously described as Point-of-Contact Interactive 
Record Linkage (PIRL) (103,104). In brief, a fieldworker conducts a short 
uptake interview with patients in the waiting area of the clinic. Patients who 
consent are asked to declare a few personal identifiers that are used to search 
a local copy of the Agincourt HDSS database using a probabilistic algorithm. 
Matches are confirmed in interaction with the patients, and the names of other 
household members are used as a key attribute to adjudicate between possible 
matches. 
6.3.4. Record review and tracing study 
Through the PIRL database, we identified patients who were more than 90 
days late for a scheduled clinic appointment from HIV services on August 15, 
2017 (the date of data extraction) at any of the eight health facilities located in 
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the Agincourt HDSS area. These patients were recruited into a cohort and 
followed up to ascertain their treatment and vital status i.e. whether they were 
still alive. 
All PLHIV aged 18 years or over, who had ever declared residency in Agincourt 
HDSS, and had enrolled in the HIV treatment and care programme since 2014 
(after the Agincourt HDSS record linkage was established at the health 
facilities) were eligible for inclusion in the study.  
Trained and supervised fieldworkers conducted a thorough record review, 
comparing the list of patients LTFU against (a) TIER.Net (b) patient clinic 
files, and (c) logbooks kept by the RtC and the HBC. The PIRL database was 
also reviewed for duplicate patients (different clinical records linking to the 
same individual in the Agincourt HDSS database, which was taken as evidence 
of silent transfers), and residency and vital status were extracted from the 
Agincourt HDSS database. This was done on a case-by-case basis. 
HBC conducted a visit to the households of all patients for whom a definitive 
outcome (defined as death, transfer out, stopped ART, migrated, re-engaged 
in care, and alive with ART status unknown) could not be established, or for 
whom routine patient tracing was not done. Finally, all patients who remained 
LTFU after the HBC visit, were searched for in TIER.Net databases at clinics 
in close proximity to their home residence to capture any further silent 
transfers.  
We also reviewed the records for a stratified random sample of 162 patient 
records who were not LTFU as of August 15, 2017, in order to assess whether 
TIER.Net misclassified any patients that were still in care. This sample was 
chosen to include 18 patients from every clinic (6 men, 6 non-pregnant women 
and 6 women who initiated ART while pregnant) with the exception of one 
clinic which had recently merged with another, and from which we sampled 18 










The last scheduled appointment for each patient as of 





The treatment status of the patient as recorded in 
TIER.Net during the comprehensive record review. 
The final 
outcome 
The outcome ascertained for each patient through the 
record review and tracing process. 
Data error A situation in which a patient was found still in care and 
<90 days late for their last appointment. Some data 
errors occurred because visit dates had not been 
properly entered in the PIRL database. Patients 




A patient was considered to have re-engaged in care if 
they were found to be still in care at the same clinic 
where they initiated treatment but were >90 days late 
for their last appointment (had been LTFU). 
Transfer out A patient was considered to have transferred if they had 
either reported taking treatment at another clinic (for 
clinics outside the Agincourt HDSS), if their ART 
initiation clinic had communicated with and ascertained 
their transfer to another clinic, or if there was record of 
them collecting treatment at another clinic within the 
Agincourt HDSS. 
Migration A patient was classified as having migrated out of the 
study site if they were recorded as having migrated 
through the Agincourt HDSS demographic surveillance, 
this migration event happened after their last clinic visit 
date and there was no proof that they were taking 
treatment at another facility. 
200 
 
Alive and not 
on ART 
A patient was considered alive and not on ART if they 
had been found and had said they had stopped ART, 




A patient was considered alive with ART status 
unknown if they were found to still be alive through the 
most recent Agincourt HDSS demographic surveillance, 
with a surveillance date after their last clinic visit and 
there was no proof that they were taking treatment at 
any facility. 
 
6.3.5. Statistical analyses 
For patients included in the record review and tracing study, we calculated 
counts and proportions for socio-demographic and baseline clinical 
characteristics, TIER.Net treatment status, the final outcome, and cross-
tabulated TIER.Net status and the final outcome.  
To assess the degree and direction of misreporting of patient outcomes in 
TIER.Net, we graphically present TIER.Net treatment status and the final 
outcome proportions by some selected patient characteristics. A Pearson’s chi-
square test was used to compare whether TIER.Net treatment status and the 
final outcome varied by all the categorical variables. We also present a cross-
tabulation of patient outcomes from the two sources. 
A binary outcome variable was created to indicate whether TIER.Net had 
misclassified a patient’s treatment status, with a second outcome created to 
identify whether the patient was recorded as LTFU in TIER.Net. All cases 
where an electronic record could not be found were removed from further 
analysis.  
To explore factors associated with misclassification in TIER.Net, we ran bi-
variate analyses with patient-level treatment characteristics, demographic 
characteristics and facility-level characteristics. All variables with p<0.1 were 
included in the multivariable logistic regression model. A parsimonious model 
was achieved using Wald tests. This same procedure was followed in order to 
understand what factors were associated with being reported LTFU in 
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TIER.Net. All analyses were conducted in Stata 15 (418) and all data 
visualisation was done using R (419). 
6.3.6. Ethics 
Ethical approval was obtained from the London School of Hygiene and 
Tropical Medicine, the University of Witwatersrand and the Mpumalanga 
Department of health.  
6.4. Results 
 
6.4.1. Database population characteristics 
Over the study period, 4089 patients were added to the PIRL database and 
met the inclusion criteria. Of these 4089, 1325 (32.4%) met the LTFU criteria 
and were eligible for inclusion into the record review and tracing study. Of 
these 1325 patients, 166 (12.5%) did not have an ART initiation date and were 
assumed to be pre-ART. Further investigation of these 166 patients found 46 
(27.7%) had initiated ART after record linkage, 59 (35.5%) were genuine pre-
ART patients and 61(36.7%) had initiated ART before record linkage began. 
These 61 patients were excluded from further analyses. Of the remaining 1264 
patients, 190 (15.0%) were found to have data errors (mostly due to missing 
clinic visits in the PIRL database) and were excluded from further analysis 
(Figure 6.1).  
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Figure 6.1: Numbers of patients that were eligible at each stage 
and the number of patients excluded at each stage 
 
Of 1074 remaining patients, 280 (26.1%) initiated ART for prevention of 
mother-to-child transmission (PMTCT), 737 (68.6%) met the ART initiation 
criteria for non-pregnant adults, and 57 (5.3%) had not initiated ART yet (pre-
ART).  
Thirteen (8.0%) of the 162 patients still in care were excluded from the analysis 
because they had not declared residency in the HDSS. The remaining 149 from 
the random sample of patients still in care were also assessed to see if 









Table 6.2:  Database population characteristics 
 
Not in sample Sample 
 
Still in care Still in care LTFU Data error 
 
2615 149 1074 190 
 
N (%) N (%) N (%) N (%) 
Sex 
   
 
Female 2016 (77.1) 94 (63.1) 807 (75.1) 147 (77.4) 
Male 599 (22.9) 55 (36.9) 266 (24.8) 42 (22.1) 
Missing 0 (0) 0 (0) 1 (0.1) 1 (0.5) 
Age 
   
 
18-29 559 (21.4) 18 (12.1) 350 (32.6) 39 (20.5) 
30-44 1298 (49.6) 76 (51.0) 509 (47.4) 102 (53.7) 
45-59 544 (20.8) 36 (24.2) 152 (14.1) 38 (20.0) 
60+ 212 (8.1) 19 (12.7) 60 (5.6) 10 (5.3) 
Missing 2 (0.1) 0 (0) 3 (0.3) 1 (0.5) 
ART reason 
   
 
Non-PMTCT women 1533 (58.6) 54 (36.2) 487 (45.3) 101 (53.1) 
PMTCT women 431 (16.5) 40 (26.9) 280 (26.1) 45 (23.7) 
Men 598 (22.9) 55 (36.9) 250 (23.3) 42 (22.1) 
Pre-ART 0 (0) 0 (0) 57 (5.3) 2 (1.1) 
Missing 53 (2.0) 0 (0) 0 (0) 0 (0) 
ART start year 
   
 
2014 320 (12.2) 62 (41.6) 211 (19.6) 41 (21.6) 
2015 773 (29.6) 42 (28.2) 414 (38.6) 84 (44.2) 
2016 951 (36.4) 32 (21.5) 350 (32.6) 54 (28.4) 
2017 571 (21.8) 13 (8.7) 42 (3.9) 9 (4.7) 
Missing 0 (0) 0 (0) 57 (5.3) 2 (1.1) 
Time on ART     
<=3 months 190 (7.3) 10 (6.7) 325 (30.3) 15 (7.9) 
3-6 months 260 (9.9) 2 (1.3) 190 (17.7) 9 (4.7) 
6-12 months 560 (21.4) 23 (15.4) 228 (21.2) 41 (21.6) 
12-24 months 842 (32.2) 40 (26.8) 219 (20.4) 75 (39.5) 
>24 months 763 (29.2) 74 (49.7) 55 (5.1) 48 (25.3) 
Missing 0 (0) 0 (0) 57 (5.3) 2 (1.1) 
Baseline CD4 
   
 
<100 468 (17.9) 25 (16.8) 220 (20.5) 20 (10.5) 
100-199 476 (18.2) 18 (12.1) 193 (18.0) 37 (19.5) 
200-349 656 (25.1) 40 (26.9) 267 (24.9) 50 (26.3) 
350-499 464 (17.7) 34 (22.8) 198 (18.4) 50 (26.3) 
500+ 455 (17.4) 30 920.1) 164 (15.3) 33 (17.4) 
Missing 96 (3.7) 2 (1.3) 32 (3.0) 0 (0) 
Refill schedule     
1 month 1056 (40.4) 38 (25.5) 714 (66.5) 72 (37.9) 
2 months 1016 (38.8) 77 (33.7) 240 (22.3) 64 (33.7) 
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3 months 314 (12.0) 26 (17.4) 86 (8.0) 17 (8.9) 
>3 months 229 (8.8) 8 (5.4) 34 (3.2) 37 (19.5) 
Health Facility 
   
 
Agincourt 540 (20.6) 18 (12.1) 282 (26.3) 160 (84.2) 
Belfast 379 (14.5) 16 (10.7) 191 (17.8) 2 (1.0) 
Cunningmore 227 (8.7) 15 (10.1) 74 (6.9) 0 (0) 
Justicia 284 (10.9) 18 (12.1) 122 (11.4) 3 (1.6) 
Kildare 462 (17.7) 18 (12.1) 120 (11.1) 6 (3.2) 
Lillydale/Bhubezi 487 (18.6) 35 (23.5) 181 (16.8) 11 (5.8) 
Thulamahashe 89 (3.4) 14 (9.4) 27 (2.5) 8 (4.2) 
Xanthia 147 (5.6) 15 (10.1) 77 (7.2) 0 (0) 
Agincourt HDSS outcome  
  
 
Still in HDSS 1827 (69.9) 107 (71.8) 530 (49.3) 122 (64.2) 
Deceased 2 (0.1) 0 (0) 83 (7.7) 1 (0.5) 
Migrated 503 (19.2) 37 (24.8) 282 (26.3) 56 (29.5) 
Not linked 283 (10.8) 5 (3.4) 179 (16.7) 11 (5.8) 
Time since last appointment    
<=1 year __ __ 539 (50.2) __ 
1-2 years __ __ 392 (36.5) __ 
>2 years __ __ 143 (13.3) __ 
Not in sample: All patients eligible for the study but not LTFU in the PIRL database and not included 
in the still in care sample; Sample: All patients included in the study (149 still in care, 1264 LTFU=1074 
really LTFU + 190 data errors); Data error: Patients included as LTFU but found to be still in care and 
<90 days late for their last appointment; For ART start year data from 2017 reflects number of ART 
initiations up to mid-August when data extraction occurred 
6.4.2. TIER.Net treatment status 
Of the 1074 patients who remained eligible for this analysis, 533 (49.6%) were 
categorized as LTFU, 222 (20.7%) as still in care, 186 (17.3%) as transferred 
out, 80 (7.5%) as deceased, and 53 (4.9%) could not be found in the TIER.Net 
database (Table 6.3).  
There was a statistically significant difference (all p<0.001) in the TIER.Net 
treatment status by sex, age, ART initiation status and reason, year of ART 
initiation, baseline CD4 count, time on ART, clinic visit schedule, health 
facility, and time since a missed appointment (Figure 6.2). Women who 
initiated ART for PMTCT were less likely to be categorized as deceased and 
more likely to be LTFU. All 149 patients sampled as still in care were also 










LTFU Deceased Transferred  Still in care Not found Total 
 
533 80 186 222 53 1074 
 
n (%) n (%) n (%) n (%) n (%) 
 
Age 
      
18-29 191 (54.6) 8 (2.3) 60 (17.1) 74 (21.1) 17 (4.9) 350 
30-44 253 (49.7) 41 (8.1) 88 (17.3) 103 (20.2) 24 (4.7) 509 
45-59 66 (43.4) 18 (11.8) 28 (18.4) 32 (21.0) 8 (5.3) 152 
60+ 23 (38.3) 13 (21.7) 9 (15.0) 12 (20.0) 3 (5.0) 60 
Missing 0 (0) 0 (0) 1 (33.3) 1 (33.3) 1 (33.3) 3 
ART initiation 
      
Pregnant women 172 (61.4) 5 (1.8) 41 (14.6) 54 (19.3) 8 (2.9) 280 
Non-pregnant women 217 (44.6) 36 (7.4) 106 (21.8) 112 (23.0) 16 (3.3) 487 
Men  124 (49.6) 35 (14.0) 34 (13.6) 52 (20.8) 5 (2.0) 250 
Pre-ART 20 (35.1) 4 (7.0) 5 (8.8) 4 (7.0) 24 (42.1) 57 
ART start year 
      
2014 108 (51.2) 25 (11.8) 30 (14.2) 41 (19.4) 7 (3.3) 211 
2015 213 (51.4) 27 (6.5) 85 (20.5) 76 (18.4) 13 (3.1) 414 
2016 179 (51.1) 20 (5.7) 62 (17.7) 81 (23.1) 8 (2.3) 350 
2017 13 (30.9) 4 (9.5) 4 (9.5) 20 (47.6) 1 (2.4) 42 
Missing 20 (35.1) 4 (7.0) 5 (8.8) 4 (7.0) 24 (42.1) 57 
Time on ART 
      
<=3 months 184 (56.6) 34 (10.5) 49 (15.1) 46 (14.1) 12 (3.7) 325 
3-6 months 115 (60.5) 8 (4.2) 34 (17.9) 26 (13.7) 7 (3.7) 190 
6-12 months 116 (50.9) 16 (7.0) 50 (21.9) 42 (18.4) 4 (1.7) 228 
12-24 months 82 (37.4) 12 (5.5) 45 (20.5) 76 (34.7) 4 (1.8) 219 
>24 months 16 (29.1) 6 (10.9) 3 (5.4) 28 (50.9) 2 (3.6) 55 
Missing 20 (35.1) 4 (7.0) 5 (8.8) 4 (7.0) 24 (42.1) 57 
Baseline CD4 
      
<100 92 (41.8) 42 (19.1) 43 (19.5) 33 (15.0) 10 (4.5) 220 
100-199 108 (56.0) 15 (7.8) 28 (14.5) 37 (19.2) 5 (2.6) 193 
200-349 147 (55.1) 11 (4.1) 42 (15.7) 58 (21.7) 9 (3.4) 267 
350-499 96 (48.5) 6 (3.0) 43 (21.7) 45 (22.7) 8 (4.0) 198 
500+ 70 (42.7) 5 (3.0) 28 (17.1) 46 (28.0) 15 (9.1) 164 
Missing 20 (62.5) 1 (3.1) 2 (6.2) 3 (9.4) 6 (18.7) 32 
Time since last appointment 
     
<=1 year 223 (41.4) 29 (5.4) 86 (16.0) 187 (34.7) 14 (2.6) 539 
1-2 years 228 (58.2) 34 (8.7) 75 (19.1) 30 (7.6) 25 (6.4) 392 








6.4.3. Outcomes after record review and tracing study 
Of the 1074 patients who remained eligible for this analysis, 326 (30.3%) were 
found to have transferred to another clinic, 234 (21.8%) to have re-engaged in 
care, 132 (12.3%) were deceased, 117 (10.9%) were alive with ART status 
unknown, 81 (7.5%) were alive but not on treatment, 53 (4.9%) had migrated 
to another place of residence, and 131 (12.2%) were still LTFU (Table 6.4). 
These outcomes differed (all p<0.001) by sex, age, ART initiation status and 
reason, baseline CD4 count, time on ART, clinic visit schedule, health facility, 
whether the patient record was successfully linked to an Agincourt HDSS 
record, and time since a missed appointment (some selected variables 
illustrated in Figure 6.3). 
 
Table 6.4: A cross-tabulation of TIER.Net treatment status and the 
final outcome 
 TIER.Net status  
 









Final Outcome N (%) N (%) N (%) N (%) N (%) N (%) 
LTFU 0 (0) 112 (21.0) 9 (17.0) 10 (4.5) 0 (0) 131 (12.2) 
Deceased 80 (100) 38 (7.1) 8 (15.1) 6 (2.7) 0 (0) 132 (12.3) 
Alive/Not on 
ART 
0 (0) 70 (13.1) 3 (5.7) 8 (3.6) 0 (0) 81 (7.5) 
Migrated 0 (0) 47 (8.8) 5 (9.4) 1 (0.5) 0 (0) 53 (4.9) 
Transferred 0 (0) 116 (21.8) 8 (15.1) 16 (7.2) 186 (100) 326 (30.4) 
Re-engaged 0 (0) 56 (10.5) 9 (17.0) 169 (76.1) 0 (0) 234 (21.8) 
Alive/ART 
unknown 
0 (0) 94 (17.6) 11 (20.8) 12 (5.4) 0 (0) 117 (10.9) 




Figure 6.3: Outcomes ascertained through record review and tracing stratified by (a) ART initiation status and 





6.4.4. Differences between TIER.Net treatment status and Final 
outcomes 
Records of patients who had died or transferred out documented in TIER.Net 
aligned with patients’ final outcome (i.e. no inaccuracies found for these two 
statuses). However, TIER.Net misclassified 52 (39.4%) of 132 deaths. Of these 
52, 38 (73.1%) were classified as LTFU, 6 (11.5%) as still in care, and 8 (15.4%) 
were not found in the system at all.   
TIER.Net also misclassified 53 patients as still in care. Of these, 10 (18.9%) 
were found to be LTFU, 16 (30.2%) to have transferred, 12 (22.6%) as alive 
with unknown ART status, 8 (15.1%) alive but not on treatment, 6 (11.3%) to 
have died, and 1 (1.9%) to have migrated to another place of residence. 
TIER.Net correctly captured 186 (57.1%) of 326 transfers.  
Of 533 patients classified as LTFU by TIER.Net, 116 (21.8%) were found to 
have transferred to another clinic, 70 (13.1%) to be alive but not on treatment, 
47 (8.8%) to have migrated to another place of residence, 38 (7.1%) to have 
died, and 56 (10.5%) to have re-engaged in care (38 of whom were resolved by 
new visit data in the PIRL database and so it is possible that their TIER.Net 




Figure 6.4: Outcomes ascertained through record review and 
tracing stratified by TIER.Net status 
 
A deceased or transferred status in TIER.Net is accurate. There are inaccuracies in the LTFU and still 
in care categories. Some patients categorised as still in care are LTFU, not currently on treatment, 
transfers out or dead. 
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As patients classified as LTFU in TIER.Net were more likely to be misclassified 
we report on the factors associated with being classified as LTFU in TIER.Net.  
6.4.5. Factors associated with being categorised as LTFU in 
TIER.Net 
In the multivariable model (Table 6.5), initiating ART for PMTCT (OR: 1.69, 
p=0.004) and baseline CD4 between 100-349 (CD4 100-199 OR: 1.76, 
p=0.012, CD4 200-349 OR: 1.72, p=0.01) were associated with higher odds of 
being categorised as LTFU in TIER.Net. Older age (age 30-44 OR; 0.71, 
p=0.042), later ART initiation date (2016 OR: 0.43, p<0.001, 2017 OR: 0.12, 
p<0.001), and longer time on ART (6-12 months OR: 0.61, p=0.015, 12-24 
months OR:0.35, p<0.001, >24 months OR: 0.20, p<0.001) were associated 
with lower odds of being categorised as LTFU in TIER.Net. Likelihood of being 
categorised as LTFU also varied by health facility with Belfast (OR: 3.11, 
p<0.001), Justicia (OR: 2.54, p<0.001) and Bhubezi (OR: 3.82, p<0.001) 


























    
Female Reference 
   
Male 0.92 (0.69 to 1.22) 0.554 
  
Age 





30-44 0.81 (0.61 to 1.07) 0.143 0.71 (0.51 to 0.99) 0.042 
45-59 0.63 (0.42 to 0.93) 0.021 0.64 (0.39 to 1.03) 0.065 
60+ 0.50 (0.28 to 0.89) 0.019 0.53 (0.28 to 1.02) 0.059 
ART reason 
    




Pregnant women 2.01 (1.48 to 2.73) <0.001 1.69 (1.18 to 2.43) 0.004 
Men 1.20 (0.88 to 1.63) 0.249 1.24 (0.88 to 1.76) 0.219 
Pre-ART 1.80 (0.88 to 3.70) 0.11 __ __ 
ART start year 





2015 1.01 (0.71 to 1.41) 0.967 0.77 (0.51 to 1.16) 0.209 
2016 0.98 (0.69 to 1.38) 0.892 0.43 (0.27 to 0.68) <0.001 
2017 0.41 (0.20 to 0.84) 0.015 0.12 (0.05 to 0.31) <0.001 
Baseline CD4 





100-199 1.73 (1.16 to 2.58) 0.007 1.76 (1.13 to 2.73) 0.012 
200-349 1.70 (1.17 to 2.45) 0.005 1.72 (1.14 to 2.59) 0.01 
350-499 1.31 (0.88 to 1.94) 0.179 1.22 (0.77 to 1.93) 0.4 
>=500 1.14 (0.74 to 1.73) 0.552 0.99 (0.60 to 1.64) 0.96 
Health Facility 





Belfast 3.28 (2.21 to 4.86) <0.001 3.11 (2.02 to 4.79) <0.001 
Cunningmore 2.00 (1.17 to 3.43) 0.012 1.64 (0.89 to 3.05) 0.114 
Justicia 2.90 (1.86 to 4.52) <0.001 2.54 (1.56 to 4.13) <0.001 
Kildare 1.63 (1.05 to 2.53) 0.029 1.56 (0.97 to 2.50) 0.067 
Lillydale/Bhubezi 3.79 (2.51 to 5.72) <0.001 3.82 (2.40 to 6.06) <0.001 
Thulamahashe 1.11 (0.48 to 2.55) 0.805 0.90 (0.35 to 2.34) 0.83 
Xanthia 1.06 (0.62 to 1.80) 0.834 1.00 (0.56 to 1.77) 0.987 
PIRL linkage 
    
Not linked Reference 
   
Linked 0.81 (0.58 to 1.13) 0.218 
  
Time since missed appointment 
< 1 year Reference 
   
1-2 years 2.22 (1.69 to 2.92) <0.001 
  
>2 years 2.36 (1.59 to 3.52) <0.001 
  
Clinic visit schedule 
    
1 month Reference 
   
2 months 1.14 (0.84 to 1.53) 0.394 
  
3 months 0.90 (0.57 to 1.44) 0.669 
  
>3 months 0.30 (0.13 to 0.68) 0.004 
  
Time on ART 
    




3-6 months 1.19 (0.81 to 1.72) 0.373 0.91 (0.60 to 1.39) 0.661 
6-12 months 0.75 (0.53 to 1.06) 0.108 0.61 (0.41 to 0.91) 0.015 
12-24 months 0.43 (0.30 to 0.62) <0.001 0.35 (0.22 to 0.54) <0.001 
>24 months 0.30 (0.16 to 0.57) <0.001 0.20 (0.09 to 0.43) <0.001 
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Figure 6.6: Proportion of patients misclassified by TIER.Net 
disaggregated by final outcome, sex, and pregnancy status at ART 
initiation 
 
6.4.6. Factors associated with misclassification 
In the multivariable model (Table 6.6), men (OR: 1.47, p=0.021) had higher 
odds of misclassification when compared to women who initiated ART for 
non-PMTCT reasons (CD4, WHO stage, tuberculosis coinfection). Higher 
baseline CD4 (CD4 100-199 OR: 1.95. p=0.002, CD4≥500 OR: 1.81, p=0.014) 
was also associated with higher odds of misclassification when compared to 
patients who initiated treatment with CD4<100. Health facility also remained 
statistically significant suggesting that facility level variability plays a role in 
misclassification. Patients who were linked to an Agincourt HDSS record in 
the PIRL database (OR: 2.09, p<0.001) were more likely to be misclassified. 
Finally, patients who were between 1 to 2 years late (OR: 1.62, p=0.001) were 
more likely to be misclassified. Older age (30-44 years OR: 0.73, p=0.046, 45-
59 years OR: 0.63, p=0.046) was associated with lower odds of 
misclassification and patients on longer refill schedules (>3 months OR: 0.31, 




Table 6.6: Factors associated with TIER.Net misclassification 
 




    
Female Reference 
   
Male 1.08 (0.82 to 1.43) 0.584 
  
Age 
    
18-29 Reference 
   
30-44 0.81 (0.62 to 1.07) 0.141 0.73 (0.54 to 0.99) 0.046 
45-59 0.62 (0.41 to 0.92) 0.017 0.63 (0.40 to 0.98) 0.041 
60+ 0.72 (0.40 to 1.27) 0.253 0.70 (0.37 to 1.33) 0.279 
ART reason 
    




Pregnant women 1.64 (1.22 to 2.20) 0.001 1.28 (0.92 to 1.78) 0.142 
Men 1.34 (0.98 to 1.82) 0.063 1.47 (1.06 to 2.06) 0.021 
Pre-ART 1.69 (0.83 to 3.47) 0.149 1.26 (0.57 to 2.78) 0.568 
ART start year 
    
2014 Reference  
   
2015 1.11 (0.79 to 1.54) 0.556 
  
2016 1.08 (0.76 to 1.52) 0.671 
  
2017 0.92 (0.47 to 1.80) 0.8 
  
Baseline CD4 





100-199 1.83 (1.22 to 2.74) 0.003 1.95 (1.28 to 2.97) 0.002 
200-349 1.29 (0.87 to 1.90) 0.201 1.45 (0.96 to 2.19) 0.074 
350-499 1.32 (0.88 to 1.99) 0.183 1.52 (0.98 to 2.37) 0.063 
>=500 1.62 (1.05 to 2.49) 0.029 1.81 (1.12 to 2.91) 0.014 
Health Facility 





Belfast 2.42 (1.66 to 3.52) <0.001 1.97 (1.30 to 2.97) 0.001 
Cunningmore 2.01 (1.16 to 3.49) 0.013 1.64 (0.91 to 2.96) 0.101 
Justicia 2.25 (1.46 to 3.47) <0.001 1.96 (1.21 to 3.17) 0.006 
Kildare 1.74 (1.12 to 2.71) 0.015 1.42 (0.89 to 2.28) 0.14 
Bhubezi 2.53 (1.73 to 3.71) <0.001 2.26 (1.50 to 3.41) <0.001 
Thulamahashe 1.14 (0.50 to 2.60) 0.762 1.47 (0.64 to 3.36) 0.363 
Xanthia 1.74 (1.01 to 2.98) 0.045 1.86 (1.07 to 3.24) 0.028 
PIRL linkage 
    




Linked 1.59 (1.10 to 2.29) 0.014 2.09 (1.41 to 3.10) <0.001 
Time since missed appointment 
   




1-2 years 1.89 (1.44 to 2.46) <0.001 1.62 (1.21 to 2.17) 0.001 
>2 years 1.58 (1.06 to 2.34) 0.025 1.34 (0.87 to 2.07) 0.181 








2 months 0.96 (0.72 to 1.28) 0.793 0.97 (0.71 to 1.34) 0.872 
3 months 1.00 (0.64 to 1.57) 0.99 0.95 (0.59 to 1.52) 0.832 
>3 months 0.19 (0.08 to 0.44) <0.001 0.31 (0.13 to 0.74) 0.009 
Time on ART 
    
<=3 months Reference 
   
3-6 months 0.83 (0.57 to 1.20) 0.314 
  
6-12 months 0.72 (0.51 to 1.01) 0.055 
  








In this paper, we described the discrepancies between the treatment, vital and 
residency status of HIV patients enrolled in care between April 2014 and 
August 2017 in a rural South African setting as recorded in the national 
treatment database (TIER.Net) and their treatment outcome following a 
comprehensive record review and tracing study.  
We found that TIER.Net misclassified 36% of the patient outcomes. ART 
initiation reason, baseline CD4, health facility attended, PIRL linkage, time 
since the last appointment, age, and ART refill schedule were all found to be 
significantly associated with misclassification. TIER.Net underestimated 
mortality and overestimated the number of patients who were LTFU. Seventy-
nine percent of patients classified as LTFU in TIER.Net had a final outcome 
ascertained, mirroring findings from a systematic review of low and middle 
income country ART programmes which found that tracing generated higher 
estimates of mortality and lower estimates of LTFU (52). Our findings show 
that LTFU is still an important problem in ART programmes in this setting, 
even with routine patient tracing in place. TIER.Net also missed 43% of 
transfers with these silent transfers being the biggest contributor to 
misclassification among those documented as LTFU. We also found that 21.8% 
of patients had re-engaged in care, a phenomenon that was previously not well 
understood, but which is now increasingly recognised as becoming a common 
feature of ART programmes (52). Using our findings to revise LTFU figures to 




In our study, we found that 40% of deaths were missed by TIER.Net, indicating 
that mortality of ART patients would be underestimated if relying on this data 
source. Given the role that national statistics play in HIV/AIDS projections 
(498–500), our findings suggest a need for correction factors for the estimates 
of the effect of ART on mortality. Although South Africa has a good vital 
registration system in place (501), these data are not currently linked to clinic-
based information. However, with the move to registering patient national ID 
numbers, clinics should consider matching patients that are LTFU to the 
national death registry and other available databases such as the national 
health laboratory services database to ascertain vital status as this has proved 
useful in other studies in South Africa (102,446,447). Clinics in the Agincourt 
HDSS study area and other HDSS sites could also consider using vital status 
data from annual demographic surveillance to ascertain vital status for all 
patients. 
The number of patient transfers to another clinic that were missed in TIER.Net 
suggests that communication between clinics is sub-optimal and that the 
current system for transferring patients between clinics can be improved. With 
studies reporting patient fear and concern about provider reactions if they 
return to care after a treatment interruption (367,502) it is possible that some 
patients considered it less stressful to self-transfer or restart treatment at 
another nearby clinic, rather than returning to the facility where they had 
initiated treatment. These silent transfers could lead to double counting of 
patients currently on treatment, the second of the 90-90-90 targets, 
potentially suggesting that the programme is performing better than it is. 
Furthermore, given that the national treatment programme relies on data 
from TIER.Net to plan and procure ART based on active patient numbers, 
misclassification in the database, and more specifically double-counting due 
to silent transfers may lead to inaccurate drug forecasts and misestimation of 
medicines and other commodities at the national level. This bias will only 
increase as the South African ART programme expands with more patients 
potentially moving into new clinics closer to their homes and more people 
initiate ART with the move to test and treat. Future work will consider how 
application of correction factors from this research would change programme 
statistics and drug forecasts. 
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It is also important to consider the risk that silent transfers pose with regards 
to drug resistance, as this misclassifies treatment experienced patients as 
treatment naïve and may lead to patients being offered regimens that have lost 
their optimal therapeutic benefit. This is particularly concerning because 
resistance testing is not commonly used in these settings, and can potentially 
lead to increases in levels of transmitted drug resistance (445). Better referral 
systems, patient education, regular information exchange between clinics, and 
provider training (364), could improve recording of transfers and clinic staff 
attitudes towards less adherent patients. The WHO also recommends 
enforcement of unique identifiers as paramount to improve patient safety, 
improve the efficient use of programme resources by reducing duplications, 
and to improve programme monitoring and evaluation (370). With national 
IDs becoming mandatory at clinic registration, information exchange could 
prove useful in identifying silent transfers. This should also become less of an 
issue when TIER.Net is upgraded to a fully networked database.      
We found several factors to be associated with misclassification of outcome in 
TIER.Net, with older age and longer ART refill schedules found to be 
protective factors. Older patients were less likely to be classified as LTFU in 
TIER.Net which probably explains why they were subsequently less likely to 
be misclassified. Given that longer ART refill schedules are synonymous with 
previous good adherence (503), these patients accounted for 11% of the 
patients LTFU and were also more likely to have re-engaged in care, a category 
that contributed very little to misclassification. Patients whose clinic record 
was successfully linked to an Agincourt HDSS record in the PIRL database 
were more likely to be misclassified. They were also more likely to have been 
resolved which could explain this association. Health facilities were also 
positively associated with misclassification, with the facilities with the highest 
proportion of patients classified as LTFU in TIER.Net being more likely to 
misclassify patients. Two of these clinics also had issues with routine tracing, 
with one clinic not undertaking any physical tracing at all, emphasising an 
additional benefit of routine tracing. Finally, patients who had been LTFU for 
a longer duration were more likely to be classified as LTFU in TIER.Net, more 
likely to have transferred to another clinic, and less likely to have re-engaged 
in care which probably explains their higher likelihood of misclassification.    
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This analysis has several limitations. Firstly, TIER.Net was only consulted at a 
specific point in time. The cross-sectional nature of TIER.Net outcomes means 
that some may have changed, but we would have no way to ascertain this. We 
checked TIER.Net 12 months after the initial record review for all patients 
whose outcome after record review and tracing was still LTFU and 85% of the 
outcomes had not changed. However, for patients whose final outcome was 
resolved through new visit data in the PIRL database, it is likely that their 
TIER.Net outcome also changed. It is also possible that some of the patients 
categorised as LTFU in TIER.Net are due to the rigidity of the system as 
TIER.Net only allows for four possible outcomes; still in care, transferred out, 
LTFU and deceased (100,504,505). It is possible that for some patients, their 
outcomes were ascertained, but the rigidity meant that they could not be 
recorded in the database and may call for the inclusion of other possible 
outcomes in the database. The exclusion of patients for whom an electronic 
record could not be found from the multivariable analyses might bias our 
findings. However, given the relatively small number we expect that this bias 
is fairly small. Finally, we did not adjudicate causes of death, so it is possible 
that patients died from causes other than those related to HIV/AIDS. A 
strength of this study is that we attempted to trace all patients that were LTFU 
and not a sample. Therefore, the findings might be more generalisable to other 
settings. The multiple methods, data sources and levels of follow-up used to 
trace patients are also a strength.  
6.6. Conclusions 
Although TIER.Net misclassified 36% of patient outcomes, this reflects the 
various challenges with the processes and upstream factors that lead to this 
misclassification and calls for their improvement rather than the utility of the 
database itself, as patients classified as LTFU were most likely to be 
misclassified. Clinics should consider training staff about ascertaining patient 
outcomes, putting more emphasis into patient tracing and using other data 
sources such as the national death register to improve ascertainment of patient 
treatment outcomes. For policy and planning purposes, programme 
evaluators should consider using correction factors to improve the accuracy of 
estimates from TIER.Net.  
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7. Paper D: “If the results are 
negative, they motivate us.” 
Experiences of early infant 
diagnosis of HIV and engagement 
in Option B+. 
 
Introduction to chapter: 
This paper (D) utilises data collected through the in-depth interviews to 
explore objective 3. Many qualitative papers cited in the literature review have 
considered factors ranging from biomedical, to individual, and structural to 
explain maternal engagement in care. During the conception phase of this 
research, some published literature described the importance of pregnancy in 
fostering engagement in care by giving women a legitimate explanation for the 
need to take their medication and attend the clinic. However, no published 
literature had explored infant characteristics and outcomes and their 
association with engagement in care for the mother in the postpartum period. 
Given that protecting the child is a major motivating factor for ART initiation, 
this was an important literature gap that needed exploration.  
Initial exploration of the data generated through the IDIs showed EID to be an 
important thematic area. This paper was conceived as a means to explore the 
interaction between postpartum women’s experiences of EID and their 
engagement in care. This paper also provides a way to conceptualise this 
interaction. The rationale for this paper is to encourage the inclusion of the 
pregnancy and its outcomes in the exploration of maternal outcomes as 
maternal engagement in care is additionally complicated by the needs of the 
infant. The mother and infant are a dyad. Failure to recognise this fact is 








Few studies have explored the relationship between early infant diagnosis 
(EID) of HIV and mothers’ engagement in care under Option B+. We 
conducted in-depth interviews with 20 women who initiated antiretroviral 
therapy (ART) under Option B+ in rural South Africa to explore the 
interactions between EID and maternal care engagement. Drawing on practice 
theory, we identified themes relating to Option B+ care engagement and EID.  
Women’s practice of engagement with HIV care shaped their decision-making 
around EID. Mothers who disengaged from care during pregnancy were less 
inclined to utilise EID as they lacked information about its availability and 
benefits. For some mothers, tensions between wanting to breastfeed and 
perceptions that it could facilitate transmission led to repeated utilisation of 
EID as reassurance that the child remained negative.  
Some mothers used their child’s negative result as a proxy for their status, 
subsequently disengaging from care. For some participants, an HIV diagnosis 
of their infant and the subsequent double burden of treatment visits for 
themselves and their infant, contributed to their disengagement. 
Women’s care-seeking practices for themselves and their infants work in a 
symbiotic ecosystem and should be viewed interdependently to tailor 




By 2015, Option B+, which involves initiating all HIV positive pregnant women 
on antiretroviral therapy (ART) regardless of immunological stage (9) and 
testing all exposed infants (183) had been adopted as national policy for 
prevention of mother-to-child transmission of HIV (PMTCT) programmes in 
the majority of sub-Saharan African countries, including South Africa (402). 
Option B+ has dramatically increased the number of pregnant women 
initiating ART, however retention has been challenging, particularly in the 
postnatal period and after breastfeeding cessation (69,241,305,318). Attrition 
from Option B+ programmes contributes to morbidity and mortality linked to 
ART cessation (56,455,496). Furthermore, if the women are not virally 
suppressed it increases their potential onward transmission both horizontally 
and vertically (in their current or subsequent pregnancies) (456,457,506). In 
addition, for PMTCT programmes to be effective, mothers need to attend 
services to receive prophylaxis for new-borns, test their infants (early infant 
diagnosis (EID)) and for those who test positive, initiate them onto lifelong 
ART.  
Serological assays used for adult testing are not reliable for infants given that 
maternal HIV antibodies can persist in infants up to 18 months. EID seeks to 
establish the presence of HIV infection in children less than 18 months old 
through DNA polymerase chain reaction (PCR) testing. EID allows for HIV-
infected infants to be linked to care and treatment early, which reduces infant 
morbidity and mortality (260,262,507). Ninety percent of HIV exposed infants 
(HEI) should be tested by eight weeks according to the World Health 
Organisation global targets, but EID uptake in many sub-Saharan African 
countries is suboptimal (110,227,264), with only half of HEI in 21 priority 
countries reported to have been tested in 2015 (26).    
A growing body of qualitative research has explored underlying reasons for 
poor retention across the Option B+ cascade (237,241,245,249). Many of these 
reasons mirror those identified among the general population on ART, 
including stigma, grappling with the lifelong commitment of daily treatment-
taking (255,339), denial of HIV status (240,245,319,355), and treatment side 
effects (251,289,353,508). Other reasons that are specific to Option B+ 
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included still feeling healthy, and lack of readiness to start ART when still 
coming to terms with a recent positive diagnosis (237,286), especially in 
settings where same-day ART initiation is offered and expected (239). 
Disengagement from care following transfer from PMTCT programmes to 
routine care can occur if women have to attend different HIV clinics for 
themselves and their child (257),  or  if they have not yet disclosed to anyone, 
and post pregnancy they no longer have an easy explanation to attend HIV 
clinics or take daily medication (245), or they do not have anyone they can 
leave the baby with (289). Some post-partum women feel their babies are no 
longer at risk of HIV transmission and no longer feel the need to take 
medication (289), while others who experience post-partum depression may 
also struggle to remain engaged in care (366).  
An infant’s engagement in care is inextricably linked to that of the mother, 
however EID rates are lower than maternal care engagement (35,509), 
suggesting additional factors drive this poor uptake. Poor quality counselling, 
fear of stigma, fear of disclosure, costs of multiple clinic visits, and a lack of 
service integration have been highlighted as barriers to achieving optimal EID 
coverage (263,326,510–513). The stressfulness of EID for the mother, lack of 
knowledge regarding EID and infant ART, the perception of health care 
workers as authority figures, fear of disclosure of own and/or child's HIV 
status, lack of psychosocial support, and intent to shorten the life of the child 
have also been shown to be significant barriers and facilitators of EID 
(267,514). However, few studies have investigated how experiences with EID 
may influence a mother’s engagement and retention in care. Given that one 
key motivation for mothers to start ART is to prevent transmission to their 
baby (237), a positive EID result for example could be a direct cause of 
disengagement.  
Practice theory is increasingly being used to understand HIV engagement in 
sub-Saharan African settings (80–82). Practice theorists treat practices – the 
elements that shape our perceptions, interpretations and actions – as their 
primary units of enquiry and contend that people’s practices can be explained 
by generic ‘elements’ which include materials or tools required to enact a 
practice, symbolic meanings associated with a practice, and competence and 
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know-how to enact a practice. Each individual has a constellation of practices 
that they engage in, with some of these practices interacting either 
harmoniously or in conflict. Consequently, the enactment of one practice is 
likely to affect other practices (83,85–87). Shove (87) and Schatki et al (86) 
speak of “bundles of practices” to describe such a grouping of inter-reliant 
practices and encourage the understanding of how these bundles evolve, share 
and compete for resources through their connections.  
We draw on theories of practice in our analysis to explore how the practices of 
engaging in HIV care and utilising EID are socially situated, being shaped by 
the materials, competences and meanings in the lives of women offered Option 
B+ in a rural South African setting.  
7.3. Methods 
 
7.3.1. Study design and setting 
Data for this analysis are part of a larger mixed methods study which aimed to 
ascertain patients’ treatment outcomes after they become lost to follow-up and 
to explore experiences of HIV services, disengagement and re-engagement in 
care from the perspective of people living with HIV living in Agincourt in rural 
South Africa. The larger parent study (not included in these analyses) involved 
a comprehensive record review of clinic records of patients meeting the LTFU 
criteria, as well as supplementary tracing by community healthcare workers 
(HCWs) (116).As part of this larger parent study, we conducted thirty-two IDIs 
between January and February 2018 (20 Option B+ women, 7 non-Option B+ 
women, and 5 men). 
The qualitative sub-study presented here includes the IDIs conducted with 
Option B+ women living with HIV (n=20, 7 not engaged in care) who had given 
birth since 2015 and who resided in the area covered by the Agincourt health 
and demographic surveillance system (AHDSS) in rural Bushbuckridge, 
Mpumalanga province, north-eastern South Africa in 2017 (20).     
The AHDSS has been tracking demographic and health events in Tsonga or 
Shangaan people since 1992. The populace of approximately 115,000 people 
spread over 30 villages is served by eight government health facilities: five 
clinics and three community health centres. PMTCT services have been offered 
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in all facilities since 2004, with Option B+ starting in 2015. Participants in the 
AHDSS who attend health facilities in the study area give consent to have their 
clinic records linked to their demographic surveillance data. 
7.3.2. Sampling and recruitment 
We drew up a sampling frame using the linked AHDSS and clinic database of 
all patients who initiated ART during pregnancy since 2015. We then recruited 
participants purposively to ensure diversity in terms of age, parity, clinic 
attended, and current treatment status. We utilised home Global Positioning 
System (GPS) coordinates collected routinely by the AHDSS to locate potential 
participants including those currently disengaged from care, many of whom 
have been lost to the health system and as a result are under-represented in 
research (422). Avoiding recruitment through health services was also to help 
limit bias that may arise from refusals that might result from participants’ 
perceptions that recruitment was an attempt to re-engage them in care. 
Participants were approached and invited by a fieldworker who explained the 
study. This population is routinely studied through demographic surveillance 
and participants give permission to be contacted at home for further research, 
so contact with fieldworkers is not unusual and would not inadvertently breach 
their privacy. Participants received an information sheet with study details and 
contact information and were asked to give written informed consent prior to 
the interview.  
The first author, a male PhD student, trained and supervised five female 
fieldworkers who conducted the interviews, four of whom had previous 
experience with conducting IDIs. The research team emphasised their role as 
researchers to participants to minimise the power dynamics that may be 
associated with patient provider interactions.  
Trained fieldworkers that were previously unknown to the participants 
conducted IDIs in Shangaan language based on a topic guide.  Interviews were 
conducted in a private location of the patient’s choice. Interviews lasted 
approximately 60-90 minutes, and participants were encouraged to speak 
candidly as their accounts would only be reported anonymously. The topic 
guide covered experiences using HIV care and treatment services, including 
EID services, and episodes of engagement and dis-engagement from care. 
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Field notes were taken and all IDIs were audio-recorded and transcribed 
directly into English. Transcripts were anonymised, password-protected and 
stored on a non-networked password-protected hard-drive.     
7.3.3. Data analysis 
We analysed the data generated thematically drawing on the principles of 
inductive coding to construct themes. Three initial interviews were transcribed 
and manually open coded by the lead author to identify emerging themes, 
refine the topic guide and develop the coding framework. We held debriefing 
sessions with fieldworkers to provide an opportunity to reflect on the 
interviews, refine the topic guides and provide guidance on interviewing 
techniques. All the transcripts were then coded with the aid of Nvivo11. The 
coding framework was continually refined as more transcripts were analysed 
to capture new codes as they emerged. Codes were then grouped and 
conceptualised to identify themes and considered in relation to the main social 
practices of interest. Interpretations were built by exploring relationships 
between the social practices mentioned by the participants and considering 
the meanings they gave to these practices and the competences they described 
in relation to enacting them. We drew quotations from individuals that 
exemplify the findings to highlight certain thematic areas and to allow greater 
depth of exploration (participant quotations are presented in Figures 7.1 and 
7.2 and numbered for easy reference, for example (Figure 7.1, 1) refers to quote 
1 in Figure 7.1).  
7.3.4. Ethics  
This study received ethics clearance from the London School of Hygiene and 
Tropical Medicine, the University of Witwatersrand and the Mpumalanga 
department of health. All participants provided their written informed consent 
for the study in addition to the consent they had already provided as 
participants of the AHDSS. They were informed that their participation was 
voluntary and that their refusal would not affect the services they received 
through the healthcare system or result in any loss of benefits pertaining to 
medical treatment.  
7.4. Results 
Overall, 32 Option B+ women were sampled to participate and 20 were 
interviewed (three were not at home, five had migrated temporarily or 
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permanently, one could not be found, and three refused to participate). 
Participants’ ages ranged from 19 to 37 years. Most participants were in 
informal relationships (12) and had some secondary school education (15) 
(Table 7.1). Participants came from 11 villages. 
The focus of this analysis is the interrelatedness of the practices of undertaking 
EID and maternal engagement with HIV services. The different elements of 
practice theory were seen to underly the enactment or impediment of both EID 
and engagement in HIV care throughout participants’ narratives and accounts. 
 
Figure 7.1: Schematic illustration with quotations to show how 
practice theory can be applied to explore the utilisation of early 
infant diagnosis 
 
*Blue quotes represent positive aspects of the elements of the practice which 
might facilitate its enactment while red quotes represent negative aspects 





Table 7.1: Demographic and treatment characteristics of the 
participants and non-participants  
 Age in years  
 19-24  25-29  30-34  35+  Total 
Participants 7 6 5 2 20 
Marital Status 
Single 1 1 1 0 3 
Married 0 2 2 0 4 
Informal 6 3 2 1 12 
Separated 0 0 0 1 1 
Education status 
Primary  0 2 1 0 3 
Secondary 5 4 4 2 15 
Tertiary 2 0 0 0 2 
Parity  
1-2 7 5 4 1 17 
3-4 0 1 1 1 3 
Self-reported treatment status   
In care 4 4 4 1 13 
Not in care 3 2 1 1 7 
Clinic treatment status 
Re-engaged 3 4 3 1 11 
Transferred 1 1 1 0 3 
Not in care 3 1 1 1 6 
Timing of HIV diagnosis 
Newly diagnosed 3 3 4 2 12 
Previously diagnosed 4 3 1 0 8 
EID done 
Yes 4 4 5 1 14 
No 1 2 0 1 4 
Incomplete (child<18 months old) 2 0 0 0 2 
Infant’s HIV status at the time of the interview 
Negative 6 4 4 1 15 
Positive 0 0 1 0 1 
Unknown 1 2 0 1 4 
Non-participants 5 4 2 1 12 
Clinic treatment status  
In care 2 3 1 1 7 





7.4.1. Theories of practice and early infant diagnosis of HIV 
Materials and tools were necessary for EID often reflecting the level of HIV 
care infrastructure. For example, one participant mentioned that EID samples 
were collected at a specific time each day and if mothers brought their infants 
to test after this time, they would be asked to come back the next day (Figure 
7.1, 1) which could have major implications for whether EID was performed. 
One advantage of dried blood spots is their stability at room temperature and 
might indicate a lack of understanding from the clinic staff which speaks to 
competence and know-how constellation of practice theory. Competence is 
further elucidated with some participants mentioning the HCWs’ 
prioritisation of breastfed infants over those that were bottle-fed (Figure 7.1, 
2). Competence could be gained through interactions with HCWs (Figure 
7.1,3) or from other family members (Figure 7.1, 4). Furthermore, if mothers 
placed some meaning on EID, usually manifested as the need to diagnose their 
infants expeditiously, they appeared to be more likely to utilise EID (Figure 
7.1, 6). Finally, maternal engagement in care and breastfeeding emerged as 
other practices that might help or hinder the utilisation of EID (Figure 7.1, 7 & 
8).   
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Figure 7.2: Schematic illustration with quotations to show how 
practice theory can be applied to explore (dis)engagement with 
HIV services 
 
*Orange quotes represent what could be interpreted as either positive or 
negative aspects of an element of a practice which might facilitate or impede 
its enactment 
7.4.2. Theories of practice and engagement in HIV care 
Materials and tools were equally important for engagement in HIV care. Lack 
of funds required for the logistics of remaining engaged in care for example to 
cover transports costs to the clinic were mentioned by some participants 
(Figure 7.2,1). Competence was acquired through HCWs and expert clients 
who helped with counselling patients and equipping them with the tools 
needed to navigate a life of daily treatment taking, regular clinic visits and 
stigma management. Where participants accepted this new normal, they were 
more likely to remain engaged in care (Figure 7.2,2). The meaning participants 
placed on remaining engaged in care could also help or hinder their continued 
engagement in care and this meaning could be derived from other practices 
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that were enacted (Figure 7.2, 5). Early infant diagnosis emerged as another 
practice that could affect engagement in care (Figure 7.2, 8). 
We found that mothers’ continued engagement in care could be undermined 
by EID especially in instances where the EID experience fostered denial or 
complicated clinic visits (usually due to scheduling conflicts regarding their 
infant and their own clinic visits). It could also foster engagement in care by 
facilitating the acceptance process. Continued engagement in care was of 
paramount significance in the utilisation of EID (Figure 7.3). 
Figure 7.3: Schematic representation of the complex relationship 
between EID and mothers' engagement in care 
 
7.4.3. Maternal engagement in HIV care and its influence on 
EID uptake 
Engagement with HIV services encouraged uptake of EID by giving it meaning 
and improving women’s competence and know-how regarding EID. The need 
for EID was not common knowledge to all the participants at their first 
antenatal care (ANC) visit, particularly those who were newly diagnosed, 
younger, or primigravida. However, information and counselling sessions 
throughout the ANC period ensured that most participants were aware of 
infant testing by the time of delivery. Consequently, women who disengaged 
from care early on in their pregnancy missed opportunities to learn about the 
procedures and benefits of EID (Figure 7.1,5). 
Interactions with HCWs (an element associated with engagement in care) 
provided opportunities to learn about EID and HCWs influenced mothers’ 
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decision to test their infants with some mothers expressing subservience or 
suggesting they did not have a choice in the matter. In other cases, HCWs were, 
according to patients, too busy and mothers missed opportunities to undergo 
EID (Figure 7.1,8). Some mothers felt that priority for EID was given to 
mothers who breastfed their babies reinforcing their perception that this mode 
of feeding was riskier than bottle-feeding (Figure 7.1,7), subsequently driving 
EID uptake.  
7.4.4. Infant testing and its influence on maternal engagement 
in care 
The practice of undergoing EID for their babies, and mothers’ responses to the 
results of the tests, had consequences for their own engagement with HIV care. 
In most cases, mothers expressed an initial fear of testing their infant, which 
they had overcome through the desire to know their infant’s HIV status so that 
they could decide the next appropriate steps to sustain their child’s health. 
However, a positive infant HIV test result was often met with fear, with little 
knowledge about the next steps and fear that the child would die if they did not 
receive proper treatment. Conversely, many women reported that a negative 
result for their child encouraged them to adhere to their own ART, because 
they wanted to live long lives to see their children grow up (Figure 7.2,8).  
For some mothers who had not fully accepted their own HIV status, the infant 
test could be seen as proxy for their own HIV status (Figure 7.2,3). However, 
discordant results for the mother and child often caused confusion and could 
hinder the acceptance process, or even reinforce denial (Figure 7.2,4). In this 
example in Figure 2 the participant’s confusion was exacerbated by the fact 
that the negative HIV status of her child did not correspond with her 
expectations of it being positive because she had not adhered to HCWs’ advice 
about taking ART. The use of the child’s status as evidence for the necessity of 
ART was also seen among some other mothers, for whom the negative HIV 
status of their child was proof of their own regular treatment-taking. One 
participant who suggested that she had problems with proving to HCWs that 
she was taking treatment as prescribed mentioned that the negative result for 
her infant proved once and for all that she was taking treatment properly.  
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For some mothers, a confluence of issues relating to EID and the subsequent 
practice of linking their child to care worked together to undermine their own 
engagement in care. One participant described how her second born fell ill, 
was hospitalised, and tested positive while she was in Gauteng province. She 
moved back to Agincourt and twice attempted to initiate her child on 
treatment but was unsuccessful because she did not have the child’s 
paperwork. She also anticipated stigma and maltreatment by the clinic staff at 
her nearest clinic, but she did not have the finances to travel to a further clinic 
(Figure 7.2,1). She only wanted to start treatment after she had “sorted” herself 
out but suggested that she felt far from achieving this. The confusing and 
difficult time she had with initiating her second born child on ART 
undermined her trust in the HCWs and undergoing EID this time around 
(Figure 7.2,5). This late seroconversion undermined her own engagement in 
care and was reinforced by her fear that her other children might also have 
HIV and the double burden this would entail (Figure 7.2,7).  
Subsequent uptake of infant treatment, for those who tested positive, could 
interfere with engagement in care for some mothers, especially if they were 
expected to visit the clinic on separate occasions for their own treatment and 
that of their infant. Some mothers expressed fatigue at this dual burden of 
appointments for themselves and their child, which resulted in them 
prioritising their infant’s treatment over their own, and in some of these cases, 
the mother stopped going to the clinic all together (Figure 7.2,6).  
7.5. Discussion 
In this study with mothers living with HIV in north-eastern South Africa, we 
explored the interplay between mothers’ engagement in HIV care and EID, 
highlighting its complexity and bi-directional nature (Figure 7.3).  
Our findings build on those from previous studies which have shown that 
mothers who remained engaged in HIV care were more likely to access EID 
(263,511), by describing the aetiology of this relationship. Mothers’ practice of 
continued engagement in care facilitated EID uptake through improved 
knowledge about the availability of EID and risk factors for transmission like 
breastfeeding, and also increased the influence of HCWs over mothers 
regarding their decision to undergo EID. However, a lack of understanding of 
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vertical transmission for some mothers could also reflect a failing of the HCWs 
who might either not understand it themselves or might not have taken the 
appropriate time to communicate effectively with the mothers for a myriad 
reasons and could reflect an over-burdened system. This highlights the need 
to consider more innovative solutions to deliver the multiple facets of care like 
ongoing counselling using lay HCWs (515).    
Other studies suggest that HCWs are often perceived  as authority figures by 
mothers, leading to mothers’ subservience towards them in the clinic setting 
(267). Whilst mothers who were engaged in care benefited from multiple 
interactions with HCWs, which often included encouragement to undergo 
EID, others may have felt pressured to test their infants. Other researchers 
have noted that the hierarchies of power that are implicitly present in patient-
provider relationships can enable potentially coercive practices to increase 
HIV testing rates among pregnant women (288,310–312), with unintended 
consequences for women’s disengagement from care in the longer term (516), 
and similar risks of disengagement should be considered for mothers who feel 
pressured to test their infants before they feel ready to receive the results. 
Health workers’ apparent prioritisation of EID for breastfed babies shows that 
this practice was not solely dependent on the competence of mothers but also 
that of HCWs. The consequences of this may include missed opportunities for 
infant testing, as well as driving concern among breastfeeding mothers about 
HIV transmission risks. 
Blue et al (85) suggest that the requisite elements necessary for a practice to 
be enacted are not evenly distributed within society. This coupled with how 
these practices are reproduced, synchronised, and coordinated in daily life and 
become more deeply embedded than others, helps to explain why some women 
utilised EID while others did not. Our findings suggest that the practice of EID 
is linked to other practices such as breastfeeding and immunisation. 
Conversely, engagement in care is linked to EID and other practices such as 
maternal testing, with counselling playing a role in how the two practices 
interact by providing meaning and supporting competencies among women 
who are enrolled in Option B+. We found that for some mothers who had not 
accepted their HIV status, the practice of EID could prove detrimental to 
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continued engagement in care especially in the case of a discordant result with 
the infant. This suggests the need for a better understanding of the ecosystem 
of practices in which EID and engagement in care are enacted, and how they 
interact, in order to effectively intervene to improve both the utilisation of EID 
and engagement with HIV services.   
Women responded to EID results in different ways. The process of acceptance 
of an HIV status is influenced by various events and experiences that are 
unique to each individual (338). Our findings suggest that receiving EID 
results can feed into this process by either helping to confirm or challenge 
mothers’ beliefs about their own HIV status. Similarly, other studies have also 
shown how denial of HIV status can manifest itself in repeat testing (516) or 
use of a partner’s results as a confirmatory test (517), highlighting the fluid and 
protracted nature of the acceptance process for some persons living with HIV 
and the need for ongoing counselling to help some mothers to accept their own 
status, particularly if it differs from that of their child.  
EID facilitated mothers’ engagement in care in many ways. Mothers desired to 
stay healthy and raise their children, expressing an innate maternal desire to 
protect their children and mirroring findings around women’s motivation to 
initiate ART in PMTCT programmes (237,245). When an infant’s HIV results 
were concordant with their own, EID could also act as an important aid in the 
mothers’ acceptance process of her own HIV status.  
Conversely, for other mothers, a negative result for her infant was seen as 
proof of their own adherence to treatment, recalling Vale’s notion of the blood 
“panopticon” whereby blood test results can be a powerful disciplining tool to 
ensure patients’ continued compliance to health provider rules and 
expectations, but may also serve to reinforce the patient’s version of their 
adherence history (518).  
Our findings also highlight the importance of testing mothers throughout the 
MTCT risk period including breastfeeding, given the additional challenges that 
mothers may face in accepting their own and their child’s seroconversion after 
earlier HIV negative results. Country policies regarding postnatal testing for 
negative mothers vary (519,520) and are linked to the infant immunisation 
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schedule, although challenges with implementation include other caregivers 
bringing the infant for immunisation. Nevertheless, given the significant HIV 
incidence in the postnatal period and the high vertical transmission risk linked 
to this (521), more emphasis should be placed on testing during the 
breastfeeding period.   
Conflicting scheduling of clinic visits for mothers and HIV-infected babies led 
to disengagement from care with mothers prioritising their infant’s visits over 
their own, in line with results from studies in Malawi and Mozambique 
(326,510), highlighting an urgent need for longer-term integrated and 
coordinated maternal and infant HIV services beyond 6-10 weeks postpartum 
as one strategy to keep more HIV-infected mothers engaged in care. 
Our findings highlighted some important areas for further research. As HIV 
programmes expand, and more pregnant women living with HIV have 
initiated ART prior to pregnancy or during past pregnancies, it will be 
important to explore how experiences and responses to EID utilisation vary 
between newly diagnosed and experienced ART patients with a view to 
optimising the timing and frequency of EID counselling for different patients. 
Future research should also consider adolescent mothers, who often have 
poorer engagement in HIV care, as their experiences may differ from those of 
women represented here. 
A strength of this study was our ability to include women that were not 
currently in care, a group that has been underrepresented in previous studies. 
Nevertheless, their response rate was lower, and it is plausible that some of the 
women who chose not to be interviewed could have had deferring views from 
the included participants. Other limitations include the fact that we 
interviewed participants once, making it difficult to get a sense of the fluidity 
of their views regarding EID or their engagement in care over time. One-time 
interviews also meant less time to develop rapport with these women which 
may have resulted in them speaking less candidly about their experiences in 
relation to EID and care engagement.  
Furthermore, although they did not emerge as findings in our study, other 
factors have been shown to affect women’s engagement in care which might 
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also influence EID utilisation in other settings, including clinic factors such as 
stock-outs and disclosure status (235,284). This is perhaps because these were 
not important issues in this setting or because we did not probe about them. 
Finally, while the women interviewed for this research share similarities with 
other sub-Saharan settings, they represent a specific population and findings 
and conclusions drawn from this research should be interpreted with this in 
mind.   
7.6. Conclusions 
We found that practice of engagement with HIV care under Option B+ shaped 
their decision-making around EID. Engagement in care, EID and other 
practices that patients enact need to be viewed and researched as an 
interdependent system. A failure to recognise this interconnectedness may 
lead to outcomes that are counter to expectations. Furthermore, since one size 
does not fit all with regards to HIV care and treatment, a more practice-
centred, differentiated care approach might enable HIV programmes to better 
serve women living with HIV and their children in the future.  
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8. Paper E: Challenges with tracing 
patients on antiretroviral therapy 
who are late for clinic 
appointments in rural South 
Africa and recommendations for 
future practice. 
 
Introduction to chapter 
This paper (E) uses data from the record review and tracing study, 
observations of health facility procedures and tools during the data collection 
process, and conversations with health facility staff to investigate objectives 2 
and 4. Most HIV programmes in sub-Saharan Africa implement some form of 
routine tracing for patients who do not return for scheduled clinic visits. 
However, this is inconsistently done and fraught with issues resulting in many 
patients becoming lost to the system. This paper was conceived as a means to 
evaluate and critique the implementation of patient tracing procedures in the 
health facilities that serve the Agincourt HDSS. I report on gaps identified as 










Background: It is common practice for HIV programmes to routinely trace 
patients who are late for a scheduled clinic visit to ensure continued care 
engagement. In South Africa, patients who are late for a scheduled visit are 
identified from clinic registers and called by telephone up to three times by 
designated clinic staff, with home visits conducted for those who are 
unreachable by phone. It is important to understand outcomes among late 
patients in order to have accurate mortality data, identify defaulters to attempt 
to re-engage them into care, and have accurate estimates of patients still in 
care for planning purposes. 
Objective: We conducted a study to assess whether tracing of HIV patients 
in clinics in rural north-eastern South Africa was implemented in line with 
national policies.  
Methods: Thirty-three person-day of observations took place during multiple 
visits to eight facilities between October 2017 and January 2018 during which 
clinic tracing processes were captured. The facility level implementation 
processes were compared to the intended tracing process and gaps and 
challenges were identified. 
Results: Challenges to implementing effective tracing procedures fell into 
three broad categories: i) facility-level barriers, ii) issues relating to data, 
documentation and record-keeping, and iii) challenges relating to the roles 
and responsibilities of the different actors in the tracing cascade.  
We recommend improving linkages between clinics, improving record-
keeping systems, and regular training of community health workers involved 
in tracing activities. Improved links between clinics would reduce the chance 
of patients being lost between clinics. Record-keeping systems could be 
improved through motivating health workers to take ownership of their data 
and training them on the importance of complete data. Finally, training of 
community health workers may improve sustained motivation, and improve 
their ability to respond appropriately to their clients’ needs.  
Conclusions: Substantial investment in data infrastructure and healthcare 




At the end of 2017, it was estimated that 34.6 million adults aged 15 years and 
older were infected with HIV worldwide, 70% of whom resided in sub-Saharan 
Africa (24). New treatment guidelines calling for immediate lifelong treatment 
for everybody testing positive for HIV (known as “Test and Treat”) resulted in 
15.4 million individuals initiating antiretroviral therapy (ART) by the end of 
2017, representing 60% of all people living with HIV (PLHIV) in sub-Saharan 
Africa (24). By the end of 2015, South Africa had the largest ART programme 
in the world (21,107). In 2016 South Africa adopted the “Test and Treat” policy 
which translated to even more people being eligible for treatment (93,95). By 
the end of 2018, an estimated 68% of  the 7.2 million PLHIV in South Africa 
were on ART (24,448). 
PLHIV who are taking lifelong ART who are late for scheduled clinic 
appointments are labelled as lost to follow-up (LTFU), a general term that 
amalgamates several possible outcomes including death, default, and self-
transfer to another clinic (14,15,55). Failure to account for the true outcomes 
of patients deemed LTFU leads to as much as five-fold underestimation of 
retention because silent (undocumented) transfers are not taken into account 
(425). Similarly, default rates are over estimated as all patients that are LTFU 
are assumed to have stopped taking treatment (52,425). Furthermore, if only 
deaths reported to the clinic are included in mortality estimates this results in 
them being underestimated. Inaccuracies in calculating the actual number of 
people alive and on ART has implications in the estimation of national ART 
coverage and corresponding ART programme budgets. Silent transfers can 
lead to double counting of the number of people who have ever initiated ART 
which could lead to overestimates of ART supplies needed, and over-estimates 
of ART programme coverage in national evaluations which could result in a 
reduced focus on reaching coverage targets (367). Finally, misclassification of 
patients who are alive and on ART elsewhere as LTFU underestimates the 
impact of ART on mortality (52,522) which is an important statistic for 
programme monitoring as well as for informing HIV modelling and 
projections by UNAIDS (498,499,523).  
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Effective tracing programmes are likely to become increasingly important in 
the context of “Test and Treat” strategy as more asymptomatic patients are 
initiating ART and may have higher rates of LTFU (524). Tracing is effective at 
improving engagement with studies showing that as many as 86% of patients 
who had defaulted from care reengage in care following tracing (55,525,526) 
and that active tracing significantly reduces attrition (52,527). Moreover, 
continued retention is crucial to mitigate the risk of development of resistance 
in patients who do not adhere correctly to ART (78,79,528,529) 
Previous studies have documented some challenges related to tracing patients 
in HIV programmes in sub-Saharan Africa including organisational 
challenges, health worker shortages, and high costs which continue to limit the 
ability of HIV programmes to trace patients who are missing or LTFU 
(361,368), but few recommendations are made to mitigate these challenges. 
This paper describes the challenges that were observed with routine tracing in 
the primary health care system in north-eastern South Africa, comparing 
policy to actual implementation. The observations were made whilst 
undertaking a study to consolidate routine tracing information and conduct 
supplementary tracing for PLHIV who were LTFU in a decentralised HIV 
treatment programme in the same setting. Recommendations to address these 
challenges are made to improve the implementation of tracing systems in this 




The clinics included in the broader tracing outcomes study were those serving 
the population of the Agincourt Health and Demographic Surveillance System 
(HDSS). The HDSS study area covers 475 km2 in Bushbuckridge, Mpumalanga 
province, north-eastern South Africa. Agincourt HDSS has been tracking 
demographic and health events (i.e. births, deaths and migration) in Tsonga 
or Shangaan people since 1992 (20,414). By 2014, the population was 
approximately 115,000 people living in 17,000 households spread over 30 
villages (20). The study site is run under the auspices of the Medical Research 
Council (MRC)/Wits Rural Public Health and Health Transitions research 
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unit, administrated by the School of Public Health at the University of 
Witwatersrand (WITS). Agincourt HDSS population is served by six primary 
health clinics and three secondary community health centres.  Every HIV-
positive patient has a clinical file that is established when they first register at 
the ART clinic and updated at each clinic visit. Following the clinic visit, visit-
level information from the patient file is entered into the national electronic 
database, TIER.Net. Since 2014, Agincourt HDSS has undertaken an exercise 
called Point-of-contact Interactive Record Linkage (PIRL) (104) where chronic 
care patient visits in the clinics have been recorded and linked to the patient’s 
HDSS record, provided that they ever lived in the HDSS. 
8.3.2. Study design  
The challenges and recommendations presented in this paper are based on 33 
person days of observations in eight primary healthcare facilities (Table 8.1) in 
the Bushbuckridge sub-district between October 2017 and January 2018. 
Clinics were chosen because they were located within the HDSS. Each clinic 
was visited at least three times over this period to ascertain tracing outcomes 
for patients that were believed to be LTFU (more than 90 days late for a 
schedule clinic appointment). Briefly, this mixed methods study involved a 
comprehensive review of available clinic records documented through 
TIER.Net (the national electronic HIV patient monitoring database) and 
paper-based patient clinic files. We also consulted logbooks from Right-to-
Care (RtC) and Home-Based Carers (HBC), two non-profit organisations that 
assist with tracing HIV patients LTFU through telephone calls and household 




We then worked with these organisations to conduct a further home visit for 
all patients for whom routine tracing had not previously been undertaken, or 
for those without a definitive outcome after record review. Observations of 
how the tracing systems operated were captured in logbooks. Primary 
healthcare facility managers usually a sister-in-charge (nurse) were informally 
consulted for further clarification of how the implementation took place in 
practice. In cases where the sister-in-charge was unavailable, RtC officers, 
clinic data typists or other nurses were consulted. We also visited ten HBC 
organisations to document how their work intersected with that of the clinics’ 
tracing system. Additionally we reviewed one national policy document(412), 
which  detailed how tracing should take place and had further conversations 
with other stakeholders and key actors.  
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Table 8.1: Selected characteristics of the eight clinics that serve the study area  
Clinic Type Number of HDSS 
residents 18+ years 
that initiated ART 
between 2014-2017  
Right to care 
presence 






Public 975 Yes  Ward Based Outreach Team 
(WBOT) nurse, Facility manager 
(Sister-in-charge), Home Based 
Carers, Right-to-Care linkage 
officer, community health worker 
6 
Belfast clinic Public 582 Yes (started July 
2017) 
 Data typist, Right-to-Care linkage 







with Lillydale clinic 
a public facility, in 
2016) 
689 Yes  Home Based Carers, 2 Data 
typists, Right-to-Care linkage 




Public 300 No (Linkage 
officer resigned 
in 2016) 
 Data typist, 2 staff nurses, Home 





Justicia clinic Public 423 No  Data typist, Home Based Carers, 
staff nurse 
4 
Kildare clinic Public 586 Yes  Facility manager, data typist, 
Right-to-Care linkage officer, 





Public  133 Attached (same 
linkage officer 
works in Belfast 
and Bhubezi) 
 Data typist, Right-to-Care linkage 
officer 
3 




 Data typist, Home Based Carers, 





8.3.3. Data collection  
As part of the comprehensive clinic record review, we collected data from 
TIER.Net and patient files for 1325 patients that met the LTFU criteria on 
August 15, 2017. Data included information on the patient’s treatment status 
(i.e. still in care, deceased, transferred out) and whether they had received a 
tracing intervention (typically a comment in their record about telephone or 
physical tracing). From RtC and HBC, we asked to view their tracing logs and 
collected data on any telephone or physical tracing interventions for each 
LTFU patient and the outcome of this tracing. Data were entered into a 
Microsoft access database. Discussions with HBCs centred around how 
physical tracing was performed in practice, and their interactions with clinic 
staff and patients. 
In each clinic, through discussions with the staff, we identified the most 
knowledgeable person regarding each step and where possible asked for an 
explanation of how tracing typically occurred. We also asked to view all data 
collection instruments used in the tracing process including late patient lists 
and the tracing registers. Data were entered into an Excel spreadsheet. 
8.3.4. Definitions 
Implementation of tracing was defined as being optimal if lists of late patients, 
tracing registers, telephone and physical tracing were used as intended in 
policy and well documented with clinic staff able to produce these instruments 
when requested. Tracing implementation was defined as “inconsistent” if it did 
not align with policy or was not well documented. In the case of telephone and 
physical tracing inconsistency could also mean that these steps were not well 
documented, but we found evidence of telephone and physical tracing in 
patient files or TIER.Net. Tracing implementation was classified as “not 
observed” where clinic staff could not produce these instruments when 
requested and we could not find evidence of any intervention in patient files, 
TIER.Net, or any documentation kept by RtC and HBC and was classified as 
“not done” where clinic staff admitted that an intervention was not performed. 
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8.3.5. Data analysis 
Data from the clinic record review was exported to Stata 14 for analysis. We 
produced a checklist for each clinic to determine whether each tracing step 
was optimally used, inconsistent, not observed or not done. Data were then 
summarised using proportions and frequencies.  
8.4. Results 
 
8.4.1. Expected implementation of the routine tracing system 
In all of the clinics in this study setting LTFU was defined as being more than 
90 days late for a scheduled appointment in accordance with national policy 
(412). All health facilities routinely traced HIV patients who were LTFU (Figure 
8.1). Each health facility manager is responsible for ensuring that there is a 
functioning paper-based or electronic appointment system such that clinical 
files for patients who are expected the following day are retrieved from the 
filing room. Files for patients who do not attend a scheduled visit should be 
kept aside for further action. A list of patients who did not attend a scheduled 
appointment should be generated every week, either through the facility’s 
appointment register or through querying the facility-level electronic database 
(TIER.Net). If a patient has not attended the facility within five working days 
to follow-up on a missed scheduled appointment, the patient’s name should 
be registered in the facility tracing register to be traced. 
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Figure 8.1: Tracing steps and personnel in charge of each step 
 
This list should be signed off by the facility manager and transferred to the 
person responsible for tracing patients, usually a designated nurse, 
community health worker (CHW) or the ward-based outreach team (WBOT) 
lead. The delegated nominee should extract contact information including 
addresses and telephone numbers (which should be updated at every clinic 
visit) of the individuals on the list (and their treatment supporter where 
available) from the patient files and enter this information into the facility 
tracing register. The facility telephone should then be used to contact all the 
individuals who were added to the tracing register that week, with the date the 
phone call was attempted and the outcome of the phone call, and patient 
outcomes recorded in the register when obtained. Three calls should be 
attempted within 14 days after each patient’s missed visit. Patients found to be 
alive, and who have not transferred to another clinic should be encouraged to 
return to treatment. Self-transfers should be further investigated usually 
through a phone call to the facility they have transferred to (Six facilities 
receive assistance with telephone tracing from RtC). The names of patients 
who cannot be reached after three attempts by phone should be transferred to 
a list of those to be traced through outreach and home visits. Patient consent 




WBOTs, CHWs and HBC linked to the facility should be involved to physically 
trace defaulters. Details of each home visit, including the outcome of the visit, 
should be reported to the facility manager. Each outreach tracing effort should 
be marked in the facility tracing register, indicating the date and outcome of 
the tracing visit.  
Patients who have not reported back to the clinic for 90 days since their last 
scheduled visit and do not have a tracing outcome e.g. transferred out, died, or 
stopped treatment are then in principle registered as LTFU. Before this entry 
is made, one more attempt at phoning or visiting the patient should be made. 
Information from this entire exercise should then be documented into the 
patients’ electronic record. 
8.4.2. Actual observed performance of the routine tracing 
system in the eight health facilities 
Overall, none of the eight clinics had optimal performance with regards to all 
of the indicators (Figure 8.2). Optimal use of late patient lists was observed in 
3 (37.5%) clinics, was inconsistent in 3 (37.5%) clinics and was not observed 
in 2 (25.0%) clinics. Similarly, tracing registers were inconsistently used in 4 
(50.0%) clinics and not observed in 4 (50.0%) clinics. Phone calls were 
optimally used and consistently documented in 2 (25.0%) clinics, inconsistent 
in 5 (62.5%) clinics and not observed in 1 (12.5%) clinic. Finally, physical 
tracing was optimally used and documented in 1 (12.5%) clinic, inconsistent 
(usually due to poor documentation) in 5 (62.5%) clinics, not observed in 1 
(12.5%) clinic, and was not done in 1 (12.5%) clinic. In both clinics, HBC and 




Figure 8.2: Performance on specific indicators from the tracing 
cascade for eight health facilities 
 
8.4.3. Challenges identified in implementing the routine tracing 
system 
Through the data collected, conversations with stakeholders and observations, 
we identified three major types of challenges to the optimal implementation of 
tracing in the eight facilities: facility-level barriers; challenges relating to data, 
documentation and record-keeping; and challenges relating to the roles of 
tracing personnel.  
Diversity in clinic procedures 
Whilst all the clinics drew guidance on patient tracing procedures from the 
same national guidelines and documents, in practice, their implementation of 
these guidelines varied. For example, each clinic that conducted routine 
tracing employed a different filing system and process for generating patient 
identification (ID) numbers. In some cases, these were based on patient 
characteristics such as birth dates, whereas in others, they were generated 
using sequential numbers. In one clinic, two different patient ID systems had 
been implemented, and while one had been discontinued in favour of another, 
both types of patient IDs remained in operation. The way in which files were 
stored was also different across the clinics, with some of them cataloguing and 
indexing files while others did not have any discernible filing system. Tracing 
procedures were also not consistent between clinics with different actors 
involved, and in some cases, certain tracing steps were not performed.  
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Furthermore, each clinic used TIER.Net independently with no links between 
the different clinic databases. This meant that if patients chose to move 
between clinics there was no clear way of identifying them as patients who 
were already in care elsewhere and a new file was opened in the receiving 
clinic. Moreover, the limited communication between clinics affected the 
efficiency and coverage of tracing activities. For example, if patients resided 
outside the catchment area of the HBC organisations attached to the clinic they 
were using, they would not be physically traced, as this would need the 
involvement of HBC from another clinic.  
Data, documentation, and record-keeping challenges 
Weekly lists of patients late for a scheduled clinic visit were always manually 
generated from TIER.Net by data managers. We observed that this was prone 
to human error with some patients who should have been categorised as late 
for a scheduled appointment being missed completely and not receiving any 
tracing interventions. In five clinics, a total of fifty-three patients who had not 
visited the clinic for more than 90 days were recorded as being still in care and 
had been missed by the data manager when the LTFU lists were generated. 
Additionally, whilst national tracing guidelines indicate that every clinic must 
keep a facility tracing register for planning, monitoring and research purposes, 
in most clinics, these registers could not be found and appeared not to be part 
of routine tracing practice. Furthermore, both TIER.Net and patient files did 
not have a dedicated space or module for capturing tracing outcomes. In some 
clinics, these outcomes were sometimes entered into the comments section, 
but this was not consistently done. Patients in some differentiated care 
models, including adherence groups and fast-track treatment collection 
appointments visited their clinic less frequently and, in some cases, do not 
have to interact with clinic staff when they pick up refills. However, TIER.Net 
and patient files did not always reflect this information about patients. This 
meant that some patients were erroneously categorised as LTFU, whereas they 
were still in care through differentiated models.     
Whilst both RtC and HBC organisations were active patient tracing partners, 
they did not always keep records of their work. In one clinic, an HBC volunteer 
admitted that they traced patients, but did not document the tracing, likely due 
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to a myriad of reasons including a lack of training, a lack of understanding of 
the importance of documenting their work, and stationery shortages. Also, 
standardised tracing forms were often unavailable, or unused in practice, and 
some HBC being apparently unaware of them. In some clinics, supplies of 
tracing forms were expected to be generated by photocopying an existing form, 
but the equipment to do this was not always available or functioning. This led 
to staff utilising logbooks or exercise books for record keeping, or in the worst 
case, not documenting their work at all. Impromptu logbooks often had 
incomplete data and, in some cases, had been lost. HCWs struggled to capture 
quality data accurately and consistently as they prioritised their clinical work.  
Additionally, tracing could only be performed if correct patient telephone 
numbers and addresses were available in their file. Also, for some patients the 
telephone number used by the clinic was only effective the first time as once 
patients recognised the clinic telephone number, they would not respond to 
any further calls received from it.   
Challenges relating to roles and responsibilities of personnel 
involved in the tracing system 
The number of actors involved in routine tracing varied between clinics, and 
we observed duplication of work or transfer of tasks and responsibilities from 
one actor to another. For example, as the list of patients who are LTFU is 
generated from TIER.Net, it is the responsibility of the data manager to 
crosscheck the LTFU list with physical files to confirm that no patient visit was 
missed and not entered into the database. However, in one of the clinics, this 
duty had been shifted to the WBOT nurse, meaning she dedicated less time to 
her clinical work. In some clinics, the different actors were not aware of each 
other’s roles, meaning that work was duplicated, or that in other cases some 
patients did not receive all the tracing interventions because some actors did 
not receive their information. In one clinic, the HBC and RtC personnel had 
never communicated, culminating in some patients never being discussed nor 
physically traced. Also, whereas tracing organisations said they informed data 
managers about tracing done, this was not always reflected in TIER.Net.  
Finally, we heard of various challenges within the different home-based care 
organisations. Many of the HBC felt that they were under-funded, and that 
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because of this HBC staff worked on a voluntary basis, only receiving a small 
stipend from the health department and some non-monetary incentives. Some 
expressed a loss of motivation to do their work which was fostered by their 
dissatisfaction with this system. Furthermore, HBC had not received formal 
training which could in some way explain the patients concerns over conduct, 
particularly in terms of maintaining confidentiality when they attempted to 
trace them. Further issues included cases whereby the HBC asked family 
members or friends of the patient why they had not attended the clinic, thereby 
inadvertently disclosing their HIV status. However, where HBC were active 
and motivated, they were more likely to become aware of a patient missing an 
appointment before they were contacted by the clinic. In one clinic, HBCs 
routinely visited patients ranking them by a colour system as stable (green – 
seen every 1-2 months) or volatile (yellow – seen fortnightly or red – seen 
weekly). If they suspected that a patient was LTFU they then confirmed this at 
the clinic, later going back to try to reengage the patient into care. This was a 
more practical system, relying less on communication between actors and less 
prone to errors due to miscommunication. 
8.5. Recommendations for future practice 
We found that most clinics had a system in place to identify and trace patients 
that had missed a scheduled clinic appointment. However, in practice, these 
procedures were heterogeneous and often led to gaps, leakages and missed 
opportunities within the tracing system. Ultimately this meant that tracing 
efforts were inconsistent and probably inefficient. We identified three main 
areas of challenges with routine tracing activities related to facility-level 
barriers; data, documentation, and record-keeping challenges; and the roles 
and responsibilities of the different actors.   
8.5.1. Improved linkages between clinics 
Each clinic in Agincourt HDSS has a catchment area that includes one or more 
villages within its vicinity. Home-based carers from the villages in this 
catchment area are attached to the clinic. However, many patients choose to 
initiate treatment at a clinic that does not correspond to their home village 
(530–532). In such instances, the current tracing strategy is significantly 
constrained due to a lack of linkages between clinics. Such challenges are 
further perpetuated by the way in which clinics are driven to achieve national 
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targets. National clinic evaluation meetings often present clinic targets in a 
way that fosters competition amongst clinics, putting unnecessary pressure on 
HCW to meet these targets (314). This competition might improve some targets 
(e.g. number of patients tested or initiated on ART) but undermine the general 
effectiveness of tracing endeavours. 
Clinics should be encouraged to coordinate efforts working together to trace 
patients. In cases where a patient is under the jurisdiction of HBC not attached 
to a given clinic, there should be procedures that allow for the clinic to 
communicate with the HBCs to facilitate tracing. This would have to be 
coupled with significant patient education and sensitisation about the system 
to make sure they do not feel that their confidentiality has been breached. 
Patients should also be sensitised on the importance of declaring prior medical 
history when presenting at a new facility. Long term, linkages between the 
different clinic electronic recording systems and better implementation of 
unique patient identification numbers would also help to identify silent 
transfers.     
8.5.2. Enhancements of recording systems 
Data quality issues including incompleteness have been reported as a problem 
for tracing in other HIV treatment programmes (15). Studies suggest that data 
quality issues can be attributed to limited engagement of HCWs with the data 
for their own planning, research, and monitoring and evaluation purposes (99) 
as well as a lack of resources (e.g. logbooks). Insufficient training of HCWs 
responsible for recording information and inadequate auditing procedures to 
ensure that incomplete records are identified and rectified in a timely manner 
further exacerbates this issue (99). Healthcare workers need to balance 
different priorities with data entry often seen as less important.  
Large investments have been made in establishing electronic medical records 
at all the clinics and each clinic has a dedicated data typist for TIER.Net, solely 
responsible for electronic data entry. However, the system still exists in an ad-
hoc fashion (the data typist copying information from paper records) and is 
not fully integrated into medical practice (i.e. healthcare providers directly 
entering information into the system). Efforts are needed to fully integrate 
data entry into good clinical practice and clinic staff should be trained on the 
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importance of recording all patients’ outcomes. Furthermore, efforts should 
be made to motivate HCWs to take ownership of and utilise their data for 
monitoring and evaluation. Whilst a dedicated module for tracing might be 
unrealistic in the near future, additional training on basic data analysis, 
provision of mentorship opportunities, as well as training on auditing records 
could lead to improvements in data completeness. Development of standard 
operating procedures for data entry and training on these could further 
improve data completeness.       
8.5.3. Training for lay community healthcare workers 
The inadequate healthcare workforce in sub-Saharan Africa has been well 
documented (533,534), and task shifting has been widely recommended and 
implemented as an efficient and sustainable strategy to expand HIV treatment 
programmes in this setting (535,536). However, we observed that the voluntary 
nature of HBCs, and the non-transparent recruitment strategies (537) can be 
problematic. These cadres are expected to be part of the health system, but not 
necessarily part of its organisation. They have shorter training than 
professional healthcare workers, and they require minimal qualifications 
(536). We observed concerns around their ability to handle confidential 
information. Over thirty years ago, Walt (538) identified several challenges to 
the success of HBC including lack of remuneration, insufficient training, poor 
management, and lack of supervision and logistical support which we found to 
still be prevalent in this setting.  
HBCs should receive specific training in conducting tracing activities as this 
has been associated with sustained motivation, as well as with improving their 
ability to respond appropriately to their clients’ needs (539) and could reduce 
issues related to breaches of confidentiality which undermine tracing efforts. 
Training could also contribute to furthering the legitimacy of HBC among 
patients and formal health workers (540,541). Future research should take a 
more in-depth consideration of the patient perspective with regards to routine 
tracing and its challenges. 
8.6. Conclusions 
Strengthening the recording and routine use of tracing data will capitalise on 
this source of information for patient monitoring at the facility level and 
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improve the accuracy of estimates of true outcomes for patients who become 
LTFU. This will necessitate significant investments in the health system, in the 
training of healthcare workers, and enhancements in data infrastructure. It is 
important that tracing systems and the data they generate keep abreast with 






This chapter collates the main findings from each paper presented within this 
thesis. Rather than repeating the detailed findings and conclusions from each 
paper, this chapter will serve as an opportunity to highlight the “big picture”, 
drawing from the different analyses undertaken and discussing any 
contradictions or findings that might seem counterintuitive. Programme and 
policy recommendations will be given, followed by a discussion of the 
strengths and limitations of the methods and data sources used. I also reflect 
on dilemmas and challenges encountered while conducting this research, how 
I addressed them, and how my choices might have influenced my findings, 
especially with regards to the qualitative research. I will also summarise efforts 
to disseminate findings from the research, and finally, I will present the 
overarching conclusions of this PhD thesis.  
9.2. Synthesis of findings 
Table 9.1 gives a summary of the main findings from each paper. This section 
will synthesise these findings in relation to the overall aim of this thesis: ‘to 
investigate women’s treatment outcomes after they become lost to follow-up 
following uptake of PMTCT services and compare their outcomes to the 
general treatment cohort in a rural community in north-eastern South Africa’.  
The overall aim led to the following objectives 
1. To investigate loss to follow-up among patients who initiated ART 
under Option B+  
a. To understand the outcomes of these patients once they become 
LTFU in South Africa (Agincourt) 
b. To compare their outcomes to the general HIV patient treatment 
cohort 
c. To explore factors associated with different outcomes following 
loss to follow-up 
2. To review and critique data sources and methods used to investigate 
retention in care following uptake of PMTCT services  
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a. To critique routine tracing procedures and methods used to 
investigate attrition from HIV treatment in South Africa 
(Agincourt) 
b. To investigate discrepancies and biases in the official HIV-
patient treatment statistics on retention rates, LTFU and 
mortality produced by TIER.Net the South African HIV-patient 
electronic monitoring system.  
3. To explore the link between maternal engagement in care and early 
infant diagnosis of HIV 
4. To identify and recommend strategies to improve women’s retention in 
PMTCT services 
The format will be guided by the specific objectives of the thesis and findings 
will be structured as they relate to these objectives.   
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Table 9.1: Summary of the main findings from the papers included in this thesis 
Paper Paper title Publication Methods Thesis 
Objective 
Main findings 
A (Chapter 4) Outcomes after being lost to 
follow-up differ for pregnant and 
postpartum women when 
compared to the general HIV 












Using multiple data sources and methods, we managed to ascertain the 
outcomes of 88% of the patients LTFU. I found that 31% of patients LTFU 
had transferred to another facility, 22% had re-engaged in care at the 
same facility, and 12% of patients had died. Outcomes for Option B+ 
women differed significantly from those of the general ART population, 
with these women less likely to have died and more likely to have stopped 
treatment or migrated. Age, pregnancy status at ART initiation, baseline 
CD4, and duration on ART predict mortality.  
B (Chapter 5) Getting on with their lives: 
Understanding clinic transfers 
among HIV patients considered 









Transfers to another facility accounted for 31% of patients LTFU. Women 
are more likely to transfer with Option B+ women the least likely to have 
a transfer documented. Option B+ women mostly transfer between clinics 
in the study area, while transfers out of the study area appear to be driven 
by labour migration.  
C (Chapter 6) Misreporting of patient outcomes 
in the South African national HIV 
treatment database: 
Consequences for programme 












Seventy-nine percent of patients classified as LTFU in TIER.Net had an 
outcome ascertained. TIER.Net misclassified 36% of the patient 
outcomes, with reason for ART initiation, baseline CD4, health facility 
attended, PIRL linkage, time since the last appointment, age, and ART 
refill schedule significantly associated with misclassification. TIER.Net 
underestimated mortality by 39% and overestimated LTFU by 62%. 
TIER.Net also missed 43% of transfers with silent transfers being the 
biggest contributor to misclassification 
D (Chapter 7) “If the results are negative, they 
motivate us.” Experiences of early 
infant diagnosis of HIV and 










Use and experiences of EID and maternal engagement in HIV care are 
inextricably intertwined. Engagement in care facilitated EID through 
increased HCW influence, improved knowledge about the availability of 
EID and risk factors for transmission. EID can either facilitate or hinder 
continued engagement for mothers by affecting the process of acceptance 
of HIV status.  
E (Chapter 8) Challenges with tracing patients 
on antiretroviral therapy who are 
late for clinic appointments in 
rural South Africa and 













Challenges identified included facility-level barriers such as heterogeneity 
in procedures; challenges relating to data, documentation and record-
keeping; and challenges relating to the roles of tracing personnel. These 
must be overcome in order to improve routine patient tracing and 




9.2.1. Objective 1: To investigate loss to follow-up among 
patients who initiate ART under Option B+ 
Loss to follow-up among pregnant and postpartum women living with HIV 
who enrol in Option B+ has not been widely researched in sub-Saharan African 
settings (17,18,102). There is a wealth of information on ART initiation rates 
and outcomes for women who remain retained in care, as well as on 
discontinuation rates and barriers and facilitators to engagement in care (both 
retention and adherence) (241,283). However, there is little information on 
those women who become lost to follow-up from the facility at which they 
initiated treatment. This is in part due to the relative novelty of the Option B+ 
approach which was first recommended by WHO in 2013. However, this is not 
the only reason; in-depth investigation into LTFU of pregnant women is 
hindered by weak healthcare infrastructure like data systems and personnel 
(99), as well as factors related to the population of pregnant and postpartum 
women such as their higher mobility which makes locating them after they 
stop attending their clinic visits significantly more difficult (18,102). Before 
2015, most Option B+ programmes existed as implementation research 
projects, with the major aim of demonstrating the feasibility of this approach. 
As such, most early research focused on acceptability of the approach as well 
as uptake, specifically in terms of ART initiation (31,189). There has been a 
relatively high coverage of research and intervention in the antenatal 
period(241), which often coincides with high motivation to remain on 
treatment and therefore fewer problems with retention in care (542).  
Objective 1 aimed to address this knowledge gap, and was further split into 
three sub-objectives namely, (i) to understand the true outcomes of PMTCT 
patients once they become LTFU in Agincourt, South Africa, (ii), to explore 
factors associated with different outcomes following loss to follow-up, and (iii) 
to compare the outcomes of PMTCT patients to the general HIV patient 
treatment cohort. The rationale for the comparisons with the general 
treatment cohort was that differences in outcomes could potentially explain 
why pregnant and postpartum women disengaged from HIV care and 
treatment at higher rates than other adults on treatment (89,543).  
Paper A showed that women who initiated ART while pregnant or 
breastfeeding had statistically significant different outcomes than the general 
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ART treatment cohort once they became LTFU. Firstly, Option B+ women 
were 4 times less likely to have died. As many other researchers have 
speculated previously, this may be explained by the fact that they often initiate 
treatment while less immunosuppressed (mirrored by baseline CD4 counts in 
this study), and often before they have experienced any symptoms of infection 
(240,252,283). This was further supported by the fact that Option B+ women 
were more likely to be alive with ART status unknown even though they were 
less likely to have their clinic record linked to an HDSS record. Risk of death 
overall in the cohort appeared to be highest immediately following a final visit 
and reduced temporally as has previously been reported by other studies 
(447,544). However, when this was stratified by reason for ART initiation, this 
pattern was not observed for Option B+ women, with deaths distributed 
almost evenly between the time immediately following a last visit, after the 
next scheduled visit, and after becoming LTFU, giving further evidence that 
mortality is not a major driver of LTFU for this group. We attempted to 
ascertain the cause of each death, however, 51.7% of 120 total deaths had no 
verbal autopsy data. Nonetheless, of the causes ascertained for Option B+ 
women (6 out of 10 deaths), no deaths were attributable to HIV.  
This paper also showed that Option B+ women were as likely as other adults 
on ART to have transferred to another health facility. Option B+ women were 
1.5 times more likely to have transferred to a clinic within the HDSS, but their 
transfers were 1.3 times more likely to be undocumented. The findings suggest 
that postpartum women’s mobility may not be over distances as long as other 
women or men. However, given that we could only investigate transfers using 
data from the clinics within the study area, the transfer data is one-sided, as 
we could not check data from clinics outside the HDSS. Consequently, it is 
likely that we missed many undocumented transfers to clinics outside the 
Agincourt HDSS. This is supported by comparisons between the transfer 
distances for documented and silent transfers. The distances for silent 
transfers (median (IQR): 9.99km (8.97,18.32)) were significantly shorter than 
those for documented transfers (median (IQR): 38.03km (14.66, 329.16)). 
Nonetheless, the geographic spread of transfer facilities indicated PLHIV in 
the HDSS are very mobile. South Africa’s Apartheid history, where the black 
populace had to migrate to economic hubs for work while still being expected 
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to reside in rural areas likely still contributes to this phenomenon. Following 
the end of Apartheid, people move around freely but still maintain links to the 
area they grew up. Other studies have documented that mobility can have a 
detrimental impact on engagement in care (349,545), and that patients 
considered LTFU may be receiving care at another ART facility by utilising 
national reference lab databases (18,102). This mobility may also be 
detrimental for PMTCT as it is associated with higher risk of vertical 
transmission (546). Furthermore, this mobility may indicate changing 
priorities and preferences for Option B+ women who may choose a clinic for 
ANC based on convenience and proximity but may prioritise confidentiality or 
anonymity following delivery and hence choose to switch clinics (285,547).   
Estimates of ART stoppage and migration were also higher among Option B+ 
women. The estimated rate of re-engagement in care was lower for Option B+ 
women, however, given that it was second only to transfers, it appears that 
reengagement in care contributes significantly to outcomes following LTFU, 
further supporting calls to stop conceptualising engagement in care as a linear 
phenomenon (45). However, while re-engagement in care may be viewed as a 
positive outcome given that people are returning to care, it means that these 
patients had at least three months where they were not taking ART. Transfers 
also potentially mean patients have gaps in treatment if they transfer their care 
well after a final visit to an initiating facility. These lapses in treatment are 
associated with higher risk of mortality and onward transmission, and the 
development of drug resistance (38,48,56,456,457,506). These gaps in 
treatment are particularly worrying for women who may still be within the risk 
period of vertical transmission as it puts their infant at risk of HIV acquisition. 
Secondly, these gaps have a negative effect on maternal health which has a 
domino effect on infant survival independent of HIV transmission (274–276). 
With the substantial success of ART for PMTCT, vertical transmission has 
dropped dramatically (21,548), however, the majority of infant transmission 
is now occurring in the postpartum period through breastfeeding (198,253).  
These results begin to explain the disparity between retention in care for 
Option B+ women when compared to the general ART treatment cohort. 
Considering that most programmes report facility specific retention and that 
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individuals with a documented transfer are often treated as retained in care, 
right-censored at the time of the transfer, or excluded from analyses (199,305), 
the higher propensity to transfer without documentation for pregnant and 
postpartum women reported in paper B explains some of the higher LTFU 
rates. Furthermore, paper C evaluated the national HIV treatment database, 
showing that it misclassified 36% of outcomes following LTFU. Option B+ 
women’s outcomes were more likely to be misclassified in TIER.Net. 
The high proportion of LTFU attributable to transfers is encouraging as it 
shows that these women are not completely stopping ART and therefore are 
still accruing the benefits of treatment. However, it suggests that ascertaining 
patient outcomes using data from a single facility may not be prudent.  
Universal ART had just started being implemented in Agincourt when this 
research was conducted, and the clinical profile of patients on ART will evolve 
over time such that it might start to resemble pregnant women in terms of 
baseline CD4, WHO staging, and having no history of HIV symptoms. Given 
that higher baseline CD4 has been shown to be associated with higher risk of 
LTFU (549), the outcomes of the general ART cohort may start to resemble 
those of pregnant women. As such, in future cohorts, mortality might account 
for a lower proportion of LTFU and outcomes such as ART stoppage and silent 
transfers may become more prevalent. However, there are still some 
important differences between pregnant women and the general population 
cohorts pertaining to pregnancy, childbirth, and child rearing which may 
influence retention in care.  I conducted the qualitative component of my 
research as a preliminary enquiry to tackle some of these differences and 
report on the findings from this exercise as part of objective three.  
9.2.2. Objective 2: To critique data sources and methods used to 
investigate retention in care following uptake of PMTCT 
services 
Given that the results from paper A cast doubt on the utility of measuring 
retention in care using only the data from the facility where ART was initiated, 
this objective aimed to critically evaluate the data sources from the initiating 
facility. The research questions were (i) how do we know whether a patient is 
retained in care or LTFU? and (ii) how reliable is the method we use to 
ascertain this? My interests were in first of all measuring the size and direction 
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of bias in utilising just one data source from the initiating clinic (in this case 
TIER.Net) versus relying on multiple data sources to measure retention in care 
with the aim of providing correction factors for similar ART programmes. 
Secondly, having measured this error, I hoped to identify practices that could 
reduce the occurrence of LTFU, whilst also improving the measurement of 
retention in care at a single facility. I hoped to achieve this by making the data 
on patient outcomes more accurate through reducing the instances of patients 
being recorded as LTFU in TIER.Net.  
Paper C showed that LTFU contributed the most to misclassification of patient 
outcomes in TIER.Net. Conservative estimates showed that 39.4% of patients 
classified as LTFU in TIER.Net were misclassified, a number that could rise as 
high as 87%. Consequently, the methods and procedures used to determine 
patient outcomes needed to be scrutinised. The results from Paper A showed 
that many patients had transferred to clinics within the region emphasising 
the need for some form of linkage and communication between clinics and a 
data infrastructure that can catch these silent transfers. The PIRL database 
provided a unique method to collate data from different facilities in order to 
track movements between facilities. Even though data aggregation was not in 
real-time, there was still utility to this method. It allowed me to resolve 
multiple patient outcomes retrospectively using data from other clinics.  
The availability of unique identifiers in the PIRL database also allowed me to 
follow individual patients and identify multiple patterns of engagement in 
care. For example, some patients collected treatment from multiple health 
facilities simultaneously (possibly to accumulate a cache of medication), often 
in preparation for travel. This suggests multiple barriers to optimal 
engagement, for example this patient might feel that the system is too rigid to 
cater to their specific need or may not be aware of the availability of longer pill 
refills as an option for travel. In a case where this patient stopped attending 
their visits, they would be assumed to have disengaged at both clinics but 
would still in theory have enough medication available to them. As such, this 
also raises questions about how we define and conceptualise optimal 
engagement. While an exception and not a rule, we may have to consider that 
patients can be adherent, but not retained in care. It also means that assessing 
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retention in care solely using the initial/initiation facility might not be very 
informative. Furthermore, it shows that LTFU is a complex phenomenon 
which will require better data to advance investigations into understanding it. 
For example, while individual clinics export a copy of TIER.Net and send it to 
the Ministry of Health where it is aggregated in order to produce reports on 
specific indicators for the national treatment programme, unique identifiers 
are not consistently entered into TIER.Net. This makes it hard to replicate an 
exercise similar to the one I was able conduct using the PIRL database. 
Consequently, an intervention that makes unique identifiers like a national 
identification number a mandatory field in TIER.Net would go a long way to 
helping improve retention estimates generated from this source.   
The PIRL database was not perfect either as 190 (15%) of 1264 patients 
classified as LTFU were in fact not LTFU and shows how relying on one data 
source could give inaccurate outcomes for patients. The PIRL database 
erroneously categorised 97 (9.5%) patients with documented transfers as 
LTFU. Furthermore, many patients in differentiated care models (65 (34.2%) 
of 190 misclassifications) were also misclassified as LTFU as well. By 
triangulating facility data with the PIRL data I managed to arrive at more 
accurate estimates for the various outcomes.   
Mothers may have different priorities when choosing which clinic to attend in 
the prenatal versus the postnatal period. Some clinics may have better child 
health services or conversely better antenatal care than others. While the 
clinics in this research catered to both pregnant women, children and non-
pregnant adults, specialised maternal and child health facilities necessitate a 
change in facility, given that postpartum women are expected to transfer to the 
general treatment cohort (South African guidelines call for this transfer 6-10 
weeks postpartum). Therefore, transfers are to be expected in the treatment 
life cycle. However, by only reporting facility-specific retention rates, retention 
estimates will inevitably be underestimated. This further illustrates the need 
for exploration of outcomes beyond a single facility in order to report less 
biased estimates. 
If the most important goal in measuring retention is to know which patients 
are still in care regardless of what facility they are attending, then every 
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treatment programme will have to adapt some context-specific hybrid data 
system in order to improve the measurement of retention. The possibilities will 
be dictated by financial and human resources, existing data systems, as well as 
available infrastructure such as telecommunication and reliable power supply. 
The system I adapted shows that data update and aggregation does not have 
to happen in real-time in order for it to be useful. Patient outcomes can be 
retrospectively resolved in order to reduce the number of patients that get 
reported as LTFU and consequently improve the accuracy of retention 
statistics.  
9.2.3. Objective 3: To explore the link between maternal 
engagement in care and infant outcomes 
The results of this thesis also give additional insight into the factors that affect 
pregnant and postpartum women’s engagement in care. Previous research has 
considered individual, biological and medical, health system, and structural 
barriers and facilitators of engagement in care (48,241,283). However, the 
relationship between engagement and infant outcomes has not been 
extensively studied.  
Paper D qualitatively explored the intersection between women’s experiences 
of EID and their engagement in Option B+. The finding that experiences of 
EID can either foster or hinder continued engagement in care further 
illustrates the complexity of engagement in care for women who initiate ART 
for PMTCT. Previous studies have shown that some women initiate treatment 
for the sole reason to protect their unborn child (237,319,340,508). It should 
therefore follow that the outcome for their infant might affect their 
engagement. Studies have also shown that a positive result for an infant can 
affect maternal engagement when maternal and infant clinic visits are not 
integrated or better streamlined. However, to my knowledge, this is the first 
study to show how an EID result can either foster or hinder acceptance of an 
HIV diagnosis and therefore have an impact on continued engagement in care. 
Paper D showed that engagement in care cannot be viewed as a standalone 
issue, other social practices can modify the effect of an EID result. For 
example, women who have received extensive and effective counselling and 
understand that their infant might still seroconvert even though they are 
taking treatment might be able to rationalise a seroconversion and 
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consequently remain engaged in care compared to those that have not. 
Mothers who have not received counselling might still be in denial about their 
diagnosis and may therefore use their infant’s negative result as confirmation 
of their own negative status.  
This research further illustrates the many differences and may further explain 
the discrepancies in retention for pregnant and postpartum women when 
compared to the general ART treatment cohort. Unlike the general treatment 
population, for pregnant women, HIV care is not just a mother’s endeavour 
but rather one that she must embrace for her child as well. The mother and her 
infant’s care and treatment can become diametrically opposed, for example, if 
her child seroconverts, which may be exacerbated by a case of separately 
scheduled mother and infant clinic visits. Consequently, future conceptual 
frameworks on women’s engagement in care should include their infant’s 
outcomes as potentially contributing to continued engagement in the 
postpartum period. Practice theory offers such a framework as it encourages 
us to look at engagement in care as part of a constellation of practices that 
women must navigate, practices which either help or hinder each other. 
Programmes should endeavour to rollout interventions that take into account 
these interactions and aim to mitigate any negative interactions.  
Reflection on the approaches taken within the qualitative 
research 
It is important to reflect on the methods used to come to these conclusions 
including fieldwork to identify and interview participants and analysis of the 
data generated.  
Data collection 
The recruitment process raised some ethical dilemmas. Given the scope of the 
research, many of the people in the sampling frame had disengaged from care, 
as such approaching potential participants to recruit them into the study came 
with some potential pitfalls. These are often harder to reach people, but it is 
important to understand their experiences as they are under-represented in 
research. This meant I had to be a bit more flexible and adaptable to give them 
the opportunity to share their voice and opinion. For these specific cases an 
approach from the clinic could be seen as an attempt to reengage them in care 
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and inadvertently cause them to refuse to participate (550) or in some cases 
HCWs might choose to only engage certain patients who meet some desirable 
criteria. I also did not wish to cause any disruption to HCWs which made 
utilising HCWs difficult. Therefore, I decided to approach participants through 
a fieldworker who could explain the study to them and ask if they were willing 
to participate. Even though it was explicitly mentioned that we were 
researchers who had no connection to the clinic and therefore could not 
influence their interactions with the treatment programme, some participants 
voiced concerns over how we knew they had been taking treatment at a given 
clinic, fieldworkers were trained to explain the study  as well as confidentiality 
in research and how they were bound by this principle with a penalty of the 
loss of their job and prosecution if it was deemed necessary. Some participants 
did not feel this was sufficient and declined to participate as a result. 
Fieldworkers were also instructed not to frame their approach of participants 
along the lines of HIV or the presupposition of HIV status to mitigate this. As 
part of the approach process, I drove a marked WITS car to participants’ 
households to look for them. Interviews happened around the time of annual 
demographic surveillance so a marked car would not have been out of the 
ordinary. In order to locate participants’ households, I used GPS coordinates 
that are routinely collected by the HDSS for the purpose of demographic 
surveillance. Without the linked data, it would have been impossible to locate 
any of the participants. This also illustrates the challenges that CHWs must 
face in trying to track patients down in a rural area without an organised 
address system. Ideally, I would have preferred to be able to approach 
participants myself but given that I do not speak Shangaan this was not 
possible. The use of a fieldworker as an interpreter was also decided against as 
participants were female and there was a desire to minimise any unequal 
power dynamics given the cultural context. For the interviews, there was also 
the consideration of potential pitfalls from discussing topics that female 
participants might not feel comfortable discussing with a man. For this reason, 
I also did not observe interviews and left the fieldworkers to conduct them with 
the hope that their training would be sufficient to help them navigate any 
issues during the interview. I therefore cannot speak for the dynamics of this 
part of the data production process. However, I took other steps to remain 
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close to the data generation process including debriefing fieldworkers 
immediately after the interview.   
With regards to the consent form and information sheet, it was decided that 
they should not contain any information specifically mentioning HIV 
treatment and care. This was to minimise the potential for inadvertently 
disclosing participants status if their consent form was read by someone else. 
Whilst I ultimately felt comfortable with this approach, I would consider it as 
an ethical “grey zone”, with both potential advantages and disadvantages in 
terms of being transparent with participants about the nature of the research, 
whilst minimising risks of inadvertent disclosure. 
With regards to benevolence in research, there were instances where, based on 
transcripts, patients appeared to be experiencing mental health challenges 
which raised some concerns for me regarding what procedures to follow under 
these circumstances. All these instances were several months removed from 
the actual fieldwork. Given how data collection was structured, most of the 
interviews were transcribed after I had already left the study area. Even with 
debriefing sessions during the fieldwork, some of these issues were not flagged 
early. I had discussions with more qualified qualitative researchers to figure 
out the best way to deal with situations where I thought a participant might 
require help without breaking confidentiality. One participant who had tried 
to reengage in care mentioned that she had been called by the clinic and 
counselled to return to care. However, when she decided to return to the clinic, 
the HCW she spoke to was not on duty that day and this made her 
apprehensive and ultimately, she did not re-engage in care. She had recently 
given birth and in her interview, she mentioned having suicidal thoughts and 
described having little motivation to wake every day.  She was flagged and 
referred to the Home-Based Carers organisation that worked in her village, but 
this intervention felt insufficient given all she was struggling with. There was 
also no way to determine whether the HBCs had followed up on her. Given the 
distressing nature of some of the topics discussed, a lesson I take away from 
this experience is to plan ahead for psychosocial support interventions for 
participants that might be in emotional distress or at risk of self-harm. 
Quantitative research often means that you are removed from the lived 
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experiences of the subjects you are researching and consequently we may 
forget that real people contribute the numbers. My experience with qualitative 
research has made me a more conscientious and empathetic researcher 
attuned to the importance of thinking of the well-being of the subjects of the 
research first before thinking of the data they can contribute.  
Data analysis 
With regards to data analysis, my limited prior experience with qualitative 
research meant that notions of positionality and reflexivity were completely 
foreign topics to me. My default during analysis was not to be reflexive or to 
consider my position and it was something that I had to inculcate into my 
approach. I have gained a lot of experience by undertaking this research and I 
believe I am a much better researcher as a result of this. However, given that 
qualitative research is co-produced and influenced by my beliefs and biases, 
these must have shaped the conclusions drawn from the data collected. For 
example, in formulating the topic guide, one of the motivating factors for my 
line of questioning with regards to infant outcomes and their effect on 
maternal outcomes was my own childhood experiences of maternal and infant 
outcomes with regards to HIV and their interdependence. Furthermore, 
throughout my research career I was always baffled by the fact that the infant 
and its outcomes were seldom considered in trying to understand the 
outcomes of the mother. These experiences also permeated the analysis 
process. Whereas IDIs were conducted for a diverse group of participants, I 
started off by coding IDIs conducted with women who had recently given birth 
and ultimately ran out of time to analyse transcripts from other participants. 
Furthermore, the theoretical framework used to frame the findings was chosen 
because it offered a succinct way to situate infant outcomes particularly EID 
within the concept of maternal engagement in care. 
9.2.4. Objective 4: To identify and recommend strategies to 
improve retention in PMTCT services 
Objective 4 is partially covered in paper E and expounded on in the following 
section on programme and policy recommendations.  
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9.3. Programme and policy recommendations 
Some of the policy implications from this research call for strengthening 
already existing interventions and are therefore immediately actionable. Some 
call for implementation of new interventions which may have to be enacted 
over the long term, and some like the call for a shift in the paradigm of ART 
provision may be a contribution to a much needed broader recognition of the 
need for more ambitious approaches in the future. However, I firmly believe 
that it is our role as researchers to pioneer. After all, the national treatment 
programmes in sub-Saharan Africa are proof and an important reminder of 
what can be achieved when we refuse to settle for the status quo. Illustrated by 
the jump in numbers of people on ART since treatment was rolled out, with an 
estimated 18 million people on ART in sub-Saharan Africa in 2019 (24).  
Furthermore, the increased vertical transmission in the postpartum period 
coincides with the period where LTFU increases significantly. Women who 
experience any gaps in their treatment including transfers, those who re-
engage and those who stop ART will therefore be an important population in 
which to intervene to further reduce the rate of new HIV infections in children. 
Programmes should therefore strive to identify the major causes of these gaps 
and implement interventions to mitigate the identified causes with the 
ultimate goal of eliminating or reducing the duration of gaps in treatment 
taking. It will be important to shift the focus away from the immediate 
outcomes of the pregnancy, such as vertical transmission, towards more 
sustained engagement in care as this will protect future pregnancies, improve 
maternal health and reduce the risk of transmission to partners as well.   
9.3.1. Policies to reduce patient drop out 
Whereas the key challenges of early ART programmes were to provide and 
scale-up access to ART, the challenges have now evolved to encompass not just 
ART coverage but retaining patients in care (Figure 9.1). Consequently, ART 
programmes must evolve to meet these new challenges. This evolution will 
include a move away from the “one-size-fits-all” model of service delivery 
towards  a patient-centred one that caters to specific patients (551). This is not 
a radical suggestion as women in PMTCT routinely receive differentiated care 
that includes integration of ANC services. However, the fact that they must still 
transfer their care to the general treatment population in the postpartum 
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period is still a major factor contributing to their disengagement from care 
(18). As such one immediately actionable policy change would be to extend 
integrated and synchronised maternal and infant HIV services beyond 6-10 
weeks postpartum in South Africa (296). This would have the added advantage 
of improving infant retention as has been reported in Kenya (552), and is 
supported by findings from paper D which showed conflicting scheduling of 
mother and infant clinic appointments contributed to disengagement from 
care.  
Interventions to reduce the occurrence of LTFU due to administrative errors 
will also be crucial. Increasing numbers of patients initiating ART will 
necessitate the use of new monitoring and evaluation approaches, as patient 
volume may contribute to data quality issues that lead to administrative LTFU 
(e.g. where patient outcomes do not get recorded). In paper C, we found 
instances of LTFU patients recorded as still in care. Instances like this could 
be reduced by implementing an automated alert system within the database 
which might have flagged this error. We also found instances of patient 
outcomes available in a clinic register but not reflected in TIER.Net. The 
amounts of data that data clerks are expected to enter might be responsible for 
these occurrences and therefore a system that requires less data could be a 
solution. Choosing quality over quantity in terms of variables collected and 
streamlining this across the entire treatment programme would be one way to 
mitigate this. On the topic of important variables and biomarkers, it appears 
that CD4 is being phased out but given how important a predictor it is for 
outcomes such as mortality, programmes would be naïve to do so (553–555). 
To do this would be to undo the astronomical work it took to make CD4 a 
regularly and consistently collected metric. 
To reduce LTFU through silent transfers, some potential interventions to 
improve the transfer process include; increased patient awareness and 
understanding of the transfer process (556), strengthening referral systems 
(364), simplifying the transfer process (557), and removal of preconditions for 
transfer (558). Finally, ascertaining outcomes beyond a single facility will need 
to become the norm to ensure that silent transfers are captured.   
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Ubiquity of mobile phones means that interventions through them will reach 
more people. Interventions such as automated reminder messages about 
upcoming appointments have shown mixed results with regards to keeping 
patients engaged in care (109,332,559). 
Figure 9.1: The evolution of ART provision in sub-Saharan Africa 
(Adapted from Grimsrud et al (61))  
 
Healthier patients including pregnant women may need to be treated 
differently given that higher CD4 is associated with LTFU (61). There are 
myriad reasons for this including exposure to the clinic experience which 
includes long queues and interactions with much sicker patients which may be 
detrimental to motivation to stay in care especially given they may have never 
experienced any sickness (240). Furthermore, some authors argue that the 
care delivery model is outdated and paternalistic, and that expecting patients 
to report to the clinic monthly might be unrealistic (61,560).  We have 
managed to bring testing to people’s doorstep, and we must endeavour to 
make treatment as convenient. As patients with higher CD4 were more likely 
to have transferred their care, paper B shows that healthier patients will also 
have other priorities with regards to treatment provision which will need to fit 
into a more mobile life. More specifically, with regards to pregnant and 
postpartum women, paper D showed that each woman will have competing 
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practices unique to her that need to be accounted for when formulating the 
best way to deliver treatment to her and her infant. 
Consequently, these patients may need different specialised counselling to 
cater to their particular hurdles and challenges. For example, given the ART 
stoppage significantly contributed to LTFU, another immediately actionable 
recommendation would be to continue emphasising the importance of ART 
beyond preventing vertical transmission and rebranding ART as not just for 
sick people but as a way to maintain health, especially because feeling healthy 
and doubts about the effectiveness of ART contribute to disengagement 
(240,281,354). 
Additionally, recognising pregnant and postpartum women’s different needs 
and perhaps moving them out of the clinics or putting them on longer refill 
schedules earlier will free-up these resources for sicker patients who may 
benefit more from them. The argument that patients need to be incentivised 
and monitored through monthly clinic visits is double-edged as a major cause 
of attrition is the time and monetary investment in monthly visits (561).  
Consider also for example that while for a clinician or a researcher, it is their 
job to be at the clinic, for a patient, clinic attendance while vital to their 
survival, also eats into time they could spend working, something some 
patients might see as a greater priority. Therefore, work might take precedence 
for women who initiate ART while asymptomatic because they perceive 
deleterious effects of their infection as still far off in the future, but hunger, 
rent, and other obligations may be more immediate and pressing needs. In 
designing treatment schedules, clinics should prioritise the clientele and it 
underlines the need for ART models that fit each person’s needs. 
Furthermore, daily treatment can be an alienating experience and a constant 
reminder of HIV even in the absence of symptoms. Therefore, innovations in 
treatment such as long-acting subdermal medical implants and injections will 
also be critical to improving retention for these types of patients. 
The current global COVID-19 pandemic shows us that now more than ever it 
is important to consider differentiated models of care. The pandemic has laid 
bare the fragility of a model where patients’ treatment is dependent on regular 
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clinic visits. Consequently, radical new approaches to ART provision for 
pregnant and postpartum women will need to be considered.  What these new 
approaches would look like is an important debate to be had and these 
approaches will have to be evaluated to determine their efficacy.  
What might an ideal PMTCT programme look like? 
Given the disproportionate number of women affected by HIV and also given 
the high fertility intentions among women in SSA, most HIV-positive women 
of child-bearing age will go through a PMTCT programme at some point 
provided that the health system emphasises the importance of ANC. 
Therefore, making PMTCT programmes as patient-centred as possible, as 
integrated as possible and as streamlined as possible will reach the largest 
number of people living with HIV. For example, longer-term integrated 
maternal and child healthcare (MCH) where all women of child-bearing age 
attend a specialised clinic with those who seroconvert automatically entering 
into the MCH programme in preparation for a possible future pregnancy and 
childbirth and only transferring once they have fulfilled their fertility intention 
or are no longer fecund. These clinics would have to include all women as other 
studies have found that such integrated clinics may not be effective if only 
HIV-infected women attend them as they potentially increase stigma 
(332,562). Contraception and other needs can be integrated including HIV 
care meaning that women get a one-stop shop. This means that their children 
are also covered and reduces the workload for HCW as it removes the need to 
probe for things like eligibility but will necessitate more broadly skilled HCWs 
(563).  
There can also be further differentiated care models for mother-infant pairs 
(198) as the best interventions to improve EID treat the mother-baby dyad as 
a single entity. This makes sense given that for the first few years of life the 
infant is completely dependent on its mother. As such, interventions to reach 
infants should include some incentivisation for the mothers such as the afore-
mentioned one-stop shop where they can access other services.  
The time immediately following delivery can also be a cause of dropout as 
women have a new-born to worry about and might still be recovering from 
delivery. They might therefore be unable to consistently keep clinic 
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appointments. Treatment and care delivery should be tailored to make sure it 
causes the least disruptions. Longer refills around this time have been 
proposed to mitigate this (367,564), as treatment interruptions can be 
disastrous for mothers (37,496,565,566). Community-based models of care 
can further improve retention in care. For example, dispensing treatment at 
distribution points in the community could be offered to Option B+ women at 
this stage. They can then move back into the clinic once the child needs to 
receive immunisation and EID. 
Immunisation coverage and maternal postnatal retention are higher than EID 
coverage indicating missed opportunities for infant testing during 
immunisation visits or ART follow-up for their mothers (198,567). Integration 
of HIV services with MCH services including immunisation programmes 
provides a critical opportunity for elimination of vertical transmission. 
Non-pregnant women can be put on differentiated care models such as longer 
refill schedules or community-based care. For older women who transfer to 
the general population after they have fulfilled their fertility intentions, their 
needs will be different such as other chronic co-morbidities so other services 
such as chronic disease care can be emphasised. This system will necessitate 
decentralisation of ART provision with most of the responsibility designated 
to CHWs. This in turn will free up the limited professional medical corps to 
concentrate on more severe cases that would benefit most from their attention. 
Decentralised treatment can improve programme effectiveness and efficiency 
(568).  
Retention promoting activities are necessary both within the facility and in the 
community. In the facility these could include adherence support and 
counselling, and defaulter tracing managed by facility staff. Outreach services 
and retention promoting activities in the community could be managed by 
community-based organisations, with coordination of all these activities by 
case manager (WBOT), and the coordination of patient information systems 
by data clerks. 
Through this all, a supportive/collective approach to treatment delivery 
should be emphasised as a sense of connectedness to the clinic in conjunction 
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with family support have been shown to fuel patients’ motivation to 
consistently overcome myriad obstacles to keep up clinic appointments (502).  
An HIV diagnosis can be an ostracising experience that frays social cohesion. 
The Western context is one characterised by individualism while the African 
setting is still predominantly social and collective, as such a treatment 
programme that mirrors this stands to gain from this approach (358,547). 
Efforts to create a sense of connectedness such as music and drama groups, 
and income generating activities (e.g. community farms) recognise that 
patients who feel disconnected from their community will have poor outcomes 
which ultimately affect them, their families, and their community. While this 
might sound utopian and un-scientific, research has shown that interventions 
that emphasise connectedness and community within the treatment 
experience consistently have better retention estimates than those that do not 
(201,342,358,569). 
9.3.2. Policies to improve tracking of patients who miss clinic 
appointments 
With the expansion of ART programmes in sub-Saharan Africa, PLHIV can 
access HIV care at myriad locations. While advantageous to the people in care 
as it increases the options of facilities to attend for treatment, this expansion 
has made it much more difficult to track patients’ movements within the 
treatment programme. Figure 9.2 shows what a treatment programme might 
look like and how patients might move between different facilities and 
different models of care. Knowing which patients are in care, regardless of 
which clinic they are attending will reduce LTFU substantially and ensure that 
appropriate resources are directed to patients that have truly disengaged from 
care. In order for a system of this nature to be effectively monitored and 
evaluated, it requires checks and balances that allow for the ascertainment of 
treatment outcomes independent of the initiating facility. 
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Figure 9.2: Models of care delivery and movements of patients 
 
A robust surveillance system is recognised by the WHO as essential for 
elimination programmes (370). A case-based surveillance approach where 
measurement and monitoring of programmatic outcomes is accomplished by 
collecting individual patient-level data for key events is recognised as the best 
practice and serves as the backbone of HIV surveillance in developed 
countries. While such a system would be ideal, in South Africa, myriad hurdles 
exist that are hampering its implementation.  
With regards to the phenomenon of self-transfer, it may be a patient’s attempt 
at achieving some anonymity (102,285), and this anonymity might increase 
the likelihood of patients remaining in care and adherent (251,286,319,340). 
The onus to report their movements must be removed from the patients, 
especially considering that patients often move because of the same people 
(HCWs) to whom they are supposed to report their transfer (237,245,340). 
Data layers that allow for those responsible for monitoring and evaluation to 
do case surveillance (to flag silent transfers), that automate patient alerts (such 
as missed appointments) and allow for monitoring of clinic procedures offer a 
way for facilities to improve their operations and correct their estimates and 
statistics without breaking patient confidentiality. 
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One immediately actionable policy that would have the greatest effect on 
programmes’ ability to track patients would be to institute a unique 
identification system (570–572). As mentioned previously, the availability of 
unique identifiers through the PIRL database significantly improved my 
ability to find patients at different clinics. Given how much LTFU is 
attributable to mobility in the form of migration and transfers to other 
facilities (which are sometimes “silent”), unique identifiers would help to 
monitor this mobility. This will ensure that patient outcomes are ascertained 
beyond the initiating facility.  
In addition to the unique identifiers, the ability to link the different clinic 
databases through the PIRL database also helped to improve ascertainment of 
patient outcomes. The WHO also recommends data linkage, as unique 
identifiers on their own would be less effective without an overarching data 
infrastructure that links facility data (370). Linked data allows for measuring 
care continuity, for patient tracing beyond the facility of ART initiation, and 
for interventions as needed. The architects of TIER.Net recognise this and it is 
intended for the disparate facility databases to be linked at some point in the 
future. This by necessity is a more long-term objective but there are some 
short-term interventions that could improve patient tracking before a linked 
facility database becomes a reality.  
Firstly, ensuring regular exchange of information between facilities (364). 
Given that TIER.Net data clerks have regular regional meetings, these could 
be restructured to include data consolidation exercises where review and 
comparison of patient lists is done using National IDs in the best-case 
scenario, and names and dates of birth in the worst case to catch silent 
transfers. 
Innovation will also be required to develop better methods to track patients. 
Tracking down patients is notoriously hard in an environment with no 
functioning address system, or poor infrastructure that means that some 
places are cut off in rainy seasons. Some policies are already recommended but 
are not consistently implemented, for example, asking if the patient’s contact 
information is accurate or if it has changed at every visit. This would ensure 
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that contact information remains up to date for the purpose of telephone 
tracing.  
Programmes also need to develop services that are more adapted to harder to 
find patients. For the qualitative component of my research, I managed to use 
household GPS coordinates routinely collected by the HDSS to locate LTFU 
patients for IDIs. Readily available data like this could be utilised to try and 
locate lost patients. In a situation of a public health emergency, is it ethical to 
share this information with clinics? Clinics typically collect location data by 
asking for important landmarks near patients’ homes. This more accurate 
location data would significantly improve patient tracing efforts. I think the 
clinics need all the help they can get, provided the data can be utilised in a 
manner that does not breach confidentiality, it would be of added benefit to 
the treatment programme. As other countries utilise all data available to them 
to track patients who go off the grid8, it makes sense to do the same in this 
setting if we are going to achieve 90-90-90 and then 95-95-95 goals.  
9.3.3. Policies to improve EID uptake and infant outcomes 
The major objective which is elimination of vertical transmission should not 
be forgotten. Mothers’ outcomes are important, and children’s long-term 
outcomes are worse if their mother dies. Equally, an unfavourable outcome for 
the infant such as seroconversion is similarly detrimental. This is the balance 
that PMTCT programmes must strike.   
Healthcare workers’ understanding of EID and the logistics of its 
implementation are an important consideration. For example, through the 
IDIs one participant mentioned that if they arrived after sample collection, 
they were instructed to come back the next day. However, one of the reasons 
for the use of dried blood spots (DBS) is because they are quite stable, provided 
they are protected from humidity and moisture, and can be stored at room 
temperature (573). This perhaps indicates a need for better training of HCWs 
regarding the logistics of EID. It might also point to a lack of understanding 
on the part of the mother. It is possible that HCWs were referring to other 
blood tests which the mother misconstrued to mean EID. Furthermore, it 
 
8 See for example https://www.gov.uk/guidance/hiv-surveillance-systems “UK HIV surveillance 
systems” [accessed 28 August 2020] 
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might speak to a breakdown in communication where a mother was requesting 
for EID for her infant but the HCW mistook her request to be one for another 
blood test.  
In South Africa infant mortality remains high, estimated at 28.5 deaths per 
1000 live births in 20199. Historically HIV exposed infants had even higher 
risk of mortality (274). Perhaps, because of this expectation, less focus was 
placed on EID, especially before the rollout of effective PMTCT programmes. 
It may be that for HEI where deaths are a more common occurrence 
independent of HIV transmission (275,276), the risk of infant mortality might 
not be a big enough incentive to encourage EID. In fact, death might be seen 
as respite or relief from a complicated life for their infant especially if mothers 
have faced challenges like stigma and ostracism due to their own diagnosis 
(267). Therefore, interventions to reduce stigma as well as interventions that 
weaken the links between a positive EID result and disengagement from care 
such as specialised counselling might mitigate fear of completing EID.    
Late antenatal clinic attendance, incident maternal HIV infections during late 
pregnancy or the postpartum period, loss to follow-up from ART, and 
persistent viremia among HIV-infected women are among reasons for ongoing 
new paediatric HIV infections (244,574). As such, interventions tailored to 
these specific barriers will also improve HEI outcomes. 
Studies have also shown that point-of-care EID testing improves uptake of EID 
(270,575,576). As such, point-of-care EID testing should be considered in 
PMTCT programmes to complement laboratory testing. Other interventions 
that may improve EID uptake include opt-out rather than opt-in testing 
policies where all infants receive an HIV test as part of their immunisation 
schedule. This may reduce the stigma of infant testing and also cast a wide net 
to capture any infant seroconversions from maternal seroconversion late in 
the pregnancy or breastfeeding period. This policy has been shown to improve 
uptake in other settings (577–579). Programmes should also consider 
improved links between mother-baby pairs in order to identify HIV-exposed 
infants. Some recent research is looking into the effects of this measure. 
 
9 See https://childmortality.org/ “UN Inter-agency Group for Child Mortality Estimation” [accessed 
28 August 2020]  
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However, given that one of the major reasons infants do not get tested is 
because the system may not be aware of their HIV exposure (198,580), any 
intervention that makes it easier to identify HEI may improve the uptake of 
EID.  Given that this research showed some mothers disengaged from care due 
to the dual burden of theirs and their infant’s clinic visits, in the unfortunate 
event that a child tests positive, at worst, their clinic visits should be arranged 
to coincide with those of the mother, or better yet their clinic visits should be 
integrated. Women should not have to decide between their infant and their 
own health.  
As these all become more prevalent as ART programmes mature, it is 
important to study if they really influence LTFU. Ascertainment of infant 
outcomes is inextricably linked with their mothers staying in care, maternal 
LTFU often means infant outcomes do not get fully and accurately reported 
(198,580). Any interventions for the mothers will influence the outcomes of 






9.4. Recommendations for future research 
Some of the findings of this research warrant further investigation. Some 
future research directions include: 
Investigation of re-engagement in care. Re-engagement in care was the 
second most prevalent outcome for patients that had been recorded as LTFU. 
More research needs to be done to understand the factors associated with re-
engagement in care. One factor that warrants further investigation is whether 
new pregnancies are associated with re-engagement in care. Furthermore, 
research testing and monitoring interventions to improve retention and 
reengagement in PMTCT such as text messaging needs some investigation. 
Repeat testing for women who test negative during pregnancy. Late 
seroconversion emerged as a reason for one mother’s disengagement from 
care in the IDIs. The timeline of this mother’s seroconversion was probably 
after the 18-month EID test, but before the end of the breastfeeding period. 
The confusion of receiving a positive result for an infant that late was 
detrimental to her engagement in care. As such, more research is needed to 
ascertain the frequency of testing for mothers who initially test negative at 
ANC. The gap between the end of breastfeeding and the 18-month EID test will 
also need further research to make sure that infant testing is continuing past 
the end of the breastfeeding period. 
Infant outcomes. While I was able to ascertain the outcomes for women who 
had been LTFU, this was not possible for their infants for many reasons. For 
example, uptake and results of EID for infants of the women interviewed as 
part of the IDIs were all self-reported and could not be corroborated. One of 
the major reasons infant outcomes could not be ascertained was a lack of 
identifiers that paired mothers and their infants. Future research should 
investigate infant outcomes to see how different outcomes for mothers 
influence the outcomes of their infants. 
More research on LTFU is needed in other settings. While these 
findings are important and add to the available research on LTFU in sub-
Saharan Africa, it might not be possible to extrapolate some of the findings to 
other settings such as those within the same region where labour migration is 
not a common phenomenon as migration probably plays a pivotal role in 
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patients’ decision to transfer their care to another facility. Future research 
should also consider LTFU for teenage mothers (<18 years). Younger mothers 
have been shown to be different from older mothers in many ways 
(69,305,331,332,581). Consequently, it is possible that their outcomes 
following LTFU will differ significantly from those of the women represented 
in this body of work. Furthermore, patients who are lost before ART initiation 
will differ significantly from the group represented in this research. As such, 
further investigation of this group is an important consideration for future 
research. Additionally, how we operationalise or define LTFU especially in the 
presence of differentiated models of care will be important work to consider as 
treatment programmes continue to expand. Similarly, more research is needed 
on how we operationalise LTFU and retention in care where several facilities 
and changes in engagement e.g.  treatment gaps, re-engagement, and transfers 
are also incorporated. If future research considers overall patterns and 
corrects for them, we may get a more accurate picture of retention in care and 
engagement in care more generally.  
With regards to the mechanisms that drive retention, future research could 
compare retention rates in settings where integrated PMTCT and ANC services 
are offered up to 6-10 weeks like South Africa, and those where it goes up to 
24 months (296). This might introduce challenges to retention especially if this 
transfer entails moving to a geographically separate clinic rather than between 
departments at the same clinic and involves accessing treatment from further 
away. The WHO has called for further research to determine the optimal time 
of transfer back to general population ART clinics and therefore more research 
on this may be needed before an official recommendation can be made 
(582,583).  
Finally, the current COVID-19 pandemic shows how volatile my findings might 
be. The pandemic and the interventions implemented to mitigate its effects 
have caused interruptions to every aspect of the PMTCT cascade both with 
regards to the demand and supply of health services (584). In some places, 
healthcare workers have either gone on strike or refused to go to clinics for fear 
of either contracting COVID-19 or being shunned by their family members 
(585–587). This has the knock-on effect that services such as ANC, HIV 
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testing, and ART initiation may be severely hampered by lack of staff. Fears 
around COVID-19 and the need for protective equipment to visit clinics (which 
they may not be able to afford) may have also led to patients foregoing 
attending ANC, or routine ART clinic visits. These will all impact LTFU 
statistics as well as the outcomes following LTFU, with some mathematical 
models making some sobering conclusions (588,589). As such, research to 
consider how the pandemic might have affected these results is warranted. 
Given that we were unable to resolve all the instances of LTFU and that 
migration was an outcome reported in the research findings, this identifies a 
new challenge in measuring retention. How best can we measure and 
incorporate mobility and migration of patients into the measurement of 
retention in care? Answering this question will be imperative to reducing 
instances of LTFU, especially for pregnant and postpartum women who may 
be more mobile (18,102). Some studies have used aggregated mobile phone 
network data retrospectively to study population mobility in relation to health 
issues such as natural disasters and disease transmission (590,591). Whether 
similar analyses could be utilised to study HIV retention especially in highly 
mobile populations might warrant some research. 
The sheer amount of data generated through the IDIs and the limited time to 
complete my research meant that many topics of interest beyond what I have 
currently presented were identified, but I was not able to analyse all the data 
collected through the IDIs. Consequently, I have only scratched the surface, 
and this is data that I will revisit in the future as further analyses are required 
to explore and unpack many of the themes that were emerging from 
preliminary analyses. I chose to present themes that aligned with my research 
and this choice frames the findings presented. Themes like seroconversion late 
in pregnancy or in the breastfeeding period and its influences on engagement 
in care, the concept of engagement in care from patients’ perspective and how 
this differs from our definition as researchers for example patients saw 
nothing wrong with say temporarily collecting treatment from another clinic 
where they worked, or collecting treatment from multiple clinics 
simultaneously in order to build up a cache before taking a short hiatus from 
visiting the clinic or travelling for work will be interesting topics to explore in 
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the future. I would also like to further explore the differences in themes that 
emerge around engagement in care comparing Option B+ women and adults 
that initiated ART for their own health. 
9.5. Strengths and limitations  
The overall strengths and limitations of this body of research are presented in 
this section with a focus on the key issues of this work with the different study 
components incorporated. 
9.5.1. Strengths 
Data used in this thesis come from a well-established cohort study. The 
availability of demographic data for 88% of the patients that were LTFU was 
invaluable in ascertaining patients’ outcomes.   
A major strength of this thesis is the mixed methods approach I adopted which 
involved both qualitative and quantitative components conducted in the same 
community around the same time. The quantitative component was essential 
to building the sampling frame for the qualitative component. Additionally, 
the methods used for the quantitative component identified new and 
important avenues for future research. Research using clinic data linked to a 
community cohort has only recently began to be undertaken in Africa. The 
analysis in this thesis provides community level statistics and estimates of 
outcomes following LTFU. The quantitative component also provided 
methodological contributions for measuring retention, and for linkage 
strategies to build a linked facility database.  
The use of routine clinic data allowed the monitoring of a health system in real 
life, many of the cohorts providing data for previous estimates of outcomes 
were large, established research intervention and clinical trial cohorts 
supported by academic and non-governmental partners and not likely to be 
representative of the national cohorts. The inclusion of participants from all 
government facilities that serve the HDSS community was an advantage as it 
provided a more complete picture of LTFU in this community. Additionally, 
the recruitment of participants for the IDIs through a sampling frame built 
from various data sources meant that we were able to include patients that 





The use of observational data for the quantitative component of this research 
is associated with potential bias and confounding. While I attempted to 
account for survivorship bias by only including patients who had initiated ART 
after record linkage began, it may be that some of these patients were in fact 
just re-initiating treatment at a different clinic. Restricting the analyses to 
patients who initiated ART after record linkage began means that the results 
of this research might only be generalisable to cohorts situated in similar time 
period especially since the advent of “test and treat” may change the 
composition of ART cohorts. Additionally, there are several private treatment 
facilities within the study area as well as government facilities just outside the 
periphery the study area. The exclusion of these facilities means that it is 
possible that some PLHIV receiving treatment in these facilities were not 
captured by this exercise.   
There were several drawbacks with regards to data quality issues both within 
the clinic and HDSS databases. Socioeconomic factors could not be assessed 
for their association with the various outcomes as variables such as education 
status, marital status, and SES had varying levels of completeness. As such, 
confounding due to unmeasured variables is a possibility.  
With regards to ascertainment of causes of death, verbal autopsy data was 
missing for 52% of the deaths we identified through this research. As such, we 
were unable to ascertain the causes for the majority of deaths reported in this 
research. These deaths could be due to other causes such as external trauma 
due to road accidents which is prevalent in South Africa (394,592) and would 
warrant different considerations if so. For example, interventions at the clinic 
level or with regards to treatment service delivery might have very little effect 
on these sorts of deaths.   
Additionally, limitations on the linkage algorithm meant that 12% of the 
participants in this study did not have an HDSS record attached to their clinic 
record. The probabilistic algorithm for finding matches is not perfect and 
unfortunately in some cases, even in the presence of the patient, the records of 
those reporting residence in the HDSS could not be linked to the HDSS 
dataset. This could mean that patients misunderstood the question regarding 
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their residency, or that they thought that there might be some incentives for 
answering in the affirmative. It could also mean that they were genuine 
residents whose record could not be retrieved for a myriad of reasons including 
differently spelled names, or that they had moved into the HDSS after the most 
recent census round meaning their record had yet to be entered into the 
database. It was impossible to differentiate the different groups, so to 
minimise selection bias, all of them were kept for the analyses. 
With the exception of paper C, this thesis only addresses losses after ART 
initiation. About 5% of patients investigated had not yet initiated treatment 
when they became LTFU. However, these were not included in papers A and 
B. This was done intentionally as the changes in treatment eligibility mean that 
the pre-ART phase has now been phased out and LTFU following ART 
initiation is a greater challenge for a myriad of reasons including risks of 
developing drug resistance. However, loss to follow-up occurs at multiple 
points on the treatment cascade and research shows that many patients 
(especially pregnant women) are lost following a positive HIV diagnosis but 
before they initiate ART (212,241,593,594). Patients who become LTFU before 
ART initiation will differ significantly from patients who might have accrued 
some benefits from ART and as such their exclusion from the research is a 
limitation. 
There was a missed opportunity in failing to synthesise and triangulate the 
qualitative and quantitative data which would have helped to bolster the 
results from each component. Whereas quantitative analyses are important for 
measuring the extent of the issue, qualitative analyses would have helped to 
understand why. It was originally planned for the qualitative component to be 
used to complement the findings from the quantitative component. This 
approach would have helped to contextualise the findings by placing them 
within the narrative of individual participants. However, because the 
production of this body of work is time-bound, some plans had to be 
postponed for future enquiry (I go into further detail on this in the section 
9.6.3).  
Furthermore, the short time frame for qualitative data collection which lasted 
just over a month meant that I was unable to conduct repeat interviews to see 
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how participant experiences might have changed temporally. However, the 
qualitative findings are still important in giving detailed descriptions of 
participants’ experiences and giving meaning to their actions (595). 
Furthermore, all infant testing outcomes were self-reported by the mother 
reflecting data quality and availability issues with no links between maternal 
and infant records.  
The participants for the IDIs came from the HDSS population, which might be 
considered an over researched group. This could be a problem for the 
qualitative component of the research as participant fatigue can influence the 
findings of qualitative research (596–598). Furthermore, there were people 
approached who chose not to participate. These non-participants might differ 
significantly from participants and their experiences might differ from those 
discussed or described by participants within this research. Finally, the 
qualitative component does not document the experiences of health care 
workers and therefore missed the opportunity to juxtapose their position with 
that of patients in this setting.   
9.6. Dissemination 
The findings of this research have already been, or will shortly be shared with 
healthcare workers, researchers and Right-to-Care officials who work in the 
Agincourt HDSS. While the plan was to travel to South Africa later this year to 
disseminate the findings locally, given the current travel restrictions due to 
COVID-19 these plans have been replaced in favour of electronic 
communications.  
9.6.1. Health workers, researchers, and community members 
in Agincourt 
As part of their routine operations, the Agincourt HDSS has a public 
engagement office responsible for the dissemination of findings from research 
conducted within the HDSS. I plan to prepare a short report to share with them 
for this purpose. The public engagement office will share these findings with 
individual health facility managers and staff as well as health officials charged 
with the management and operations of all the Home-Based Carers 
organisations that operate within the HDSS. All my papers were co-authored 
by researchers who work primarily in the HDSS, so they are already aware of 




I was in conversation with the RtC programme manager over email, in order 
to get permission to access their data. Data sharing was agreed on condition 
that findings from the research would be shared with them in order to improve 
their operating procedures. The same report distributed to the Agincourt 
public engagement office will be made available to the Right-to-Care 
organisation via email. 
9.6.3. Researchers – Academic conferences and publications 
Some of the papers contained within this thesis have already been published 
in peer-reviewed journals with broad international readership in the fields of 
HIV and other public health research. Additionally, the following 
presentations were made at conferences in 2018-2019 (posters or slide sets are 
included in the appendix): 
Appendix 11.1.5: Etoori D, Wringe A, Reniers G, Renju J, Ndhlovu V, Ndubana 
S, Sihlangu E and Gomez-Olive FX. “Mothers’ experiences of early infant 
diagnosis for HIV in Option B+ programmes and the implications for their 
engagement in care: Qualitative evidence from South Africa” Poster presented 
at the International AIDS Conference (AIDS), Amsterdam, Netherlands; July 
2018. 
▪ A precursor to the qualitative paper on EID and maternal engagement 
(paper D) presented in this thesis. 
Appendix 11.1.4: Etoori D, Wringe A, Kabudula C, Gomez-Olive FX, Reniers G 
“Re-engagement in care following loss to follow-up from HIV treatment and 
care: findings from a cohort study in rural South Africa” Poster presented at 
the International Workshop on HIV and Hepatitis Observational Databases 
(IWHOD), Athens, Greece; March 2019. 
▪ A quantitative analysis of the factors associated with re-engagement in 
care for women, non-pregnant and Option B+ following loss to follow-
up.  
Appendix 11.1.3: Etoori D, Wringe A, Kabudula C, Gomez-Olive FX, Reniers G 
“Use of linked clinic and demographic surveillance data to improve estimates 
of outcomes of HIV patient tracing in Agincourt Health and Demographic 
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Surveillance System (AHDSS)” Poster presented at the International 
Workshop on HIV and Hepatitis Observational Databases (IWHOD), Athens, 
Greece; March 2019. 
▪ Preliminary analyses for one quantitative results paper (paper A) 
presented in this thesis.   
Appendix 11.1.1: Etoori D, Wringe A, Rice B, Renju J, Gomez-Olive FX, 
Kabudula C, Reniers G “Mobility and clinic switching among HIV patients 
considered lost to follow-up in north-eastern South Africa.” Oral presentation 
at the African Population Conference (APC), Entebbe, Uganda; November 
2019. 
▪ Preliminary analyses for one quantitative results paper (paper B) 
presented in this thesis.  
Appendix 11.1.2: Etoori D, Wringe A, Rice B, Renju J, Gomez-Olive FX, 
Kabudula C, Reniers G “Mobility and clinic switching among HIV patients 
considered lost to follow-up in north-eastern South Africa and consequences 
for estimating the second 90-90-90 target.” Poster presented at the 
International Conference on AIDS and STIs in Africa (ICASA), Kigali, Rwanda; 
December 2019. 
▪ Preliminary analyses for one quantitative results paper (paper B) 
presented in this thesis.  
Plans for future publications in peer-reviewed journals include a paper on re-
engagement in care following loss to follow-up. Papers based on the qualitative 
data are also planned, for example, a qualitative analysis of the differences in 
experiences of engagement with care for Option B+ women compared to the 
general treatment population will be undertaken as an extension of this body 
of work as one of the emerging themes from the qualitative data was how the 
treatment experiences of pregnant and postpartum women differ from those 
of the general ART cohort particularly because of their pregnancy and the extra 
services they must navigate for their infant’s treatment.  
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A presentation on the quantitative component of my research is planned for a 
Measurement and Surveillance of HIV epidemics (MeSH) consortium meeting 
in late September 2020. 
 A pre-Viva seminar was undertaken to present the overall findings from my 
research to other researchers at LSHTM. 
9.6.4. Feedback to funders 
I collaborated with the deputy director of the MeSH consortium which funded 
my fieldwork. He has received regular updates and reports regarding my 
progress. He has also participated in the write-up and is a co-author on three 
of my publications. A presentation on the quantitative component of my 
research is planned for a MeSH consortium meeting in late September 2020. 
9.6.5. Data sharing 
The record review and tracing dataset will be anonymised and stored securely 
within the data infrastructure of the Agincourt HDSS. These data will be made 
available on request through the Agincourt HDSS data manager and following 
the signing of a data sharing agreement. The qualitative data may be available 
on request to me. Transcripts have been thoroughly checked to ensure data are 
confidential.   
9.7. Conclusions 
This thesis investigated loss to follow-up with specific considerations for 
women who initiated treatment for PMTCT under Option B+. The major 
finding of this research is that outcomes following lost to follow-up differ for 
pregnant women when compared to the general ART treatment cohort. As 
such findings from this research begin to explain the differences in retention 
rates for these two groups. Mortality and actual ART stoppages contributed 
very little to LTFU for women who initiated treatment for PMTCT under 
Option B+ and therefore interventions that target transfers to other facilities 
and re-engagement in care may be more effective for these patients. These 
interventions must strive to incorporate the constellation of practices that 
these women engage in, including practices connected to their infant, in order 
to account for any interactions and prevent unintended consequences.  
Low retention rates for Option B+ programmes may negate their potential 
positive impacts and may explain the increasing occurrence of vertical 
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transmission in the postpartum period. Therefore, programmes should strive 
to reduce the occurrence of LTFU and actively trace patients who do become 
LTFU as this will have positive effects for the mother, her infant, future 
pregnancies, and serodiscordant partners.  
Health systems may need to consider differentiated and patient-centred 
models of care to make treatment more convenient for patients. Similarly, 
addressing health system weaknesses in the ascertainment of patient 
outcomes following LTFU may have a great impact on retention estimates in 
this setting and in sub-Saharan Africa as a whole and therefore improve 
PMTCT programmatic outcomes.  
Finally, while these findings are important and add to the compendium of 
research on LTFU from HIV programmes in sub-Saharan Africa, it takes one 
unexpected but widespread event like the COVID pandemic to demonstrate 
their fragility. The knock-on effect of COVID in terms of EID, testing, clinic 
visits, mobility, drug refills, and how all these might be influenced for women 
initiating treatment for PMTCT under Option B+ will be felt for a very long 
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